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ABSTRACT 
Central metabolism plays an intrinsic role in the regulation of gene expression, as cells 
adapt their epigenetic profile in response to nutrient availability. Moreover, 
epidemiological studies revealed a strong correlation between various pathologies, such as 
metabolic syndromes and cancer with nutrient status. To address the molecular 
mechanisms of this link, a cancer model (HeLa) and β-cell model (INS-1) were exposed to a 
sustained acetate and galactose nutrient regimes. Under this treatment, assessment of 
gene expression and epigenetic profiles, both from IDH2 and insulin gene in INS-1 cells, and 
IDH2 and NIX in HeLa cells showed active regulation of DNA promoter methylation. 
Moreover, using a targeted dCAS9-Tet system, IDH2 epigenetic regulation was induced by 
promoter hydroxymethylation. In addition, acetate treatment led to the accumulation of 
DNMT3a protein in INS-1 cells, a process which was also enhanced by inhibiting 
proteasomal activity. Moreover, galactose led to reduction in the DNMT3a protein in HeLa 
cells.  
Functionally, acetate-treated INS-1 cells showed a significant reduction in mitDNA content, 
mtCOI expression, total α-ketoglutarate/ATP contents and increased histone acetylation 
levels, resulting in reduced insulin content. Whereas, galactose-treated HeLa cells showed 
a significant increase in mitDNA content, mtCOII expression, total α-ketoglutarate and 
reduction in histone acetylation, resulting in reduced proliferation and increased apoptosis. 
Overexpression of IDH2 effectively reverted the effects acetated-induced effect in INS-1 
cells, as shown by DNMT3a protein abundance, histone acetylation and ATP content. Our 
results also show that the alterations in the nutrient availability of INS-1 cells, such as 
elevated acetate levels, led to a modified epigenetic control of IDH2 and insulin gene, 
subsequently altering cellular functions. Moreover, cell cycle analysis showed that IDH2 
acetylation but not expression is regulated in cell cycle, and acetate (in the absence of 
glucose) can be sufficient in surpassing the nutrient sensitive restriction point during cell 
cycle. Collectively, these observations provide a mechanistic link between nutrient 
availability and epigenetic control in diabetes, cancer and cell cycle models, and highlight 
the rationale for interventions in this process as part of therapeutics strategies in cancer 
and diabetes. 
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The trans-generational epigenetic inheritance has emerged as a new area of research and 
challenged the central dogma of biology stating that the genetic code is the sole basis for 
biological inheritance. The area of epigenetics has provided new insights into the 
underlying biological mechanisms that can be involved in transmitting traits to following 
generations (Zakhari 2013; Rissman, Adli 2014). Understanding the cues leading to 
epigenetic changes in normal and cancer cells remains an essential factor to be further 
investigated. It was previously established that metabolism and epigenetic modifications 
are directly linked, and epigenetic changes can cause several pathologies, including 
diabetes, cancer, neuronal disorder and cardiovascular diseases (Hanahan, Weinberg 
2011). Many of these conditions are associated with altered DNA methylation status of 
several genes (Lin, Wang 2014). DNA methylation and histone acetylation are important 
processes in epigenetic transcriptional regulation, and each cell type has a differential 
epigenetic pattern that correlates with its function. For example, epigenetic 
reprogramming of the cells leads to DNA promoter demethylation of pluripotency genes 
during pluripotency induction or somatic cell nuclear transfer (Reichetzeder et al. 2016). 
Previous studies have shown that genes involved in development have a considerable 
overlap with genes involved in various diseases, and these genes were also altered in adult 
renewal system with majority being regulated by epigenetics (Mohammad, Baylin 2010). 
In human body the genetically homogeneous cells are divided into different tissue types, 
each displaying heterogeneous qualities and functions. This heterogeneity is due to the 
differential gene expression profiles, that are initiated during early stage of development 
and differentiation, thereafter, maintained during mitosis. This heterogeneity is also 
referred to as epigenetic profiles, which is heritable without incorporating any permanent 
genetic changes in the cell (Jaenisch, Bird 2003). Epigenetics influences gene expression 
profiles which can show effect prenatally and after birth, leading to long term health 
outcomes. These changes can be driven by diet, exercise and environment; raising from a 
complex combination of factors (Katada et al. 2012). 
The central dogma of biology, suggested by Sir Francis Crick, connected the transformation 
and control of biological information, i.e. DNA to RNA to proteins (Crick 1957). The 
fundamentals of this dogma are correct; however, recent discoveries of non-coding RNA 
and epigenetics revolutionised and provided layers of transformation and control of 
biological information (Figure 1.1). The basis of central dogma states that the majority of 
the genome is non-coding (at one point referred to as ‘Junk’ DNA). However, as the 
evolution progressed, these non-coding regions increased in more complex multicellular 
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organisms, such as homo sapiens, in comparison to other species (Ganesan 2018). 
Moreover, genotypically identical monozygotic twins are not physically identical, and these 
phenotypic differences arise with time and growth. Monozygotic twins have played an 
important role in studies conducted to understand the connection between environment 
and epigenetics. Differential gene expression has been observed as the twins age, which 
correlated with epigenetic changes and therefore suggesting epigenetic modification can 
naturally arise in individuals in addition to the inherited patterns (Aquino et al. 2018).  
 
1.1. Epigenetics 
The mechanisms of environmental adaptation in eukaryotes is mediated by active 
epigenetic modifications. The genome of cells remains constant, whereas, the epigenome 
is dynamic, therefore, it responds to the nutritional and environmental changes. These 
epigenetic changes play a pivotal role in health and disease. This dynamic nature of 
epigenetics can essentially be reversed with beneficial outcomes in the disease without 
editing the genomic sequence (Ganesan 2018). Epigenetic silencing of genes is commonly 
found in many cancers (Ohm et al. 2007). Our current understanding of epigenetics 
originates mainly from cancer cell models, therefore, studies conducted in other disease 
models are essential to fully elucidate the mechanism involved in epigenetic regulation. 
There are three main types of epigenetic modifications, including DNA methylation, 
chromatin modifications and RNA-mediated processes (Table 1.1). The well-established 
epigenetic aberrations in health and disease are histone acetylation and DNA methylation, 
which can regulate the accessibility of DNA in eukaryotic cells by modulating chromatin 
accessibility (Sterner, Berger 2000). Silencing of tumour suppressors associated with 
hypermethylated DNA promoter regions, is commonly found in many cancers. DNA 
methylation occurs mostly at the Cytosine-Phosphate-Guanine (CpG) sites of gene 
promoter regions. Roughly 3x107 CpG islands have been identified in the human genome, 
providing a wide range of possible methylation patterns that can control gene expression 
and therefore increase the potential epigenetic information content of the cell (Edwards et 
al. 2010). Clinical trials targeting epigenetics started in 1967 with 5-azacytidine, meanwhile 
lacking the knowledge of drug’s mechanism of action on DNA methyltransferases (Ganesan 
2018). The Food and Drug Administration (FDA) has already approved 'Epi-drugs' targeting 
the epigenetics for the treatment of some cancers, e.g. Vorinostat is used in the 
management of cutaneous T cell lymphoma by targeting histone acetylation (Bubna 2015). 
4 
 
DNA methylation has also played a crucial role in epigenetic targeted interventions. DNA 
methylation has long been considered the central player of the epigenetic network, 
therefore, studies focusing on DNA methylation has contributed most significantly towards 
our understanding of epigenetics (Zhang 2015). 
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Figure 1.1: The relationship between central dogma of biology and epigenetics. The 
biological information encoded in DNA can be decoded to RNA and amino acid sequence 
in the proteins, which was originally proposed by Sir Francis Crick (1957). Beyond the 
central dogma, epigenetics has emerged as an essential heritable form of biological 
information and a key regulator of the genetic biological information. Epigenetics is an 
important factor in the flow and inheritance of biological information, which can greatly 
add to our understanding of how nutrients and environmental factors effect this molecular 
form of data.  
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Table 1.1: Epigenetic modifications and their role in gene regulation 
Epigenetics Modification  Consequence 
DNA methylation 
 
5th position of the cytosine residues are 
covalently modified with the addition 
of a methyl group donated from S-
adenosylmethionine, resulting in 
production of 5-methylcytosine in a 
DNA methyltransferase mediated 
reaction (Newell-Price et al. 2000). 
  
Gene repression by inhibiting 
transcription factor binding, 
repressor complex recruitment 
and chromatin remodelling (Lim, 
Maher 2010). 
DNA hydroxy 
methylation 
 
5-hydroxymethylcystosine is generated 
from 5-methylcytosine by Ten eleven 
translocation-methylcytosine 
dioxygenase enzyme mediated 
oxidation. 5-hydroxymethylcytsoine 
can be converted to 5-formylcystosine 
and 5-carboxylcytosine as additional 
intermediates in an passive 
demethylation process (Ponnaluri et al. 
2017). 
  
Gene expression by passive 
demethylation of cytosines, 
regulating co-transcriptional 
splicing and possibly chromatin 
modulation (Ponnaluri et al. 
2017). 
Chromatin 
modulation 
 
Histone acetylation: Lysine residues on 
the protruding histone tails can be 
acetylated and deacetylated by Histone 
acetyltransferases and Histone 
deacetylases, respectively. Other forms 
of chromatin modulation includes but 
are not limited to: sumoylation, 
ubiquitylation, methylation, 
phosphorylation, ADP ribosylation, 
non-covalent proline isomerisation and 
deamination (Gibney, Nolan 2010). 
  
Gene expression by acetylation 
and gene repression by 
deacetylation of histones 
mediated by structural 
chromatin modulation, 
disruption or recruitment of 
proteins binding to chromatin 
(Gibney, Nolan 2010). 
Small non-coding 
RNAs 
 
 
Usually derived by RNAse III-family 
enzymes mediated cleavage, resulting 
in mainly Short interfering RNAs and 
micro RNAs (Agarwal, Weinstein 2018).  
 
Gene repression by drosha 
and/or dicer dependant 
pathway (Agarwal, Weinstein 
2018). 
Long non-coding 
RNAs 
RNA molecules with more than 200+ 
nucleotides, that can serve as decoy, 
signal, scaffold, short peptides and 
enhancer RNAs (Fang, Fullwood 2016). 
 
Controversial transcription 
regulation. Responsible for gene 
expression and repression in 
response to various stimuli 
(Fang, Fullwood 2016; Gibney, 
Nolan 2010).  
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1.1.1. DNA Methyltransferases  
Methylation of cytosines is the most common DNA covalent modification known in 
eukaryotes, that has been shown to play an important role in development and disease. 
Following the discovery of DNA methylation in eukaryotes, Holliday et al. (1975) speculated 
that methyltransferase enzymes need to be present in cells at all times to maintain the DNA 
methylation status. Initially it was speculated that two methyltransferases ‘E1’ and ‘E2’ 
need to exist simultaneously, where the first enzyme (E1) methylates one strand and the 
second enzyme (E2) completes and maintains the DNA methylation during the cell cycle. 
These theories have now been validated, by showing that the maintenance of DNA 
methylation is carried out by DNMT1, 3a and 3b. DNMT1 is most abundant during the entry 
into S phase and is targeted to the hemimethylated sites on the parental strand. This 
feature allows the correct methylation pattern to be incorporated onto the new strand, 
which also requires the methyltransferases DNMT3a and DNMT3b activity (Shen et al. 
2014; Kishikawa et al. 2003). DNMT3L is also a member of the DNA methyltransferase 
family and is highly expressed in germ cells. DNMT3L lacks the catalytic domain (Kobayashi 
et al. 2012), however despite the absence of catalytic domain, DNMT3L acts as a cofactor 
regulating DNMT3a and DNMT3b activity (Zhang et al. 2010). DNMT2 targets cytosine-28, 
which is located at the transfer-RNA in the anticodon loop and therefore does not 
methylate DNA (Aquino et al. 2018). 
DNMT3a and DNMT3b, as the central mediators of de novo DNA methylation, were shown 
to play a key role in cellular identity and differentiation (Yan et al. 2011). The term de novo 
methylation was initially referred to developmental associated methylation process 
observed in embryonic cells and fertilised gametes, where newly synthesised DNA strands 
or not previously methylated strands were subjected to DNA methylation (Chen et al. 
2003). The remodelling of DNA methylation is carried out during the fertilisation in zygotes 
and primordial germ cells. De novo methylation determines the cell-specific DNA 
methylation profile that defines the functionality, and therefore may play a key role in the 
development of disease (Robertson et al. 1999; Yan et al. 2011). Moreover, mouse model 
of DNMT3a and DNMT3b knockouts have been shown to block de novo methylation in 
embryonic stem (ES) cells and early embryos, resulting in severe phenotypes and death 
(Okano, Bell, Haber, Li, et al. 1999). DNMT3a is a 130 kD protein located at 2p23 with 
several domains performing differential function in the methylation process (Robertson et 
al. 1999). DNMT3a encodes for two variants (DNMT3a1 and DNMT3a2) via alternative 
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splicing, DNMT3a2 is the smaller isoform found in human and mouse, and expressed 
predominantly in ES cells in the testes and ovaries (Chen et al. 2002). The DNMT3a2 is 
transcribed from the isoform initiated at the downstream intronic promoter, which results 
in the loss of N-terminal. The N-terminal of DNMT3a plays a regulatory role, allosterically 
controlling the catalytic activity of the protein (Jeltsch, Jurkowska 2016). DNMT3a 
mediated reaction involves several modifiers, that interacts with different domains of the 
methyltransferase to perform DNA methylation (Figure 1.2). Therefore, it is important to 
understand the underlying mechanisms and variabilities that regulate the structure and 
modifications of DNMT3a. The ATRX/DNMT3-DNMT3L (ADD) domain of DNMT3a is guided 
by the binding with histone tails; this binding can be disrupted by di/trimethylation or 
acetylation of K4 and phosphorylation of T11, S10 or T3 (Zhang et al. 2010). In addition, 
ADD domain plays a key role inducing autoinhibition of DNMT3a, and regulates the 
interaction with unmodified histone tails (e.g. histone H3 peptides unmodified in position 
K4 (H3K4me0)) in order to upregulate the enzymatic activity of DNMT3a (Guo et al. 2015). 
H3K27me3 has also been shown to be associated explicitly with the hypermethylated 
regions of DNA (Jeong et al. 2014). Collectively, these findings suggest the interaction 
between DNMT3a and histones is complex and require further elucidation. 
Unlike DNMT1, that has high preference to hemimethylated DNA, DNMT3a and DNMT3b 
do not differentiate between unmethylated or hemimethylated DNA. Despite the genetic 
and biochemical similarities between DNMT3a and 3b, both exert different cellular 
functions. DNMT3a targets single copy genes and retrotransposons for methylation. 
Whereas, DNMT3b, targets repetitive DNA in pericentromeric satellite regions (Chen et al. 
2003; Okano, Bell, Haber, Li 1999; Kaneda et al. 2004). DNMT3a was shown to be expressed 
at different levels in various tissue types, whereas, DNMT3b is expressed at much lower 
levels in majority of tissues, except for testis, bone marrow and thyroid (Xie et al. 1999). 
The de novo methylation is critical for the pluripotent cells to differentiate and carry out 
specific organelle related functions. Moreover, germline mutations in DNMT3a, have been 
shown to be associated with a number of pathologies (Figure 1.2) including developmental 
disability, intellectual disability, distinctive skeletal features and Acute myeloid leukaemia 
(AML) (Tatton-Brown et al. 2014). Almost one third of AML with normal cytogenetics 
display DNMT3a mutations, which have also been reported in myelodysplasia (Nikoloski et 
al. 2012). The predominant mutation reported is a point mutation targeting the Arg882 
position in DNMT3a. According to predictive modelling of DNMT3a protein structure, this 
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mutation affects the DNA binding site, and therefore causes aberrant DNA methylation in 
the cell (Tatton-Brown et al. 2014).  
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Figure 1.2: The structure of DNMT3a, and disease associated (pathogenic) mutations in 
the protein. The sequence and domains of DNMT3a protein and domains was obtained 
from NCBI (NCBI 2019)(created using SnapGene viewer), and the mutations reported in 
patients obtained from publicly available ClinVar database (NCBI 2019), classified as 
Pathogenic or Likely Pathogenic according to ACMG guidelines. Mutations identified as 
Unknown Significance or intronic mutations were not included in this figure. The mutations 
that have been associated with disease observed in patients spanned the entire protein, 
suggesting a highly functionally important structure. Additionally, multiple diseases were 
shown to be associated with DNMT3a, suggesting a diverse and crucial role of the protein. 
(PWWP: Pro-Trp-Trp-Pro domain, ADD: ATRX-DNMT3-DNMTL domain, MTase: SAM-
dependent methyltransferase C5-type domain). 
 
 
 
  
DNMT3a - 912 Amino acids 
Unknown/not provided conditions Tatton-Brown-Rahman syndrome 
Lung adenocarcinoma/Acute myeloid leukaemia/Myelodysplastic syndrome/Early T cell progenitor acute 
lymphoblastic leukaemia 
A form of Inborn Genetic Disease 
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1.1.2. Methylation and Demethylation of DNA 
The methylation of cytosine involves a reaction catalysed by DNA methyltransferases, 
where a methyl group is transferred from S-adenosyl methionine (SAM) to the fifth carbon 
on cytosine base within the CpG island (Moore et al. 2013). In the mammalian genome, 
most of the housekeeping and tissue-specific genes correspond to promoter regions with 
the CpG islands (Cohen et al. 2011). The methylation of cytosine residues is carried out at 
the 5th position of the pyrimidine base cytosine (5-mC) (Taleat et al. 2015). The CpG islands 
are distributed unevenly across mammalian genomes, with an increasing number of genes 
showing 5-mC in the promoter regions. Methylation of these islands provokes long-term 
but reversible changes leading to transcriptional repression of the associated genes (Jones, 
Takai 2001). Moreover, this epigenetic feature is well conserved among most animals, 
plants and fungi kingdoms (Feng et al. 2010). The inactivation of mammalian X 
chromosome in females is mediated by epigenetics (Panning 2008). X-inactive specific 
transcript (Xist), a non-coding RNA, was shown to regulate X-inactivation. Xist gene 
promoter was found to be methylated at the inactive chromosome in ES cells of females, 
and this de novo methylation was shown to be modulated by DNMT3a (Sado et al. 2004). 
Another notable example of gene expression regulation by DNA methylation is the 
imprinting of DNA, which is dependent on paternal and maternal. During development, 
differential DNA methylation controls the expression of alleles in imprinted genes, resulting 
in the selection of either maternal or paternal copy of the gene to be expressed. 
Centromeres and other repeat regions may also contain methylation that can support 
chromosol and genome stability (Bhagavan et al. 2015).  
DNA methylation is a genetically and chemically stable modification; however, it can be 
reversed by the maintenance-proteins. In order to reverse the methylation of cytosine, the 
methyl group from 5-mC is passively or actively removed (Figure 1.3).  For example, ten 
eleven translocation-methylcytosine dioxygenase enzymes (TET) mediates 5-mC 
conversion in to hydroxymethylcytosine (5-hmC) (Wen et al. 2014). However, the function 
of this modification is currently not well understood. In addition to transcription regulation, 
DNA methylation can provide structural support for the centromeres and gene splicing 
control (Moarefi, Chédin 2011). The active method of demethylation has been suggested 
to be mediated by TET proteins by using α-Ketoglutarate (α-KG) as a substrate through 
three sequential oxidative reactions converting 5-mC to 5-hmC to formylcytosine (5-fC), 
and finally to carboxylcytosine (5-caC) (Wu, Zhang 2011). TET also mediates the reaction 
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that oxidises 5-mC into 5-hmC by hydrolysing α-KG in Fe2+ dependant reaction (Etchegaray, 
Mostoslavsky 2016). Penn et al. (1972) initially detected 5-hmC in mammals using 2D 
chromatography of DNA components, UV spectra in alkaline and acid solution. The analysis 
of tissues collected from brain and liver of mouse and frog demonstrated that 15% to 17% 
of cytosines were modified to 5-hmC. Moreover, high levels of 5-hmC were also been 
detected in ES cells (Huang et al. 2010). Additionally, evidence to support the findings of 
TET was provided by a computational approach to search for homologs of J base 
deoxygenase 1 (JBP1) and JBP2 in trypanosome species. JBP1 and JBP2 are involved in the 
conversion of thymine into base J (in trypanosomes). J base acts as methylated cytosines 
and is associated with gene silencing (Yu et al. 2007). TET proteins 1,2 and 3 were shown 
to have 5-mC hydroxylase activity, and both hemimethylated and methylated CpG islands 
can serve as a substrate for TET mediated demethylation (Wu, Zhang 2011). 5-fC and 5-caC 
levels are difficult to detect due to their low abundancy; however, both types of cytosine 
modifications have been detected by Ito et al. (2011) in the DNA of mouse ES cells. 5-fC and 
5-caC may also be excised by thymine DNA glycosylase (TDG) and thereafter replaced by 
base excision repair (BER) protein with an unmodified cytosine (Aquino et al. 2018). 
Evolutionary studies showed that CpG island functions was conserved amongst various 
species, suggesting a crucial role of CpG islands (Illingworth et al. 2010). The methylation 
and demethylation of CpG islands have been shown to modulate gene expression by 
multiple mechanisms, such as the interaction of DNA promoter region with histone 
methylation, resulting in permissive transcription chromatin state around the methylated 
promoter region (Inoue, Zhang 2011). Additionally, the regions on DNA harbouring CpG rich 
sites tend to serve as binding motifs for transcription factors, and the methylation of these 
sites is correlated with lower binding affinity (Prestridge, Burks 1993). Furthermore, the 
methylated CpG islands controls the compactness can adjust the stiffness found in double 
helix structure of DNA, which can alter nucleosome positioning and therefore regulate the 
binding of transcription factors as well as reducing the access and activity of RNA 
polymerases (Segal, Widom 2009). Methylated CpG islands have also been shown to 
facilitate methyl-CpG-binding proteins (MBP) leading to the recruitment of chromatin 
modifiers, resulting in gene repression (Joulie et al. 2010). Moreover, protein with different 
structural domains can contain CpG binding domains e.g. methyl binding domain (MBD), 
set and RING finger-associated domain (SRA) and zinc finger family domain. MBD is part of 
methyl CpG binding protein 2 (MeCP2), MBD1, MBD2 and MBD4. SRA is found in ubiquitin 
like with PHD and ring finger domains 1 (UHRF1) and UHRF2 regulatory protein, and zinc 
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finger domains in zinc finger and BTB domain containing 4 (ZBTB4) and ZBTB33 regulatory 
protein (Joulie et al. 2010). SRA and zinc finger domains allow the binding of these 
regulatory proteins onto methylated CpG islands and therefore controlling the gene 
expression. However, mice lacking proteins comprised of MBD and zinc finger domains, 
such as MeCP2, MBD2 and ZBTB33, did not hinder embryonic development suggesting a 
complex mode of expression controlled by methylated CpG islands that need to be further 
elucidated (Martín Caballero et al. 2009). The methylation pattern of specialised cells has 
been shown to play an important role in the regulation of differential gene expression. In 
contrast to the well documentation of CpG islands and their association with de novo 
methylation, the cues that designate the de novo methylation of specific CpG islands are 
not well-documented (Edwards et al. 2017). Therefore, further investigations are required 
with emphasis on the regulation of de novo methylation and methyltransferases to 
elucidate the mechanisms involved in health and disease. 
A global decrease in DNA methylation accompanied by variability in the methylation 
pattern is termed epigenetic drift. Epigenetic drift has been evident in the ageing 
population. Moreover, monozygotic twin also demonstrated discordant methylation 
prolife with age. Based on the DNA methylation profile, the epigenetic models can be used 
to predict an individual's age. Interestingly, all tissue types demonstrated an epigenetic age 
except for embryonic and induced pluripotent stem cells, where the DNA methylation 
variability was zero; therefore demonstrated no sign of epigenetic ageing (Aquino et al. 
2018). In stem cells, the predominant methyltransferase that maintains DNA methylation 
is DNMT3a (Jeltsch, Jurkowska 2016). Epigenetic ageing is associated with adverse changes 
in gene expression, transcriptional process, downstream protein structure and cellular 
function. Epigenetic ageing was associated with increased risk of age-related diseases, such 
as diabetes and cancer. The underline reason for this epigenetic ageing is due to the 
regulatory mechanisms of the DNA methyltransferases. The loss of regulatory mechanism 
due to epigenetic aging, can distort cellular ability to respond to environmental cues 
resulting in loss of epigenetic modulation (Aquino et al. 2018). 
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Figure 1.3: The methylation and demethylation of cytosine, carried out by DNMTs and 
TETs respectively. Methylation on the 5th position of cytosine base is carried out by DNMTs 
using S-adenosylmethionine (SAM) as a methyl donor, resulting in the production of 5-
methylcytosine; cytosines targeted for methylation are generally located next to guanine 
and therefore forming a cytosine-phosphate-guanine island in the double stranded DNA. 
5-methylcytosine can be oxidised by TET group of enzymes using α-ketoglutarate (α-KG) in 
the reaction and converting the methylated cytosine to 5-hydroxymethylcytosine, which is 
first and important step involved in the demethylation process, subsequently leading to 
unmethylated cytosine. These two forms of modified cytosines, i.e. 5-methylcytosine and 
5-hydroxymethylated cytosine are the most stable forms of modifications of cytosine.  
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1.1.3. DNA methylation and pathology 
In simple non-mammalian multicellular organisms, the gene expression profiles of different 
specialised cells are highly similar. However, in mammals, the gene expression profiles vary 
more than 50% amongst different tissue types. These differences are mainly induced and 
regulated by epigenetic modifications, such as DNA methylation, to provide the tissue its 
identity and function (Bergman, Cedar 2013). Additionally, population based epigenetic 
epidemiologic studies have shown that aberrant DNA methylation plays an important 
pathological role in a growing number of diseases, such as diabetes (Jin, Liu 2018). Yang et 
al., (2003) provided one of the first substantial evidence indicating the role of DNA 
methylation in diabetes caused by aberrant genomic imprinting. Yang group showed that 
DNA methylation regulated the imprinting control (IC) region of insulin-like growth factor 
2 (IGF2/H19), thereby, distorting the binding of zinc finger CCCTC-binding factor (CTCF) 
resulting in the downregulation of IGF2/H19 expression. The mechanisms underlying 
epigenetic transgenerational inheritance involves genomic imprinting. Aberrations of 
imprinting can result in a number of pathologies, including Prader-Willi syndrome, 
Beckwith-Wiedemann syndrome and types of cancers (Jin, Liu 2018). 
Genome-wide methylation analysis in cancer patients have confirmed that defective DNA 
methylation is associated with the onset symptoms of the disease (Jelinic, Shaw 2007). 
Additionally, changes in the expression of DNMTs and TETs have been shown to play an 
important role in the pathogenesis of cancer (Cui et al. 2002). Jin and Liu ( 2018) stated that 
after the development of cancer, epigenetic modifications can cause the observed 
heterogeneity in patients. This heterogeneity plays an important role in drug resistance to 
conventional therapeutics in cancer. Moreover, autoimmune diseases, such as rheumatoid 
arthritis, were shown to display changes in the DNA methylation of peripheral blood 
mononuclear cells, where the response to anti-rheumatic drugs was also dictated by the 
DNA methylation profile of the patient (Liu et al. 2013; Glossop et al. 2017). Systemic lupus 
erythematosus, another autoimmune disease, was shown to display aberrant DNA 
methylation profile, and included a number of genes associated with auto-antibody 
production (e.g. NLRC5 gene) (Chung et al. 2015).  
World Health Organisation (WHO 2019) and Centres for Disease Control and Prevention 
(Center for Disease Control and Prevention 2018), estimated the economic burden of 
cancer and diabetes to be amongst the top four diseases. The role of DNA methylation in 
cancer and diabetes is poorly understood. DNA methylation mediated changes, including 
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hypermethylation of promoter regions, global DNA hypomethylation, loss of imprinting and 
chromatin remodelling, contribute to the development of cancer (Estécio, Issa 2011; 
Gopalakrishnan et al. 2008; Yamada et al. 2005). Locus specific DNA methylation of 
promoter region is common in cancers, and is associated with tumour suppressor genes 
silencing (Gopalakrishnan et al. 2008). The aberrant DNA methylation was suggested as one 
of the underlying causes of pancreatic cancer, and was detected in early stages of 
precancerous cells development (Peng et al. 2006). Tumour initiating cells arising from 
stem cells, progenitor cells or dedifferentiated cells are suggested to be generated by 
epigenetic changes. This transformation occurs by epigenetic or genetic inactivation of 
tumour suppressor genes resulting in the loss of highly regulated self-renewal system and 
consequently initiating tumour progression (Gopalakrishnan et al. 2008). 
Diabetes arises from a combination of epigenetic and genetic factors. Type 2 diabetes (T2D) 
is the most common type of the diabetes mellitus. Genome-wide DNA methylation studies 
of pancreatic islets showed aberrant DNA methylation in T2D patients, which was 
associated with differential gene expression profile (Dayeh et al. 2014). Obesity is another 
factor that correlates with increased risk of T2D, and was shown to induce aberrant DNA 
methylation on hypoxia-inducible factor 3 in adipose tissue (Dick et al. 2014). Moreover, 
CpG islands on the promoter regions containing single nucleotide polymorphisms (SNP), 
resulted in aberrant locus specific DNA methylation and were associated with elevated 
plasma triglyceride levels, consequently, increasing the risk of T2D (Toro-Martín et al. 
2016). Nitert et al. (2012) investigated the DNA methylation status of muscle cells obtained 
from individuals that do not harbour the disease but have a family history of T2D, the 
outcome demonstrated differential DNA methylation profile and exhibited reduced 
expression of more than 60 genes, relative to control subjects without T2D or its history. 
The majority of these downregulated genes were also shown to be differentially 
methylated in T2D patients, suggesting a major role of DNA methylation in the inheritance 
of T2D. These findings combined suggest that the pathological role of DNA methylation is 
not yet clear; however, more recent studies provided evidence implicating DNA 
methylation in various pathologies, including cancer and diabetes. 
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1.1.4. Histone acetylation  
DNA associate with histones to form nucleosomes. A nucleosome consists of eight histone 
proteins, two of each: H2A, H2B, H3 and H4, wrapped in 147 bp of DNA with high specificity. 
H1 is the histone linker protein that connects the nucleosomes to DNA, providing structural 
support, thus playing an essential role in the structure of chromatin (Gibney, Nolan 2010; 
Speranzini et al. 2016). Chromatin structure plasticity and dynamics play an important role 
in defining the cell's function and therefore its role in a multicellular organism (Speranzini 
et al. 2016). Histones are predominantly positively charged proteins, which supports the 
binding of negatively charged DNA (Gibney, Nolan 2010). Transcription factors regulate 
gene expression by binding to specific regions on DNA sequence around the histones. The 
association between histone, transcription factors and DNA can be determined by the 
interactions between histone amino acids and DNA (Speranzini et al. 2016). Collectively, in 
the context of interactions between DNA and histones, these findings suggest that 
investigations carried out on epigenetics of the cells need to address both, DNA 
methylation and histone modification. 
The discovery of histone acetylation was solely associated with transcriptional activation. 
However, subsequent investigations showed that histone acetylation can also mediate 
DNA repair (Gibney, Nolan 2010; Verdone et al. 2005). The flexible histone tails can serve 
as a primary target for epigenetic modifications. In the process of histone acetylation, the 
Nε-acetylation of lysine residues acquires the acetyl group, thereby neutralising the positive 
charge and distorting the electrostatic interaction between histones and DNA, resulting in 
an open-chromatin formation leading to increased DNA accessibility (Figure 1.4) (Dawson, 
Kouzarides 2012). Sirtuins (SIRT) are deacetylases that were originally found to regulate the 
life cycle in Caenorhabditis elegans, and also shown to play a critical role in the histones 
deacetylation process in mammals (Zou et al. 2017). Loss of SIRT1 was shown to increase 
histone acetylation, resulting in modified expression of numerous genes. However, SIRTs, 
are not histone specific and can deacetylate other proteins. For example, SIRT1 can also 
deacetylate the tumour suppressor p53, and brain and muscle ARNT-like 1 (BMAL1), which 
regulates mammalian circadian clock (Stünkel, Campbell 2011). In addition to SIRTs, histone 
acetylation status is regulated by coordinated actions of histone acetyltransferases (HAT) 
and histone deacetylases (HDAC). HDACs are very similar to SIRTs, and function by 
modulating the PTM of lysine residues on histone (Su et al. 2016). Site specific acetylation 
and deacetylation have been highly associated with chromatin modulation and 
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transcriptional competency (Keating, El-Osta 2015). There are seven known SIRT isoforms, 
SIRT 1 to 7 with nuclear, cytoplasmic and mitochondrial localisation with a possibility of 
intercompartment movement. This subcellular localisation likely dictates the specific 
function and targets of these deacetylases (Flick, Lüscher 2012). 
The histone tails are prone to other PTMs including methylation, ubiquitination, 
phosphorylation, deamination, sumoylation and ADP (Adenosine diphosphate) ribosylation 
(Table 1.1). The histones mainly consist of basic amino acids such as lysine and arginine, 
which increases the possibility of PTMs, and consequently structural regulation mediated 
by epigenetic modifications (Gibney, Nolan 2010). Acetylation of histones is also regulated 
by the intracellular acetyl-CoA levels; however, the precise mechanism and fundamentals 
are not known. More recently, Mews et al. (2017) demonstrated a positive correlation 
between decreased and increased acetyl-CoA levels, and histone deacetylation and 
acetylation, respectively.  
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Figure 1.4: Schematic representation of the key epigenetic modifications. A model of 
chromatin structure from chromosome to double helix DNA is illustrated above. 
Acetylation of histones results in chromatin structural changes from a closed to an open 
conformation, increasing the DNA accessibility, mediated by the removal of positive charge 
in the process of acetylation, which interferes with the interaction between negatively 
charged DNA. Histone acetylation is carried out by HATs on the lysine residues located at 
the N-terminal tail, which can be deacetylated by HDACs. Acetylation and deacetylation of 
histones results in opposing outcomes, i.e. open and closed chromatin conformation, 
respectively. Histone methylation, another histone modification is targeted towards the 
gene transcription depending on the target amino acid. The rate of DNA methylation at the 
promoter region of the gene is inversely correlated with transcription, and the rate of 
hydroxymethylation is positively correlated with transcription.  
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1.2. Nutrients and epigenetics  
Nutrient availability mediates the cellular adaptability, in order to sustain multiple cellular 
processes, including viability and proliferation. This adaptability requires the activation of 
specific transcriptional and metabolic programming, allowing cells to respond to the 
environmental changes (Sebastián, Mostoslavsky 2017). Lifestyle and environmental 
factors, such as exercise, diet, smoking and alcohol consumption, have been shown to 
influence epigenetics. Exercise combined with low-fat diet was shown to affect the 
metabolism, resulting in delayed ageing (Aquino et al. 2018). Additionally, epigenetic 
changes from short term caloric restriction diet displayed a profound effect on DNA 
methylation. Hahn et al. (2017) profiled global DNA methylation changes and their 
correlation with gene expression in response to diet restriction, i.e. reduction in intake of 
food without reaching malnutrition. The study demonstrated that age related DNA 
methylation changes were substantially reduced in individuals with reduced food intake, 
and the DNA methylation profiles remained unaffected. These findings outline the 
connection between epigenetics and ageing, and the ability of nutrients to impact 
epigenetics, and subsequently, health and disease. Furthermore, ageing mice showed a loss 
of DNA methylation and imbalance between methylated and unmethylated promoter 
regions of several genes (Kim et al. 2016). Mathers et al. (2008) stated that the differences 
in epigenetic markings may explain discrepancies observed in inter-individual disease 
susceptibility and response to nutritional interventions. DNA methylation can be regulated 
by nutrients, either globally or in a locus-specific manner. The nutrition status of a cell can 
affect key metabolic intermediates and therefore gene expression (Bhagavan et al. 2015). 
For examples, DNA methylation can be controlled by regulating the substrate SAM for 
DNMTs and therefore limiting the rate of enzymatic activity. During DNA methylation, 
DNMTs utilises SAM, methyl (CH3) donor derived from methionine cycle, to methylate 
cytosine at the 5th position. The methylation of cytosines at the CpG islands is influenced 
by the metabolic pathway of methionine, in addition to other components of this metabolic 
pathway, such as folic acid, vit B6 and vit B12 (Bhagavan et al. 2015). In addition, the 
different metabolic pathways dictating the availability of methyl donor (SAM) can 
consequently result in DNA methylation changes. Metabolic pathways, such as folate-
mediated one-carbon metabolism and serine pathway, can also regulate methionine cycle, 
subsequently modulating the production of SAM (Maddocks et al. 2016). Moreover, the 
serine pathway regulated by histone modification, can sequentially mediate cofactor for 
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DNA methylation (Ding et al. 2013). In addition to regulating the cofactors used by DNMTs 
or TETs, and targeting the enzymes that regulate these cofactors (Zhang 2015). 
Malnutrition can mediate locus-specific DNA methylation changes, hypomethylation or 
hypermethylation, depending on target gene (Straten et al. 2010). An example of locus-
specific regulation by nutrient mediated DNA methylation exists in the renal carcinoma 
cells, where epigallocatechin-3-gallate (nutrient found in green tea) decreased DNA 
promoter methylation at the tissue factor pathway inhibitor 2, leading to apoptosis and 
decreased proliferation (Ding et al. 2009; Zhang 2015). Curcumin, the major functional 
component of turmeric, which is commonly used in south east Asia, was found to induce 
global DNA hypomethylation in leukaemia cell line by inhibiting DNMT1, via covalent 
binding to the protein and therefore blocking the catalytic thiolate C1226 (Liu et al. 2009). 
S-adenosylhomocysteine (SAH) is the by-product of the methylation reaction carried out 
by DNMTs. Following DNMT mediated reaction, SAH can be converted into homocysteine 
and recycled back into the methionine cycle and subsequently converted into methionine. 
The ratio between SAM and SAH is maintained tightly, because SAH is a potent inhibitor for 
DNA methylation (Etchegaray, Mostoslavsky 2016). Moreover, TET mediated DNA 
demethylation uses vitamin C as a cofactor. Vitamin C enhances the activity of TET by 
interacting with its catalytic domain (Etchegaray, Mostoslavsky 2016). Chung et al. (2010) 
correspondingly reported that high vitamin C levels in human embryonic stem cells (hESC) 
can lead to global DNA demethylation. Chung group suggested that some of demethylated 
genes were involved in the differentiation process of hESC and reprogramming of 
fibroblasts into iPSCs. 
Acetyl-CoA, an important metabolic intermediate, is the universal substrate for histone and 
protein acetylation, that is also a key metabolite of catabolic and anabolic reactions. Acetyl-
CoA is mainly derived from glycolysis and TCA cycle, and can be generated from acetate, β-
hydroxy acids and β-ketoacyl-CoA (Etchegaray, Mostoslavsky 2016). ATP Citrate Lyase 
(ACLY), an enzyme regulating the conversion of citrate into acetyl-CoA, has been shown to 
directly affect the acetylation of histones. Moreover, silencing of ACLY was shown to 
decrease histone acetylation levels (Wellen et al. 2009). Cai et al. (2011) correspondingly 
demonstrated that the availability of nutrients and intracellular acetyl-CoA levels in yeast 
correlated with the acetylation of histones and increased growth-associated gene 
expression. Other metabolites, such as butyrate, have been shown to regulate acetyl-CoA 
production, subsequently increasing the intracellular concentration of this metabolite and 
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regulating epigenetics. Butyrate, a short-chain fatty acid, is produced in large quantities by 
colon microbiota, mediated by diet (Etchegaray, Mostoslavsky 2016).  
A number of metabolic intermediates are required for epigenetic modifications, therefore 
dietary intake is essential in determining the metabolic rate and intermediates, 
consequently modulating cellular epigenetics (Figure 1.5) (Keating, El-Osta 2015). Central 
metabolism and epigenetics can be modified by altering the source of nutrients, such as 
glucose, acetate, galactose and curcumin (Liu et al. 2009; Dott et al. 2014; Jacob et al. 1997). 
Galactose, a highly homologue metabolite to glucose, has been shown to enhance 
mitochondrial activity (Palmfeldt et al. 2009). Acetate, have also been shown to regulate 
energy metabolism and therefore functions of specific tissues (Jacob et al. 1997). In stem 
cells, the nutritional utilisation is different depending on whether the cell is in a 
differentiative, proliferative or quiescent state (Cavallucci et al. 2016). One of the key 
characteristics of stem cells includes its plasticity that is provided by the active epigenetic 
modifications, giving the cell its heritable developmental cues and response to the 
environment accordingly (Atlasi, Stunnenberg 2017). The epigenetic changes, in most cases 
are reversible without genetic interventions and therefore are attractive targets for future 
therapies (Allis, Jenuwein 2016). 
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Figure 1.5: Nutrients can modify epigenetics and regulate transcription. Fatty acids, 
carbohydrates and amino acid metabolism can produce metabolic intermediates including 
acetyl-CoA; co-factor in the histone acetylation reaction. Acetyl-coA is mainly generated 
from oxidative metabolism of free fatty acids (FFA), glycolytic pyruvate (Pyr), branched 
amino acids (BCAA), Acetate (Ace) and Acetylcholine (Ach) (Pietrocola et al. 2015). 
Methionine, an essential amino acids found in a variety of dietary intakes can also produce 
S-Adenosylmethionine (SAM); a co-factor in DNA methylation reaction (Orgeron et al. 
2014). α-ketoglutarate (α-KG), a co-factor in TET mediated demethylation reaction can be 
obtained from the TCA cycle, that has been shown to be modulated by variety of dietary 
intake. (DNMTs: DNA Methyltransferases, TET: Ten Eleven Translocation, HATs: Histone 
acetyltransferases)  
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1.3. Nutrients and Pathology 
Historical events such as the 1944-1945 winter Dutch famine in the Netherlands (this was 
a 5-month period of extreme food shortage) and its implications on disease in later life 
have demonstrated the importance of diet in health and disease, especially during 
development. A study conducted by Painter et al. (2005) on subjects that were born during 
or immediately following this period showed lower birth weight that was associated with 
the development of T2D, cardiovascular diseases and obesity. Other studies have also 
associated the risk of cardiovascular diseases, hypertension and T2D of the offspring to 
mother's nutrition intake during her childhood. Moreover, the nutrition of grandmother 
during pregnancy has been shown to dictate the health of grandchild (Kaati et al. 2002). 
Collectively, these studies indicate the direct connection and long-term effect between 
nutrition and disease. Birth weight has been associated with the development of 
pathologies in adult life, and growing evidence suggests that ~62% of birth weight 
variations can result from an intrauterine environment including nutrients (Guilloteau et 
al. 2009). Conversely, 18% to 20% variation of the birth weight was shown to reside to the 
maternal and paternal genetic variants (Holt 2002). It is not just the nutrition intake but the 
time of nutrition during pregnancy that was also shown to contribute to different 
pathological outcomes, whereas, the nutrition restriction during early gestation results in 
cardiovascular disease risk, and later gestation results in increased risk for T2D (Guilloteau 
et al. 2009). In addition to nutrients, hormones can also largely regulate metabolism. 
However, hormones in large physiological quantities, are restricted from crossing over to 
fetus through the placenta. Therefore, the nutrients in maternal circulation, not the 
hormones, dictates the fetus metabolism (Guilloteau et al. 2009). These findings support 
the evidence of pathologies arising from changes in nutrient and metabolism. In addition 
to the prenatal, the postnatal effect of nutrients has also been associated with metabolic 
reprogramming and pathological changes. For instance, a high protein diet in new born rats 
resulted in insulin resistance and modified the expression of glucose transporters (Robert 
et al. 2009). Also, the high carbohydrate diet in neonatal rats resulted in hyperinsulinemia 
(Srinivasan et al. 2000).  
Reprogramming of energy metabolism are one of the hallmarks of cancer and diabetes 
(Hanahan Weinberg 2011, Feng et al. 2016). Diabetes arises from intricate interaction 
between diet and genetic factors, yet the mechanism of this interplay is to be fully 
understood (Park et al. 2015). Metabolic deregulation is directly linked to diabetes end-
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point effects, including insulin secretion (Friedrich 2012; Suhre 2014). Moreover, Warburg’s 
observations also connect the metabolism to end-point effects observed in cancer cells, 
such as converting glucose mainly into lactate even in the presence of sufficient amounts 
of oxygen (Warburg et al. 1927). However, this metabolic feature of cancer cells has also 
been observed in normal proliferating T cells, suggesting an intrinsic property of 
proliferation (Colombo et al. 2010). Cell metabolism, such as glycolysis and glutaminolysis, 
is strongly co-ordinated in proliferating cells. Anaphase-promoting complex/cyclosome 
(APC/C) and Skp1/cullin/F-box (SCF) have been shown to regulate the degradation of cell-
cycle proteins as well as glycolysis promoting proteins, such as 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase, isoform 3 (PFKFB3) and the glutaminolysis pathway 
(e.g. Glutaminase 1, GLS1) (Moncada et al. 2012). Furthermore, the glycolysis promoting 
PFKFB3 enzyme is necessary for progression into S phase of the cell cycle, in a point which 
has previously been described as ‘nutrition sensitive’ (Moncada et al. 2012). In addition, 
sustained supply of nutrients (e.g. fatty acid and high levels of glucose) to β-cells from 
pancreas, leads to functional changes in insulin secretion. The utilisation of nutrients by β-
cells is an essential component of their sensing system mediated glucose homeostasis. 
Changes in the sensing system can lead to a global alteration of the hormonal secretion, 
resulting in intrinsic pathophysiological consequences (e.g. diabetes development). The 
impact of nutrients on cellular function have provided the rationale for its characterisation, 
and ultimately, with the concept that interventions on these links could be used as 
potential therapeutic targets for cancer and diabetes. 
Epigenetic-metabolomic interplay has been associated with normal physiological functions 
and various pathologies. For example, Purushotham et al. (2009) showed that a 
combination of high-fat diet and knock out of SIRT1 in mice, results in impaired fatty acid 
oxidation and ketogenesis leading to inflammation, ER stress and hepatic steatosis. In the 
same study, mice lacking SIRT1 displayed no abnormal weight gain on chow diet (grain-
based diet); whereas, western diet increased the weight significantly in comparison to 
control mice. These findings highlight the importance of diet in the development of 
pathophysiological risks. In tumorigenesis, cellular metabolism and oncogenic mutations 
are directly or indirectly linked, resulting in metabolic reprogramming (Pavlova, Thompson 
2016). The ability of cancer cells to acquire nutrients from a nutrient-deficient environment 
to generate biomass and maintain viability has been the focus of research for decades 
(Pavlova, Thompson 2016). The combination of nutrient utilisation and metabolic 
reprogramming leads to the phenomenon termed ‘The Warburg effect’ (Warburg et al. 
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1956). The Warburg effect state that cancer cells primarily rely on aerobic glycolysis instead 
of mitochondrial oxidative phosphorylation (OXPHOS), and obtain around 50% of their ATP 
by metabolising glucose to lactic acid (Heiden et al. 2009).  
 
1.3.1. Mitochondrial and IDH2 regulation  
Mitochondrial dysfunction is a key modification in cancer that plays a significant role in the 
emerging research of cancer therapies. Furthermore, common diseases including 
neurodegenerative disorders, obesity and cardiomyopathies, are linked to dysfunctional 
mitochondria (Nunnari, Suomalainen 2012). The number of mitochondria present in 
aerobic eukaryotes varies depending on the developmental stage and functional activity. 
In addition to the number of mitochondria, the shape and size also differ depending on the 
cell, where mitochondria can undergo fission or fusion to accommodate the volume and 
size requirements. The nuclear genome encodes the genes required for fission and fusion, 
therefore a nuclear-mitochondrial communication plays a key role in metabolic regulation 
(Bhagavan et al. 2015). Nuclear respiratory factor (NFR) transcriptional activity on the 
peroxisome proliferator-activated receptor alpha (PPARα) and mitochondrial transcription 
factor A (mtTFA) synchronises the mito-nuclear regulation, which are accordingly 
controlled by the ‘master regulator of mitochondria’, peroxisome-proliferator-activated-
receptor gamma co-activator (PGC1α). NRFs increase the expression of mtTFA and number 
of other nuclear encoded subunits of TCA cycle and the complexes of electron transport 
chain (ETC). Thereafter, mtTFA binds to the enhancer located upstream of mitochondrial 
DNA (mitDNA) and increases mitochondrial activity. Mitochondrial complexes, PGC1α 
expression and targeted transcription factors in healthy subjects (with no indication of 
mitochondrial defects) showed a high correlation with maximal oxygen uptake (Rosca, 
Hoppel 2013). PGC1α expression and promoter activity can be increased by reactive oxygen 
species (ROS), resulting in increased ETC associated gene expression and cyclic adenosine 
monophosphate (cAMP) mediated mitochondrial and cytosolic ROS-detoxifying system. 
These findings indicate that moderate ROS production by mitochondrial biogenesis is 
important. However, ROS generated by complex I and III was shown to damage cellular 
components, such as DNA, lipids and proteins (Nunnari, Suomalainen 2012). In addition to 
the hypoxia response for adaptive stress signalling, ROS has been shown to regulate 
differentiation and proliferation of cells (Hamanaka, Chandel 2010).  
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Mitochondria regulates cellular NADH, amino acids, enzymatic co-factors, lipid synthesis, 
pyrimidine biosynthesis, fatty acid β-oxidation pathway and acetyl-CoA production (Figure 
1.6). Furthermore, mitochondria plays an important role in metal metabolism, which is the 
central part of the Fe-S cluster and heme production and is essential for DNA repair and 
oxygen carrier machinery (Lill, Mühlenhoff 2008). The energy requirements of the cell are 
also met by the oxidation of proteins, lipids, carbohydrates, therefore, yielding reduced co-
enzymes including FADH2 and NADH. ETC of the mitochondrial respiration utilises the 
oxidised FADH2 and NADH using four enzymatic complexes (complex I, II, III and IV). 
Complex IV, also known as the terminal complex of mammalian cytochrome c oxidase 
(COX), consists of 13 subunits, where cytochrome c oxidase subunit 1 (mtCOI), 2(mtCOII) 
and 3(mtCOIII) are encoded by the mitDNA forming the functional core of complex IV 
(Capaldi 1990). The energy in mitochondria is captured in the form of ATP, generated by a 
step-wise cycle combining oxygen consumption with ETC and OXPHOS. OXPHOS utilises 13 
proteins encoded by the mitDNA, that are maternally inherited (e.g. mtCOII). MitDNA is 
another central component of mitochondria that is modulated in cancer (van Gisbergen et 
al. 2015). MitDNA is a double stranded circular form of 16.6 kb long DNA. The initiation of 
mitDNA replication and expression is regulated from the D-loop region that contains the 
transcription promoter and an origin of replication (Seidel-Rogol, Shadel 2002). MitDNA 
copies are present in human cells in large quantities ranging from 100-10,000 copies/cell. 
The modulated copy number of mitDNA in the cells has been shown to contribute to 
pathologies, including encephalopathies and neuropathies by impairing mitochondrial 
respiration (Reznik et al. 2016). Ishikawa et al. (2008) correspondingly reported that 
‘swapping' mitDNA from highly metastasised cancer cells with cells of lower ability to 
metastasise, results in the reversion of the metastatic ability.  
Mitochondria consist of two membranes, the outer and inner. The outer membrane is 
highly permeable to smaller solutes (<5 kDa). However, the inner membrane has lesser 
permeability, in which case the mitochondrial carriers play an important role in 
transportation. Mitochondrial carriers are the nuclear-encoded family of transport 
proteins, that regulate the flux of nucleotides, metabolites and coenzymes across the 
mitochondrial membrane. Because of cellular compartmentisation, metabolites need to be 
transported in and out of mitochondria for many metabolic reactions. Metabolites, such as 
citrate, malate and ATP, need to be exported out of the mitochondria to be utilised in other 
reactions, including the conversion of citrate into acetyl-CoA which serves as an important 
precursor in epigenetic modifications. Citrate carrier has also been shown to play a 
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significant role in histone acetylation (Palmieri, Pierri 2010). The citrate carrier is a 
significant component of the citrate-malate and oxoglutarate shuttles, playing a vital role 
in the intermediary metabolism by connecting lipogenesis and carbohydrate catabolism, in 
addition to epigenetics. The role of citrate carrier is to transport citrate, that is mainly 
derived from the breakdown of sugar sources out of mitohondria. This transportation is 
carried out via a voltage-dependant anion channel in a passive diffusion manner. This 
reaction catalysed by citrate carrier as either citrate-citrate or citrate-malate exchange 
(Gnoni et al. 2009). In both directions of transport (i.e. from and to mitochondria), the 
rearrangement of the bound form is faster than of the free form. In addition, the 
dissociation constant for the internal (mitochondrial) substrate is higher than of the 
external citrate. As a result, the citrate transport rate by citrate carrier is larger when the 
transport is carried out with the exchange of another substrate, e.g. malate (Palma et al. 
2005). 
Currently, there is no treatment available for mitochondrial related disorders, but 
symptom-based interventions are being used in patients. In most cases, complexities 
arising in mitochondrial disorders are tissue-specific and largely heterogeneous. For 
example, mitochondrial aminoacyl-transfer RNA synthetases defects can give rise to 
clinically variable conditions, including ovarian dysfunction, cerebral white matter disease, 
hearing loss and/or cardiomyopathies. This heterogeneity indicates the diverse role of 
mitochondria in each cell and tissue type. Mitochondria have been traditionally known for 
energy production; however, the heterogenous role of mitochondria in several diseases 
suggest a more diverse role within the cell that extends beyond energy production 
(Nunnari, Suomalainen 2012). 
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Figure 1.6: Schematic of the mitochondrial and central metabolism of cell. Glycolysis and 
oxidative phosphorylation are tightly linked together. In glycolysis, glucose is converted to 
pyruvate thorugh a number of steps (providing a net gain of 2 ATPs), which is then 
transported into the mitochondria. Pyruvate Dehydrogenase Complex then converts the 
pyruvate into acetyl-CoA. Fatty acid β-oxidation of fatty acids and acetyl-CoA esters is 
performed thorough a number of enzymatic reaction leading to the production of acetyl-
CoA. Acetyl-CoA generated from glycolysis and β oxidation can be further oxidised by the 
TCA cycle, or converted into citrate and exported out of mitochondria before being utilised 
by IDHs: which leads to an increase in the pool of cytosolic acetyl-CoA, where citrate is 
converted to acetyl-CoA by ACLY conversion. Moreover, the pool of cytosolic actyl-CoA can 
also be directly increased by nutrients, e.g. acetate. (PDC: Pyruvate Dehydrogenase 
Complex, ACS: Acetyl-CoA synthetase, ACLY: ATP citrate lyase) 
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1.3.1.1 The role of IDH2 in mitochondria and disease 
Mitochondrial-generated metabolites regulate cellular activity. In mitochondria, the 
metabolites are processed using the TCA cycle to produce energy through the electron 
carriers such as NADPH. ETC then utilises this energy in the generation of ATP. In addition, 
an essential part of the TCA cycle is the Isocitrate dehydrogenase (IDH) mediated reactions. 
Human IDHs different isoforms are encoded by IDH1 gene located at 2q33.3, IDH2 gene at 
15q26.1, IDH3A gene at 15q25.1 and IDH3B gene at 20q13 (Al-Khallaf 2017; Bhagavan et 
al. 2015). The gene expression levels of either IDH1/2 vary depending on the tissue types, 
therefore, suggesting two distinct pathways in the TCA cycle that regulate a cell specific 
function. Muscle, heart and lymphocytes have shown higher IDH2 expression levels. 
Interestingly in T-cells IDH1 is undetectable, and only the IDH2 is expressed in resting and 
activated state (Al-Khallaf 2017). IDH2 supplies NADPH that is required for glutathione 
production against oxidative damage in mitochondria, therefore, is a key factor in the 
antioxidation process during oxidative stress (Jo et al. 2001). IDH2 consists of 18 beta sheets 
and 14 alpha helices forming homodimer (Ceccarelli et al. 2002). IDH2 is an NADP-
dependant mitochondrial isocitrate dehydrogenase and is considered a tumour suppressor 
protein in many cancer types (YI et al. 2016). Mutations in IDH2 have been associated with 
multiple cancer types (e.g. R172K, R172M, R172W associated with Gliomas, R140Q, R172K 
associated with Myeloid malignancies, R140G, R172G, R172K, R172T with 
Angioimmunoblastic T-cell lymphoma, R172W with Cholangiocarcinoma and R172S with 
Enchondromas) (Dang et al. 2016; Yang et al. 2012). IDH2 functions as part of TCA cycle, 
catalysing the conversion of isocitrate to α–KG by oxidative decarboxylation (Reitman et al. 
2010) (Figure 1.7). In IDH2, the interaction between Ser95 and Asp279 blocks the active 
site access, coversley, Mg2+ -isocitrate complex, located at the active site, can increase the 
catalytic rate of IDH2 mediated reaction. Additionally, IDH2 mediated catalysis is one of the 
irreversible reactions (due to the large negative free energy change) in TCA cycle, therefore 
it is allosterically regulated by ADP and ATP. In this reaction, ATP inhibits, and ADP positively 
regulates the reaction (Pelosi et al. 2016). IDH2 dehydrogenates isocitrate to 
oxalosuccinate and then decarboxylates to α–KG, in the process producing NADH (Akram 
2014). NADPH is involved in many vital cellular functions, including fatty acid synthesis and 
cholesterol biosynthesis, in addition to the defence against oxidative stress (Yang et al. 
2012). The isocitrate converted by IDH2 (NADP dependent enzyme) into α-KG to produce 
NADPH continues into the TCA cycle for other reactions, but the remaining isocitrate, that 
31 
 
is not catalysed by IDH2, is converted back into citrate through the reversible mitochondrial 
aconitase enzyme. The citrate from the mitochondria is then transported into the cytosol, 
where ACLY converts the citrate into acetyl-CoA to be utilised in cholesterol synthesis, fatty 
acid synthesis and epigenetic changes (Schug et al. 2015). Thus, IDH2 is thought to be 
important for cell growth due to its effect on many cellular processes and involvement in 
the TCA cycle.  
IDH2 in primates, bats and cetaceans was shown to have a parallel evolution, because 
primates and cetaceans have larger brains in comparison to other species and bats 
locomotion of flight requires a high amount of energy. This parallel evolution indicated the 
importance of IDH2 in meeting the higher energy demand in different species (Ai et al. 
2014). Moreover, a study carried out in Saccharomyces cerevisiae showed that disruption 
of IDH2 resulted in its incapability to utilise acetate, glycerol or lactate (Cupp, McAlister-
Henn 1991). Collectively, it is unequivocal that nutrients and metabolism are inlfuencing 
epigenetics. This active relationship has been recognised and refered to as 
nutriepigenomics or nutritional epigenomics. Substainal evidence have been provided with 
DNA methylation analysis directly and actively correlating with the gene expression. 
However, locus specific DNA methylation studies are required to further extend our limited 
knowledge on the connection between nutrients, metabolism and the ‘Readers’ and 
‘Writers’ of epigenetics (i.e. DNMTs).  
Previous work from our group (Dr M Turner – Secondary supervisor) showed that HMGCR 
expression was downregulated in INS-1 cells treated with high levels of glucose and lipids 
(GLT). This HMGCR downregulation was associated with a reduction in insulin secretion. 
GLT and acetate have previously been shown to associate with diabetes. Moreover, 
glucose, lipids and acetate are known regulators of intracellular acetyl-CoA levels (Bagnati 
et al. 2016). In addition to being an important metabolic intermediate, acetate, contributes 
to unfavourable outcome in diabetes (Hameed et al. 2015). Herein, to characterise the role 
of acetate in the development of diabetes, INS-1 cells in acetate nutrient regime were 
investigated. Following the findings from INS-1 model, HeLa cells were characterised under 
the galactose nutrient regimes. 
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Figure 1.7: IDH2 mediated conversion of isocitrate into α-Ketoglutarate. IDH2 is located 
in the mitochondrial matrix, catalysing the reaction in TCA cycle. The enxymatic reaction 
catalysed by IDH2 converts Isocitrate to α-Ketoglutarate, with concomitant production of 
CO2 and NADPH from NADP+. 
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1.4. Aims and objectives of the thesis 
1.4.1. Aims 
• Assessing the role of acetate and galactose on epigenetics of selected genes 
(e.g. IDH2, insulin, NIX) in a diabetic and cancer model, respectively 
• Elucidating the effect of acetate and galactose on mitochondrial function and 
functional consequence of the cellular models (e.g. insulin synthesis, apoptosis 
and proliferation) 
• Characterising the modulation of cell cycle and associated proteins by acetate 
nutrient regime 
 
1.4.2. Objectives 
• Identifying potential mitochondrial associated genes regulated by acetate and 
galactose 
• Studying the potential role of IDH2 in regulating metabolism in terms of lactate, 
ATP content and mitochondrial function 
• Investigating the role of acetate and galactose in DNA methylation, histone 
acetylation and protein abundance of DNMT3a 
• Evaluating the role of promoter DNA methylation in regulating IDH2, insulin and 
NIX  
• Characterising the effect of nutrient regimes on DNMT3a 
• Evaluating effect of genetic interventions in diabetic and cancer cellular models, 
including the effect of IDH2 overexpression and dCAS9-TET mediated DNA 
promoter hydroxymethylation of IDH2  
• Evaluating the role of differential nutrient regime on insulin content in the 
diabetic model, and proliferation and apoptosis in cancer model 
• Evaluating the effect of acetate on regulating key metabolic proteins during cell 
cycle 
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CHAPTER 2: MATERIALS AND METHODOLOGY 
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2.1. Cell culture 
Three different cell lines were utilised in this research: HeLa, HEK293 and INS-1 cell lines. 
These cell lines were passaged at regular intervals in T25cm2, T75cm2 or T175cm2 tissue 
culture flasks with DMEM (Life Technologies UK) (HeLa, HEK293) or RPMI-1640 (Life 
Technologies UK) (INS-1) and maintained at 37°C with 5% CO2 in humidity. Cells were 
collected and counted using haemocytometer and 1% trypan blue (Life Technologies UK) 
for protein/DNA/RNA extraction. Insulin secreting cell line (INS-1 cells) established from an 
x-ray induced rat transplantable insulinoma (Asfari et al. 1992) (kindly provided by Dr M 
Turner) were cultured in RPMI-1640 (11mM Glucose + 10% Fetal bovine serum, and 1% v/v 
sodium pyruvate supplemented). Human embryonic kidney cell line (HEK293 cells) 
transformed with sheared AD5 DNA (Thomas, Smart 2005) and HeLa cells were cultured in 
DMEM (25mM Glucose + 10% Fetal bovine serum supplemented).  
Upon reaching 80-85% confluency, the cells were passaged. To passage, firstly the medium 
was removed, and cells were washed with prewarmed PBS (Life Technologies UK) twice for 
the removal of any residual FBS (Fetal bovine serum) (Life Technologies UK). Afterwards, 
1mL of trypsin-EDTA (for T75cm2) (Life Technologies UK) was added to the cells to ensure 
the complete coverage of culture flask surface area. The cells were then incubated at 37°C 
for 5 minutes and gently agitated. Following observations by Olympus inverted light 
microscope, 10 mL of media was added to the cells to neutralise trypsin-EDTA, followed by 
transfer to sterile 50 mL flacon tube and centrifugation at 200 x g for 5 minutes. Finally, the 
supernatant removed, pellet reconstituted, and cells passaged at a ratio of 1:3 (INS-1 cells) 
and 1:4 (HeLa and HEK293 cells). Cells were passaged for a maximum of 12 passages.  
Cells were stored/preserved using Synth-a-freeze media (Life Technologies UK) following 
manufacture’s instruction at a cell density of 2 x106 cells in cryovials. The cryovials were 
stored in -80°C freezer in a cryogenic freezing container overnight and then transferred to 
vapour phase of liquid nitrogen. To revive from frozen stock the cells were thawed at 37°C 
and added to pre-warmed media. Cells were then centrifuged and reconstituted in fresh 
media and replaced in a T75cm2 flask. 
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2.1.1. Acetate and Galactose treatments  
For acetate nutrient regime, INS-1 cells were cultured in T25cm2 flasks for 24 hours prior 
to subjecting with 5mM acetate. Sodium acetate (Sigma Aldrich) was prepared as 500mM 
stock and filtered using 0.2µm pore size filter. Thereafter, acetate was added to cultured 
cells at a concentration of 5mM for 48 hours in RPMI-1640 media. For galactose nutrient 
regime, HeLa cells were cultured in T25cm2 flasks for 24 hours prior to subjecting with 
25mM galactose DMEM media (Thermofisher-glucose negative media supplemented with 
galactose). HeLa cells were incubated in galactose nutrient regime for 2 or 5 days, and cells 
collected using the methodology described above (section 2.1). Following the nutrient 
regimes, cells were harvested for total DNA, RNA and protein, as instructed by the 
manufacturer (Qiagen),for downstream analysis.  
 
2.1.2. Cell transfection 
pcDNA3.1 IDH2v5 plasmid was co-transfected with green fluorescent protein (GFP) using 
Polyethylenimine (PEI) as per manufacturer’s guidelines (Figure 2.1). Prior to transfection, 
cells were seeded into 6 well plate at density of 3x105 cells/well and incubated in RPMI 
(INS-1) or DMEM (HEK293) media for 24 hrs to achieve 40% confluency. Cells were then 
transfected at 1:3 ratio of plasmid DNA:PEI (Sigma Aldrich) diluted in 250 µl Opti-MEM 
(Thermofisher) without serum. PEI/plasmid DNA mixture was then added to the cells and 
incubated at 37°C for 24 hours. Thereafter, cells were subjected to the selection process 
with 400 µg/mL G418 (Sigma Aldrich) for an additional 7 days, before being subjected to 
experiments. 
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Figure 2.1: Plasmid maps indicating restrictions digest enzyme sites in pcDNA3.1 IDH2v5 
and LentiGuide-Puro.  
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2.2. Gene expression: cDNA synthesis  
Typically, the cells were grown at density of 2.5 x 106 under the nutrient regimes, and were 
used to obtain RNA, extracted using an RNAeasy minikit (Qiagen) following the 
manufacturer's instructions. RNA concentration and quality were analysed by Nanodrop 
(Thermofisher). Total RNA (1µg) was reverse-transcribed using a High-Capacity cDNA 
Reverse Transcription Kits (Applied Biosystem) in combination with StepOneplus 7500 
(Applied Biosystem), with thermal cycler steps consisting of 10 minutes at 25°C, 2 hours at 
37°C and final 5 minutes at 85°C, followed by storage at -80°C until further use.  
 
2.3. Primer design for mRNA expression and DNA promoter analysis 
The primers used in this research for mRNA expression and DNA promoter analysis were 
designed using NCBI primer blast, IDT primer quest and Zymoresearch seeker primer 
designer software. The parameters for a set of primers included optimum Tm with a 
maximum difference of 1°C, primer length to be ideally between 15 to 25 nucleotides and 
optimum amplicon size between 80bp and 140bp (except for insulin mRNA, mitDNA and 
DNA methylation analysis primers(Figure 2.2), where the size span was extended to 220bp). 
Primers were designed to target different exons, and at least one primer from the pair to 
span an exon-exon junction (except for primers used in DNA methylation analysis (Table 
2.2)). Primers with GC content of 55% or more (exception for primers used in Bisulfite 
combined sequencing analysis), and maximum Self complementarity of ≤6.00, maximum 
Self 3'complementarity of ≤2.00 were selected (Table 2.1). The designed primers were 
generated by Sigma Aldrich with Synthesis scale of 0.05, Desalt purification, Dry format and 
diluted to 100µM in dH20 for final use in PCR and qPCR.  
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Figure 2.2: Schematic example of rat IDH2 targeted primer for DNA methylation analysis. 
The underscored nucleotides represent CpG islands found in the region. In red, the CCGG 
domain harbouring an internal CpG island, and susceptible to digestion by HpaII and/or 
MspI. Arrows indicate primer binding regions. 
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Table 2.1: Human and rat gene expression primer sequences 
Primer target Primer sequence Amplicon 
hIDH2 mRNA 
NM_002168.3  
AGACCGACTTCGACAAGAATAAG 
GACTGCACATCTCCGTCATAG 
127  
hBnip3 mRNA 
NM_004052.3  
TAGCTCCAAGAGCTCTCACT 
CTCTCCAATGCTATGGGTATCTG  
97  
hGAPDH mRNA 
NM_001256799.2  
CTAGCTGGCCCGATTTCTC 
GATGGCAACAATATCCACTTTACC 
122  
hTet2 mRNA 
NM_001127208.2 
AGGTTTGGACAGAAGGGTAAAG 
CGAACCACCCACTTAGCAATA 
104  
hLDHA mRNA 
NM_005566.4  
AGATTCCAGTGTGCCTGTATG 
ACCTCTTTCCACTGTTCCTTATC 
108  
hmitDNA* 
NC_012920.1 
CACCCAAGAACAGGGTTTGT 
TGGCCATGGGTATGTTGTTA 
108  
hnuc B2-mg* 
NM_004048.3 
TGCTGTCTCCATGTTTGATGTATCT 
TCTCTGCTCCCCACCTCTAAGT 
86  
hNix mRNA 
NM_004331.3 
GGAAGTCGAGGCTTTGAAGAA 
GTTTAGGGTGTCTGAAGTGGAA 
101  
rDNMT3a mRNA 
NM_001003958.1 
ACAGAGAAACCCAAGGTCAAG 
GGCTCCCACATGAGATACAAA 
115  
rHMGCR F 
NM_013134.2 
AAGAGTCGCTGTGTTCATCTC 
AAACTGCTCCCACACTCTAAG 
143  
rLDHA mRNA 
NM_017025.1 
TGGCTTGTGCCATCAGTATC 
CCATCATCTCTCCCTTTAGCTTATC 
93  
rHKII mRNA 
NM_012735.2 
ACTCAGCCCAGAACTCCTTA 
GCCTTCTCGATTCCATCCTTATC 
87  
rHKIV mRNA 
NM_001270849.1  
GGAAGACCTGAAGAAGGTGATG 
TCCCAGGTCTAAGGAGAGAAAG 
108  
rSlc16a1 mRNA 
NM_012716.2 
GACCAGTGAAGTGTCATGGAT 
CTGGACGGCTGCCATATTTA 
101  
rIDH2 mRNA 
NM_001014161.1  
CACTACCGAGAACACCAGAAG 
AGAGTCTGTGCAAACCTGATG 
134  
rInsulin mRNA 
NM_019129.3 
CCCTAAGTGACCAGCTACAATC 
GGACTTGGGTGTGTAGAAGAAA 
217  
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rmitDNA* 
KF011917.1 
CCTCCCATTCATTATCGCCGCCCTTGC 
GTCTGGGTCTCCTAGTAGGTCTGGGAA 
211  
rNuclear DNA* 
NC_005100.4  
TCCTCAAAGCAGCAGTAAGAC 
AGGGATTAAGGCGACGTTTC 
101  
*Primer sequence obtained from Rooney et al. (2015) 
(r=Rat, h=Human) 
 
Table 2.2: Human and rat DNA methylation analysis primers 
Primer target Primer sequence Amplicon 
rIdh2 DNA 
NC_005100.4 
GCTGTGCGGTGGGGACT 
TCCCGGGTGAGACCCAATG 
92 
rInsulin DNA 
NC_005100.4 
CCAGAACCTGTTTCCCAAAGT 
GTGCTTGATCTCTCCTGTTCTC 
92  
hIdh2 Primer 4 F 
NC_000015.10 
CCATGTAAACCTGGATGTCAGT 
TAATGCGCCTTTGGGTTCA 
108  
hBnip3CpG nF1 
NC_000010.11 
CCACTAGCAGGATGGAAAGAC 
GCCGGGTTCTCCTTTGAA 
112  
hNixV2 CG P1 F 
NC_000008.11 
TCTTCTATTTACCAGCACTTGATACTAC 
CTGAGCTTCAGCTTCCTCATTT 
93  
BiSulfite-rIDH2 DNA**  GGTTGTTTYGGTTAGTTGGGGATATTTAGTGTAG 
CCCRAACTCTAAAACAAACCCAAAACTATC 
298  
**Primer sequence designed using ZymoResearch Primer design seeker 
(r=Rat, h=Human) 
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2.4. Polymerase Chain Reaction (PCR) 
2.4.1. PCR, Gradient PCR and gel electrophoresis 
Primer efficiency and optimum annealing temperatures were determined using gradient 
PCR and gel electrophoresis analysis (Figure 2.3). PCR reactions were performed using Taq 
2x master mix (NEB) on a StepOnePlus 7500 (Applied Biosystems) with PCR cycling 
conditions of 30 second at 95°C (Initial denaturation), 30 cycles (denaturation, annealing 
and extension) of: 20 seconds at 95°C, 20 seconds at 59°C-62°C (depending on primers) and 
20 seconds at 68°C. Followed by the final extension for 5 minutes at 68°C. The PCR product 
was then resolved on 1.5% agarose gel (1.5g of agarose in 100mL of TBE buffer 1x with 10µl 
of SYBR safe-Invitrogen), and separated DNA bands were observed using Syngene 
InGenius3 Gel documentation system. 
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1: Ladder, 2: 55°C, 3: 56°C, 4: 57°C, 5: 58.5°C, 6: 59.5°C, 7: 60.5°C, 8: 62°C 
Figure 2.3: Gel electrophoresis analysis of gradient PCR carried out on rat HMGCR 
primers. Lanes 2-8 represent different annealing temperatures analysed for optimum 
amplification. The data obtained showed highest specificity at temperature 60.5°C for 
annealing. 
  
100 bp 
1000 bp 
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2.4.2. Real Time quantitative PCR (RT-qPCR) 
Following primer validation by gradient PCR, qPCR analysis was performed using 
Quantinova SYBR green master mix (Qiagen) on a StepOnePlus 7500 with qPCR cycle design 
consisting of 2 minutes at 95°C (Initial denaturation), 40 cycles (denaturation and combined 
annealing/extension) of: 5 seconds at 95°C and 15 seconds at 59°C-62°C (depending on 
primer). Followed by melting curve analysis consisting of 0.3°C/sec (changed from the 
default of 1°C/sec) rise in temperature to obtain a higher resolution of specificity and 
identity of qPCR product. Low concentration of ROX dye (passive reference dye) was used 
in the master mix (1:10 ratio) and pre-defined in the qPCR protocol in StepOnePlus 7500 
for the adjustment of background fluorescence in order to obtain normalisation of 
fluorescent signal. Expression of target genes was quantified and normalised to the internal 
housekeeping control GAPDH/18s, using 2-ΔΔCt comparison method, and results were 
presented as fold change relative to the control condition. Internal qPCR primer specificity 
was determined using melting curve analysis.  
 
2.4.3. Mitochondrial DNA copy number analysis by qPCR 
Optimised primer sequences for mitDNA analysis were obtained from Rooney et al. (2015). 
human mitDNA primers were normalised to human nuclear DNA primers, and rat mitDNA 
primers were normalised to rat DNA primers. 
 
2.4.4. Statistical analysis of RT-qPCR 
Initially, GAPDH and 18s reference genes were analysed to be used for statistical 
comparison of gene expression. The housekeeping gene with least standard deviation and 
closest ct value to target gene were selected. Statistical analysis of 2-ΔΔCt values was 
performed using GraphPad PRISM 7, where student's t-test was performed on the data 
obtained from two groups (e.g. control vs acetate treated) and one-way ANOVA analysis 
for the comparison of data obtained from multiple groups (e.g. control vs galactose 
treatment post 2 days vs galactose treatment post 5 days). P values obtained from the 
statistical analysis of <0.05 were considered to be statistically significant. 
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2.5. DNA Methylation analysis  
2.5.1. Me-DIP 
CpG islands on IDH2, NIX, BNIP3 and insulin promoter regions were identified using 
Genome Browser (GB) and specific qPCR primers sets were designed based on regions 
containing high frequency of CpG sites, both embedded or not, in CCGG motifs (Table 2.2). 
For methylation analysis, DNA was extracted using DNAeasy Kit (Qiagen) from cells under 
different nutrient regime. Afterwards, DNA was immunoprecipitated using 5-mC rabbit 
mAb (monoclonal antibody – Cell Signalling Technology) followed by qPCR determination 
to confirm promoter methylation of IDH2 and insulin.  
 
2.5.1.1. DNA Sonication 
The first step of Me-DIP analysis was to sonicate the DNA. 5µg of genomic DNA was eluted 
in 130µl buffer TE and placed in microtube (Covaris). The microtube was then placed in 
dH20 filled S-Series Covaris tank for acoustic shearing. To achieve the target peak of 300 bp, 
sonication was carried out for different durations (40, 55, 80 seconds) at 140W (Peak 
incident power) 10% duty factor and 150 – 250 cycles per burst. Subsequently, 
fragmentations of DNA were analysed by 1.5% agarose gel electrophoresis and visualised 
using Syngene InGenius 3 gel imager (Figure 2.4). Adequate sonication setting was selected 
according to gel electrophoresis, and optimised conditions were used in the experimental 
repeats. 
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1: Ladder, 2: Sonicated DNA for 80 seconds, 3: Non-sonicated DNA, 4: Sonicated DNA for 55 
seconds, 5: Non-sonicated DNA, 6: Sonicated DNA for 40 seconds 
Figure 2.4: Gel electrophoresis analysis of sonicated DNA for 40 – 80 seconds. 5µg of DNA 
was sonicated using Covaris S-series at 140W and 150-250 cycles per burst. ~300ng of DNA 
was loaded onto the 1.5% agarose gel and analysed alongside non-sonicated DNA. The 
desired size of sheared DNA (400-700 bp) with the highest intensity was obtained from 80 
seconds bursts. 
 
 
  
100 bp 
1000 bp 
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2.5.1.2. DNA Immunoprecipitation and qPCR 
For immunoprecipitation, protocol from the manufacturer was followed (NEB – MeDIP Kit). 
Briefly, DNA was denatured to obtain single stranded product and incubated with mAb 
against 5-mC for immunoprecipitation (IgG mAb Isotype control was used as a negative 
control – Cell Signalling Technology). Initially, 5-mC antibody or IgG Isotype control was 
added to samples and incubated overnight at 4°C. Thereafter, ChIP grade magnetic beads 
(Cell Signalling Technology) in combination with magnetic separation rack was used to 
precipitate antibody bound DNA (5-mC rich DNA fragments). The elution of DNA was 
carried out using Thermomixer at 65°C for 30 minutes. Beads were separated by magnetic 
rack, and eluted DNA obtained. Once the DNA was purified and isolated from mAb and 
beads, qPCR quantification was carried out. An 10% DNA input reaction was carried out 
alongside as a control measure to assess immunoprecipitation efficiency determination, in 
addition to IgG isotype control and qPCR negative control (without DNA) (Figure 2.5). 
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Figure 2.5: Overview of MeDIP combined qPCR methodology for the analysis of DNA 
methylation (5mC). Initially, genomic DNA is sonicated into fragments of ~300bp and 
denatured into single strands. Antibody directed against the methylated cytosines is then 
employed to immunoprecipitate 5mC using magnetic beads. Subsequently, purified DNA is 
quantified using qPCR, with primers specific for the target genes.  
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2.5.2. DNA methylation analysis by SREMA 
DNA methylation assessed using sensitive restriction enzyme methylation analysis (SREMA) 
was carried by digesting 1µg of DNA with the methylation-sensitive enzyme HpaII (5 Units) 
(NEB) (isolated from E. coli strain carrying the gene from Haemophilus parainfluenzae) for 
5 hrs at 37°C. HpaII, is a sequence specific restriction enzyme that cleaves the C^CGG sites 
when the internal cytosine in CCGG motif is unmethylated. Following HpaII digestion, the 
enzyme was heat-inactivated at 85°C for 20 minutes. Then, the resulting fragments were 
analysed by qPCR, assessing a subset of gene promoter CCGG sites in the genes (IDH2, NIX, 
BNIP3 and insulin). Finally, promoter methylation status was normalised to the 
quantification of a region of DNA lacking the CCGG motifs, and data presented relative to 
control condition. 
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Figure 2.6: Overview of SREMA combined qPCR methodology for the analysis of DNA 
methylation. HpaII is a methylation-sensitive enzyme that targets CCGG nucleotide 
sequence; which will cut the CCGG sites only in the absence of DNA methylation, whereas 
the action of this enzyme is blocked by methylated cytosines. The product from the HpaII 
restriction digest reaction is then quantified using qPCR, with primers targeting specific 
gene promoter region. 
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2.5.3. DNA Hydroxymethylation analysis by SREMA 
Hydroxymethylation status of IDH2 and NIX was analysed by modified SREMA analysis, 
using differential methylation analysis employing isoschizomers MspI and HpaII restriction 
enzymes. Genomic DNA from HeLa was initially treated with T4-BGT: converting the 
hydroxymethylated CpG sites to glucosylated CpG sites (5-ghmC) in a sequence 
independent manner, which in turn prevents cleavage by MspI. MspI acts in a sequence-
dependent manner (C^CGG), cleaving 5-mC and 5-hmc, but not 5ghmC. Whereas, HpaII 
cleaves only unmodified cytosine, but not 5-mC, 5hmC and 5-ghmC. Following MspI and 
HpaII digestion, the enzymes were treated with proteinase k. Then, the resulting fragments 
were analysed by qPCR, assessing a subset of gene promoter CCGG sites in the genes (IDH2 
and NIX). Finally, promoter hydroxymethylation status was normalised to the 
quantification of a region of DNA lacking the CCGG motifs, and data presented relative to 
control condition. 
 
2.5.4. DNA Methylation analysis by Bisulfite combined Sequencing  
2.5.4.1 Bisulfite combined sequencing and primer design 
Bisulfite treatment of the DNA converts the unmethylated cytosines to uracil and then to 
thymines in the PCR reaction. Therefore, in order to design the primers according to the 
converted DNA sequence, Zymoresearch bisulfite primer seeker software was utilised. The 
first primer in the pair of primers was designed to target the bisulfite converted sequence 
and the second primer in the pair is designed towards the sequence of the amplicon 
generated by the first primer. Due to lesser GC content in the converted DNA, the primer 
Tm was compensated by increasing the length of the primers. Bisulfite conversion of DNA 
from cells was carried out using EpiMark Bisulfite conversion kit (NEB) following 
manufacturer’s instructions.  
 
2.5.4.1 PCR and purification of amplicon 
Following bisulfite treatment, the converted DNA was then used as a template and 
amplified using PCR with specific bisulfite primers. PCR product was resolved on 1.5% 
agarose gel using electrophoresis. PCR amplicon was purified from agarose gel using QIprep 
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miniprep (Qiagen), following manufacturer’s instruction. The purified product was 
analysed using Nanodrop, subsequently sequenced by Sanger sequencing. Data from 
sequencing was analysed using TIDE software. 
 
2.6. Protein extraction and determination 
Proteins were extracted using RIPA lysis buffer (Thermofisher) supplemented with Protease 
inhibitor (Roche Applied Sciences). Following the appropriate nutrient regime incubation 
and pelleting (as explained above), the cells were resuspended in PBS and counted using 
haemocytometer. 5x104 cells were transferred to 1.5mL Eppendorf tube and centrifuged 
at 200 x g for 5 minutes. Thereafter, cells were resuspended in 400µl of cold RIPA buffer 
and incubated on ice for 30 minutes. Cells were then centrifuged at 14,000 x g for 30 
minutes to pellet the cell debris, and protein containing supernatant was then collected. 
Protein determination was carried out using BCA Assay Kit (Thermofisher) and Bio-Rad 
iMark Microplate absorbance reader. BSA standards were used to generate a standard 
curve and determine protein concertation in a 96-well plate. 25 µl of collected samples 
were added to each well in triplicates, followed by addition of 200 µl BCA working reagent. 
Finally, the 96-well plate was incubated for 30 minutes at 37°C and colourimetric analysis 
carried out at 595nm. 
 
2.7. Western blotting analysis and Densitometry 
For western blotting, 20µg of proteins from appropriate samples were subjected to 95°C 
heating for 5 minutes with laemmli buffer (NEB) and separated by SDS-page on Bio-Rad 
gradient pre-cast gels. Separation of proteins was achieved by running the gel at 150 volts 
for 1 hour. After the resolution by SDS-Page, proteins were transferred onto PVDF-
membrane (BioRad) (activated in methanol) using Bio-Rad Trans blot. The membrane was 
then incubated in 10% blocking buffer for 1 hour at room temperature. Thereafter, the 
membrane was incubated with the appropriate primary antibody overnight at 4°C (Table 
2.3). On the subsequent day, the membrane was washed three times in TBST and incubated 
with appropriate secondary antibody at room temperature for 1 hour, followed by three 
more washes with TBST (10 minutes each). Lastly, the membrane was visualised using Bio-
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Rad ECL detection reagent on LAS-3000 Fuji Imager. Subsequently, the process was 
repeated for control (e.g. GAPDH-Sigma Aldrich) protein expression analysis. 
The image obtained from Fuji Imager was uploaded to ImageJ and converted to 8-bit 
format. Appropriate sections were selected using ‘Rectangular’ selection tools and plot 
profile formed. The background intensity was subtracted from the selection by ‘Straight 
line’ selection. Following the selection, intensities of the area were measured with the 
‘Wand’ tool and data obtained analysed as a fold change. 
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Table 2.3: Antibodies used for Western Blot analysis 
Target Source Dilution 
IDH2 Protein Tech 1:500 
DNMT3a Santa Cruz Biotechnology 1:1000 
GAPDH Abcam 1:10,000 
mtCOI Abcam 1:1000 
mtCOII Abcam 1:1000 
NIX Santa Cruz Biotechnology 1:500 
Bnip3 Cell Signalling Technology 1:500 
β-actin Abcam 1:10,000 
Acetylated Histone 3 Active Motif 1:1000 
Acetylated Histone 4 Active Motif 1:1000 
Histone 3 Total Active Motif 1:500 
Histone 4 Total Active Motif 1:500 
Cdh1 Calbiochem 1:1000 
Acetylated IDH2  GeneTel Laboratories LLC 1:1000 
5-mC Cell Signalling Technology 1:50 
IgG Cell Signalling Technology 1:50 
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2.8. Cell cycle co-ordination and Flow cytometry analysis 
HeLa cells were coordinated with 0.1 µg/mL Nocodazole (NCZ) for 14 hours to achieve cell 
cycle synchronisation, thereafter, the cells were released in standard DMEM media. In 
order to assess the effect of acetate on cell cycle, the coordinated HeLa cells were released 
in either glucose or 5mM acetate media. The cells were then collected at 0, 4, 8 and 12 
hours post-release from NCZ. Flowcytometry analysis was carried out by pelleting NCZ 
coordinated 1×106 cells and fixing at 80% methanol at −20 °C for overnight. Thereafter, cells 
were removed from methanol by centrifugation, and resuspended in 50 μg/mL propidium 
iodide (PI) containing PBS. 200 µl of HeLa cells (fixed and stained) were diluted as 1:5 in PBS 
prior to subjection onto flow cell to obtain 1x106 cells/mL concentration. Cell cycle analysis 
was carried out with Merck MUSE analyser by quantifying the populations in G1, S and 
G2/M, following manufacturer’s instructions. 
In order to determine the protein content and acetylation during cell cycle. The 
coordinated HeLa cells were subjected to protein extraction (as describe in section 2.6) at 
0, 4, 8 and 12 hours post release into DMEM. The extracted proteins were then analysed 
by western blotting.  
 
2.9. Metabolite determination 
2.9.1. ATP assay 
To determine ATP levels of INS-1 cells treated w/wo 5mM acetate, a Firefly luciferase 
(Photinus pyralis) based assay was employed. Protocol from the manufacturer was 
followed (PerkinElmer – ATPlite assay). Briefly, 100µl of cells alongside ‘Mammalian cell 
lysis solution’ were added to 96 well plate to lyse and stabilise. After adding the substrate 
solution consisting of Luciferase, the plate was ‘dark’ adapted for 10 minutes, and finally 
the luminescence was measured. Data obtained was then normalised to proteins per µg 
(determined using BCA kit as described above). 
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2.9.2. Lactate assay 
HeLa and INS-1 cells were grown in 6 well plate at 1x106 cells/well in DMEM for 24 hours. 
Thereafter, cells were subjected to the appropriate nutrient regime. Following treatment 
of cells with acetate (INS-1 cells) or galactose (HeLa cells), the culture media was collected. 
Lactate assay (Trinity Biotech) was utilised in the analysis of lactate production by the cells 
under different nutrient regime. The assay was carried out in 96 well plate, generating a 
standard curve by lactate reagent and standards provided with the kit; where lactate 
oxidase converted the lactic acid to pyruvate and hydrogen peroxide, which was then 
measured. 10µl of the sample was added to plate alongside lactate reagent and incubated 
for 10 minutes at room temperature, thereby reaction was analysed at 540 nm on Bio-Rad 
iMark microplate reader. The data collected was ‘Blank’ adjusted and normalised to protein 
per µg. 
 
2.9.3. -Ketoglutarate assay 
Intracellular -KG levels of INS-1 (w/wo acetate) and HeLa (w/wo galactose) were 
measured using -ketoglutarate Assay Kit (Abcam). Cells were seeded at a density of 1x105 
cells/well in 6 well plate under the nutrient regimes. Cells were then washed with cold PBS 
(stored at 4°C before use) and resuspended in assay buffer on Ice. After centrifugation 
supernatant was collected and subjected to deproteination by Perchloric acid (4M and ice 
cold). Thereafter, samples added to a 96 well plate alongside reaction mix and fluorescence 
of the cells was examined using BMG Labtech ClarioSTAR at Ex/Em 535/587. 
 
2.10. Apoptosis and Necrosis assay 
Apoptosis and Necrosis of HeLa cells was evaluated using Apoptosis/Necrosis kit (Abcam) 
utilising apoxin green for apoptosis and 7-AAD for necrosis. Cells were seeded at a density 
of 1x105 cells/well in 96 well w/wo 25mM galactose for a total of 5 days. Culture media 
decanted and cells were washed with assay buffer. The cells resuspended in 200 µl of assay 
buffer and subjected to 2 µl Apopxin green, 1 µl of CytoCalcein and 1 µl of 7-AAD. 
Thereafter, cells were incubated at room temperature for 1 hour and the assay buffer was 
replaced. Finally, the fluorescence of the cells was examined using BMG Labtech ClarioSTAR 
at Ex/Em 490/525 (apoptosis) and 550/650 (necrosis).  
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2.11. Proliferation assay 
Proliferation analysis of galactose treated HeLa cells was evaluated using WST-1 assay 
(Sigma Aldrich), following manufacturer’s instructions. Briefly, cells were seeded at a 
density of 1x105 cells/well in 96 well w/wo 25mM Galactose for a total of 5 days. WST-1 
was added and incubated at 37°C. Cell proliferation analysed after 1 hour of incubation 
with Bio-Rad Microplate reader at 415nm. 
 
2.12. Insulin content analysis by ELISA 
INS-1 cells were passaged in 6-well plates at the density of 1 x 106 cells/well and grown for 
24 hours prior to the differential nutrient regime (i.e. acetate). After 24 hours of acetate 
treatment, 2 mL of Krebs-Ringer Modified Buffer (KRB) consisting of 20mM KCl and 400mM 
NaCl was added for 2 hours directly to the existing 2 mL of RPMI media and incubated at 
37°C with 5% CO2. Following the completion of 2-hour incubation, the media was replaced 
with standard RPMI or RPMI+5mM acetate. Total insulin content was quantified using an 
Insulin ELISA kit (Mercodia). Cells were lysed as described before with RIPA, and clarified 
supernatant was used for insulin content determination using anti-insulin antibody coated 
ELISA plate. Insulin content was normalised to protein concentration, using BCA kit 
(Thermofisher).  
 
2.13. Modulation of hydroxymethylcytosine levels in the IDH2 promoter by dCAS9-
Tet1CD 
Fuw-dCas9-Tet1CD, a gift from Rudolf Jaenisch (plasmid # 84475, (Liu et al. 2016)) and 
lentiGuide-Puro, a gift from Feng Zhang (plasmid # 52963, (Sanjana et al. 2014)) were 
obtained from Addgene. Suitable guidance RNA sequences targeting the IDH2 promoter 
(Figure 2.7) region were designed using the online tool E-CRISP (E-crisp.org, (Heigwer et al. 
2014)). Selected candidate sequences were cloned into the pLentiPuroGuide following 
instructions described by Sanjana et al. (2014). HEK293 cells were transfected with a 
combination of both plasmids (or alternatively with an empty pLentiPuro-guide in control 
cells) using a PEI protocol as outlined in section above. Finally, transfected cells were 
selected for 48 hours in 1 µg/mL of puromycin and then, used for DNA and proteins 
58 
 
analysis. Hydroxymethylcytosine content was evaluated using an SREMA 5-hmC protocol 
as described above. 
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Figure 2.7: Plasmid maps indicating restrictions digest enzyme sites in Fuw-dCas9-Tet1CD.  
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Figure 2.8: Schematic representation of the mechanism of action of dCAS9-Tet1CD and 
the small guidance RNA. The IDH2 locus is recognized by the specific identification of the 
hybrid sgRNA + DNA target. The Tet1CD domain modifies all the methylcytosines in the 
boundaries of the dCAS9 binding site into hydroxymethylcytosine residues. Panel B: 
Targeted sequence in the IDH2 promoter region for dCAS9-Tet1CD + sgIDH2 RNA. Sequence 
highlighted in green is the specific guidance RNA sequence recognized in the IDH2 
promoter. Underscored nucleotides are the CpG islands in the sequence. Sequence in red 
indicates the CCGG domain used for SREMA hydroxymethylation analysis. Arrows indicate 
primer sequences used for qPCR analysis. Blue sequence indicates Protospacer adjacent 
motif (PAM) sequence. 
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2.14. Mycoplasma testing 
All cells used in the research were regularly tested for Mycoplasma infection using EZ-PCR 
Mycoplasma Test Kit (BioInd). PCR in combination with 1.5% agarose gel electrophoresis 
was utilised for this testing methodology. Supernatant from cell culture media was 
collected after at least 48 hours of incubation of cells at 37°C with 5% CO2. The supernatant 
was briefly centrifuged at 250 x g to pellet cell debris, and the supernatant transferred to 
fresh tube. After sedimentation of potential mycoplasma by centrifugation at 14,000 x g 
for 10 minutes, the supernatant was decanted, and any remaining pellet resuspended in 
50µl of buffer solution provided with the kit. The solution was heated at 95°C for 3 minutes 
and subjected to PCR with the following cycling conditions: 30 second at 94°C (Initial 
denaturation), 35 cycles (Denaturation, Annealing and Extension) of: 30 seconds at 94°C, 2 
minutes at 60°C and 20 seconds at 72°C. Followed by final denaturation, annealing and 
extension for 30 seconds at 94°C, 2 minutes at 60°C and 5 minutes at 72°C. The PCR product 
was then resolved on 1.5% agarose gel (1.5g of agarose in 100mL of TBE buffer 1x with 10µl 
of SYBR safe-Invitrogen) and separated DNA band with the size of 270bp were observed 
using Syngene InGenius3 Gel documentation system. This reaction was carried out 
alongside positive control templates provided by the manufacturer. 
 
2.15. General statistical analysis 
All statistical analyses were performed using Microsoft Excel and GraphPad Prism 
(GraphPad Software Inc.), where student's t-test was performed on the data obtained from 
two groups (e.g. control vs acetate treated) and one-way ANOVA analysis for the 
comparison of data obtained from multiple groups (e.g. control vs galactose treatment post 
2 days vs galactose treatment post 5 days). Data was expressed as means ± standard error 
of the mean (SEM). A p value of <0.05 was considered to be statistically significant. 
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CHAPTER 3: THE EFFECT OF ACETATE ON EPIGENETICS AND 
METABOLISM IN THE DIABETIC MODEL INS-1 
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3.1. Introduction 
 
The number of adult patients reported globally with diabetes have increased radically in 
the last few decades from 108 million in 1980 to 422 million at present, with expected 193 
million undiagnosed cases. Although population increase and the rising number of ageing 
population may account for some of this increase, but it does not explain the near four-
fold rise in diabetes prevalence. By 2030, Diabetes is predicted to be one of the top 10 
causes of morbidities, with globally rising costs of care (Ang 2018). More than 90% of 
diabetic cases are T2D. The underlying characteristics of T2D, include insulin deficiency in 
pancreatic β-cells, insulin resistance in targeted organs, β-cell failures/loss, 
hyperinsulinemia, hyperglycaemia, increased platelet reactivity and fibrinolysis (Chatterjee 
et al. 2017). In order to manage these complications, the current first-line therapy for T2D 
is metformin, which reduces glucose output from the liver, stimulates Glucagon like 
peptide-1 (GLP-1) secretion and enhances peripheral tissue sensitivity (DeFronzo et al. 
2016). However, there are number of complications arising from the use of metformin, 
including chronic kidney disease, vitamin B12 deficiency and GI difficulties (Rena et al. 
2017). Additionally, caloric intake control and bariatric surgery may also be explored for 
diabetes remission. However, both options are difficult to implement on wide-scales and 
growing numbers of diabetic patients. Currently emerging T2D treatment strategies, 
include stem cell therapy aimed at increasing or replacing the lost β-cell volume, and bionic 
pancreas therapy to regulate the insulin levels (Chatterjee et al. 2017).  
Different types of diabetes are differentiated into Type 1 Diabetes, T2D and 
Monogenic/MODY (Mature onset of diabetes of the young). Recently, this differentiation 
has been challenged by the increasing number of T2D cases diagnosed at a young age. The 
changes in lifestyle and diet have been suggested to play an important role in the onset of 
T2D in younger population, but there is a lack of molecular and biochemical evidence to 
support this statement (Chatterjee et al. 2017). Additionally, diabetic patients have been 
shown to be affected by hyperglycaemic associated complications, even when their blood 
glucose is mostly controlled by therapeutic approaches (Katada et al. 2012). Collectively, 
these findings suggest certain metabolic reprogramming and/or epigenetics could play a 
key role in the development of these complications. In some cases, T2D patients have been 
shown to achieve remission of the disease, which further indicates the role of reversible 
epigenetic modifications. Remission is defined by the control of blood glucose levels 
64 
 
without pharmacological or surgical interventions; fasting glucose of 5.6 mmol/l for at least 
1 year (Buse et al. 2009). 
 
3.1.1. Diabetes and Epigenetics 
Environmental and nutritional factors have been suggested to drive epigenetics and 
therefore alter disease susceptibility. Genome wide association studies analysing T2D 
heritable genetic markers, such as nucleotide polymorphism, were only able to identify a 
small number of genetic markers (Prasad, Groop 2015). Dayeh et al. (2014) identified 16 
T2D associated CpG Single nucleotide polymorphisms (SNPs), that were targeted DNA 
methylation sites. SNPs at CpG islands deregulate the methylation at the site it occurred 
on, and the methylation levels at nearby CpG sites. Davegårdh et al. (2018)  correspondingly 
reported 40 SNPs that were strongly associated with T2D. From these 40 SNPs, 19 CpG sites 
were associated with aberrant methylation. DNA methylation also plays a significant role 
in regulating mitochondrial genes. For example, the aberrant DNA methylation of CIX7A1, 
known to be regulated by PGC1-α (master regulator of mitochondria), was associated with 
ageing and diabetes in mouse models (Ling, Groop 2009). These findings indicate that the 
DNA methylation mediated deregulation of mitochondrial associated genes can be 
involved in diabetes pathogenesis. Collectively, these findings suggest a potential role for 
DNA methylation in the pathogenesis of T2D; however, further research is required to 
understand the underlying mechanism that regulate this epigenetic change in diabetes. 
Other factors known to regulate epigenetics, including diet (e.g. acetate, glucose and fatty 
acids), physical inactivity, age and obesity; are emerging as key regulators of diabetes and 
mitochondrial diseases, emphasising the importance of epigenetic changes in gene 
regulation of T2D (Davegårdh et al. 2018).  
 
3.1.2. Insulin synthesis 
Until the isolation of insulin, the management of young diabetic insulin dependent patients 
was carried out using Frederick Allen's starvation diet. Following the isolation of insulin (by 
Banting and colleagues in 1921) for treatment of these patients, the management of insulin 
dependent diabetes became manageable (De Meyts 2004). This discovery led to improved 
understanding of insulin and insulin-receptor biochemistry and structure. Monomeric 
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insulin consists of two chains, Chain A and B consisting of 21 and 30 amino acids, 
respectively, linked by three disulphide bonds. The secondary structure of the B chain 
contains β-sheets and α-helices (Fu et al. 2013). In β-cells, insulin (approximately 40mM) is 
stored in dense and clustered granules, containing insoluble crystalline hexamers (De 
Meyts 2004). Insulin is a small protein (5.8 kDa) consisting of 51 amino acids that forms a 
complex secondary and tertiary structures with evolutionarily conserved regions 
throughout the phylogeny tree among different species (Fu et al. 2013). These conserved 
regions have been shown to play an important role in insulin-receptor binding affinity. 
Interestingly, the insulin gene codes for 110 amino acids that translates into preproinsulin 
consisting of hydrophobic N-terminal signal peptide. The role of this peptide is to interact 
with signal recognition particles from the cytosolic ribonucleoprotein resulting in the 
translocation of preproinsulin through rough ER to the lumen, subsequently, leading to the 
cleavage of the signal peptide by signal peptidase. This cleavage results in the formation of 
proinsulin, which folds and forms three disulphide bonds and is then transported to Golgi 
apparatus where proinsulin is packed into the immature secretory vesicles and is cleaved 
to yield C-peptide and insulin. Finally, insulin and C-peptides are stored as granules ready 
to be secreted (Fu et al. 2013). 
 
3.1.3. Nutrients and Diabetes 
Maintaining the insulin storage in pancreatic β-cells depends on the expression of the 
insulin gene. Moreover, metabolism plays an essential role in the biosynthesis of insulin, 
especially glucose metabolism, a well-known regulator of insulin transcription and 
translation. The promoter region of insulin gene has been shown to play a key role in the 
biosynthesis of insulin. Several transcription factors involved in the gene expression 
regulatory network interact with the insulin gene promoter region and thereby control its 
expression. In terms of pancreatic β-cell’s insulin regulation by metabolism, glucose 
metabolism controls preRNA splicing and mRNA stability, in addition to regulating histone 
methylation and acetylation: which has been suggested to play an important role in the 
regulation of insulin gene expression (Poitout et al. 2006). The stabilisation of insulin mRNA 
serves as an crucial step in controlling its gene expression, which has been proposed to be 
mediated via the action of glucose-regulated pyrimidine-rich sequence binding with 
polypyrimidine tract-binding protein; the pyrimidine-rich sequence lies in the 3’-UTR of 
insulin mRNA (Tillmar et al. 2002).  
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The high concentrations of glucose, termed glucotoxicity, can also dysregulate the insulin 
gene expression. Glucotoxicity of pancreatic β-cells has previously been shown to impair 
insulin gene expression. It was also shown that the mechanism involved in glucotoxicity-
mediated insulin dysregulation is carried out in a number of ways, including binding 
impairment of transcription factors, oxidative stress and dedifferentiation of pancreatic β-
cells. The glucotoxicity mediated dedifferentiation occur as a result of large number of gene 
dysregulation, specifically genes involved in defining β-cell and its functionality. Another 
form of β-cell toxicity is mediated by high concentrations of lipids or fatty acids, termed 
lipotoxicity, that can also dysregulate the insulin gene expression. Lipotoxicity has been 
suggested to dysregulate insulin, at least partly, through a shared mechanism with 
glucotoxicity; hence the combination of both, i.e. high concentrations of glucose and lipids; 
glucolipotoxicity (GLT) was shown to hinder the insulin content and secretion by pancreatic 
β-cells (Poitout et al. 2006). 
In addition to glucose and fatty acids, acetate was shown to correlate with the progression 
of diabetes. The sources of acetate include the breakdown of dietary fibres by gut 
microbiota either by acetogenesis or saccharolytic fermentation, through lumen and colon 
bacteria mediated fermentation resulting in short-chain fatty acids acetate, from diary and 
meat products (Schug et al. 2016; Schug et al. 2015). Akanji et al. (1989) demonstrated an 
impairment in acetate metabolism of diabetic patients, which exhibited relatively higher 
fasting plasma acetate levels in comparison to control. In addition, it was also shown by 
Hameed et al. (2015) that acetate contributes to unfavourable outcome in diabetes, by 
regulating Free fatty acid receptor 2 (FFAR2), known factor of diabetes pathogenesis. 
Furthermore, acetate was previously identified as a major carbon source for yeast and 
bacteria, and recently, was shown to be utilised as an alternative carbon source in humans 
along with glutamine, glucose and fatty acids (Gao et al. 2016). For example, acetate can 
be ligated to coenzyme A forming acetyl-CoA, that plays a central role in various 
intermediary metabolic pathways. This ligation is mediated by three isoforms of 
mammalian Acyl-CoA synthetase (ACSS) (figure 3.1) located at nuclear/cytoplasm (ACSS2) 
and mitochondrial (ACSS1/ACSS3) (Lyssiotis, Cantley 2014). The ACSS-mediated generation 
of acetyl-CoA plays a central role as a metabolite linking glycolysis to TCA cycle. Acetyl-CoA 
is a also a major component, widely involved in the PTM of proteins and histones, and 
synthesis of ketones, hexosamines and sterols (Schug et al. 2016).  
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Previous work from our group (Dr M Turner – Secondary supervisor) showed that HMGCR 
expression was downregulated in INS-1 cells treated with high levels of glucose and lipids 
(GLT). This HMGCR downregulation was associated with a reduction in insulin secretion. 
GLT and acetate have previously been shown to associate with diabetes. Moreover, 
glucose, lipids and acetate are known regulators of intracellular acetyl-CoA levels (Bagnati 
et al. 2016). In addition to being an important metabolic intermediate, acetate, contributes 
to unfavourable outcome in diabetes (Hameed et al. 2015). Herein, to characterise the role 
of acetate in the development of diabetes, INS-1 cells in acetate nutrient regime were 
investigated. 
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Figure 3.1: Schematic diagram depicting the function and metabolic fate of acetate in 
mammalian cells. The monocarboxylate transporter mediates the transfer of acetate from 
extracellular environment into the cell. Acetate can then serve as a metabolic source that 
can be transported into the mitochondria or directly converted into acetyl-CoA by the 
cytosolic ACSS2. Mitochondrial acetate can be converted into acetyl-CoA via ACSS1. Acetyl-
CoA in the mitochondria can then join the TCA cycle for oxidation, and before getting 
catalysed by IDHs, can be exported into cytosol by Citrate-Malate shuttle. Exported citrate 
is then converted into acetyl-CoA by ACLY. (ACSS: Acyl-CoA Synthetase Short Chain Family 
Member (1 and 2), ACLY: ATP citrate lyase) 
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3.2. Aims of Chapter 3: Diabetic Model/INS-1 cells 
• Evaluating the role of acetate in regulating key metabolic genes involved in 
mitochondrial function  
• Characterising the effect of acetate on promoter DNA methylation of the IDH2 
and insulin gene 
• Characterising the cellular content of insulin following acetate nutrient regime 
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3.3. Results 
 
Insulin secreting cells INS-1 β-cells were subjected to acetate nutrient regime for 2 days. 
RT-qPCR and western blotting were utilised to assess the impact of acetate treatment on 
the gene expression profile. Initially, cells were grown in 5mM acetate and number of 
metabolically relevant genes were analysed for mRNA expression. The genes with 
significant regulation under acetate nutrient regime were selected for further analysis. 
Subsequently, protein expression, DNA methylation and functional consequence of the 
modulated genes were investigated. In order to examine the DNA methylation status of 
acetate treated INS-1 cells, MeDIP, SREMA and Bisulfite combined sequencing were 
employed. 
 
3.3.1. Assessment of gene expression profiles in acetate treated INS-1 cells 
The regulation of HMGCR in acetate treated INS-1 cells was investigated using RT-qPCR. 
After establishing the impact of acetate treatment on the expression of HMGCR, a number 
of other key metabolic genes, including IDH2, HKII, HKIV, LDHA and Slc16a1, known to 
associate with diabetes, were also assessed. The primer specificity for the candidate genes 
were evaluated using gradient PCR, and further confirmed by melting curves. The optimal 
annealing temperature were then selected and used in downstream mRNA analysis using 
RT-qPCR.  The RT-qPCR data showed a significant regulation in the mRNA expression of 
HMGCR (0.6 fold), IDH2 (0.6 fold) and LDHA (3.7-fold) in acetate treated INS-1 cells relative 
to control treatment (glucose). The IDH2 protein expression was confirmed using western 
blotting, demonstrating a significant downregulation by 0.7-fold (Figure 3.2B).  
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Figure 3.2: The effect of acetate on the expression of IDH2, HMGCR, HKII, HKIV, LDHA and 
SLC16a1. (A) mRNA expression levels of IDH2, HMGCR and LDHA were significantly 
regulated in INS-1 cells subjected to acetate nutrient regime. (B) IDH2 protein expression 
was significantly reduced in INS-1 cells subjected to acetate, relative to control (glucose). 
The average mRNA expression levels were normalised to GAPDH. Western blotting of IDH2 
was normalised to GAPDH. Values are mean ±SEM (n=3), *P<0.05 (Glu: Glucose 11mM, Ace: 
Acetate 5mM).  
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3.3.2. DNA methylation analysis of the IDH2 promoter region 
In order to examine the relationship between gene expression and promoter DNA 
methylation status of IDH2, the target CpG and CCGG dinucleotide islands were identified 
using UCSC Genome browser (GB) (March. 2012 assembly genome (NCBI Assembly ID: 
382928) (Rnor_5.0)) (Figure 3.3A). Using GB, the range of potential CpG and CCGG islands 
were mapped on the promoter region within -1200 bp from gene transcription start site 
(TSS) (according to the default reference genome build). It was also indicated by GB, that 
the majority of target CpG and CCGG islands were located within -200 bp from the TSS of 
IDH2. Notably, five CCGG islands were identified within the high frequency region (-200 bp 
from TSS) and were further subjected to DNA methylation analysis (Figure 3.3B). 
 
3.3.2.1. DNA methylation analysis of IDH2 by SREMA 
Initially, to examine promoter DNA methylation of IDH2, a methodology combining the 
action of specific restriction enzyme (i.e. HpaII) with qPCR was employed. Briefly, primers 
designed to target the amplification of different IDH2 promoter regions containing a CCGG 
island were utilised in SREMA assay. Specificity of primers used in SREMA were validated 
by detection of unique amplicons in agarose gel electrophoresis and qPCR melting curves. 
After selecting the optimal primers for qPCR, the analysis of IDH2 was carried out alongside 
a control primer designed to target the genomic region excluding any CpG islands (non-CpG 
primers). The data obtained from SREMA analysis showed that acetate nutrient regime 
increases DNA methylation of IDH2 promoter region. This observation was depicted in 
acetate treated INS-1 cells, where significantly increased levels of 5-mC content were 
detected relative to control cells (Figure 3.3C). Also, no change was observed in the region 
targeted by non-CpG control-primers. The overall promoter methylation status of IDH2 
using SREMA was significantly increased by 6-fold in acetate nutrient regime of INS-1 cells. 
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3.3.2.2. DNA methylation analysis of IDH2 by Me-DIP 
The IDH2 DNA methylation status was further confirmed by an independent method, Me-
DIP. This method is based on antibody (5-mC) DNA precipitation. The precipitated 
methylated DNA was thereafter analysed using qPCR to quantify the methylated CpG 
islands in acetate treated INS-1 cells. Briefly, total DNA obtained from INS-1 cells was 
sonicated using Covaris S220 Focused-ultrasonicator, to achieve DNA to fragments of 250-
300 bp spanning the IDH2 promoter region and a group of CCGG islands (as indicated by 
GB) (Figure 3B). Sonication was optimised as stated in method chapter 2 (Figure 2.4). In 
correspondence to the SREMA results, Me-DIP detected high levels of 5-mC content on 
IDH2 promoter region in acetate treated INS-1 cells (Figure 3.3D). The overall promoter 
methylation status of IDH2 using MeDIP was significantly increased by 4-fold in acetate 
nutrient regime of INS-1 cells. The methylation status of these CpG islands was negatively 
correlated with the gene expression of IDH2.  
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Figure 3.3: SREMA and Me-DIP analysis of the IDH2 DNA promoter methylation in acetate 
treated INS-1 cells. (A and B) Distribution of CpG islands in the IDH2 promoter region. The 
gene of interest (i.e. IDH2) and predicted CpG islands are represented by green strand and 
rectangle (outlined in red). Each grey box represents a CCGG island within -200bp upstream 
of TSS (high frequency CpG region identified using GB), and primers spanning these CCGG 
islands are highlighted above the IDH2 DNA strand representation. After acetate 
treatment, the DNA promoter methylation of IDH2 in INS-1 cells was significantly increased, 
confirmed using (C) SREMA (D) and MeDIP. Values are mean ±SEM (n=4), *P<0.05. (Glu: 
Glucose 11mM, Ace: Acetate 5mM) 
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3.3.3. Bisulfite combined sequencing for IDH2 DNA methylation analysis 
Bisulfite combined sequencing was also used to further confirm the observations from 
SREMA and Me-DIP. Briefly, DNA was treated with bisulfite to convert non-methylated 
cytosines to thymines. The treated product was then amplified using PCR with primers 
designed to target IDH2 promoter region (Figure 3.4A). The amplified products, including 
the converted and non-converted DNA (untreated) were then analysed by Sanger 
sequencing. The TIDE-Sanger sequencing analysis demonstrated trivial increase of DNA 
methylation status in IDH2. The data showed partial methylation of CCGG islands upstream 
of IDH2 TSS (Figure 3.4B and C) relative to the control (glucose). 
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Figure 3.4: Bisulfite combined sequencing analysis of the IDH2 DNA promoter region in 
acetate treated INS-1 cells. (A) Predicted bisulfite converted DNA of the IDH2 promoter 
region. Primers used to target bisulfite converted DNA are shown in the purple outlined 
arrows, consisting of a group of CCGG islands (1 to 4). (B) Schematic of CCGG islands 
obtained from two independent experimental repeats (red line, experimental repeat 1; 
black line, experimental repeat 2). Circles represent CCGG island (black, methylated; blue, 
unmethylated). (C) TIDE analysis of bisulfite combined sequencing data represented in DNA 
chromatograms.  
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3.3.4. Acetate increases DNMT3a protein abundance in INS-1 cells 
Data from SREMA and Me-DIP demonstrated significant changes in DNA methylation of 
IDH2 promoter region in acetate treated INS-1 cells. As part of the analysis of epigenetic 
regulation of IDH2 expression in INS-1, DNMT3a, a key regulator of DNA methylation, 
mRNA and protein expression were assessed by RT-qPCR and Western blot analysis, 
respectively. The data obtained showed a substantial increase by 4.9-fold change in 
DNMT3a protein abundance in cells treated with 5 mM acetate (Figure 3.5B). However, RT-
qPCR analysis showed no significant change in DNMT3a mRNA levels and remained 
unchanged in the acetate nutrient regime (Figure 3.5A). Furthermore, we investigated the 
effect of acetate treatment on DNMT3a protein abundance in IDH2 overexpressing INS-1 
cells. Briefly, INS-1 cells were transfected with IDH2 expression plasmid (pcDNA3.1) and 
enriched by mammalian antibiotic puromycin. The transfection efficiency was assessed by 
fluorescence microscopy and confirmed by western blotting. DNMT3a protein abundance 
was evaluated in acetate treated IDH2 overexpressing INS-1 cells. The data obtained 
showed that the overexpression of IDH2 reverted the acetate mediated increase of 
DNMT3a protein abundance in INS-1 cells (Figure 3.5B), with a substantial decrease by 2.7-
fold, relative to wild type INS-1 cells treated with acetate. 
The lack of correlation between mRNA and protein expression, and reversion by IDH2 
overexpression, suggested that DNMT3a may be regulated by factors such as PTMs, that 
may mediate its protein content in INS-1 cells. To address a possible PTM regulatory 
mechanism in the control of DNMT3a abundance, INS-1 cells were treated with the 
proteasomal inhibitor MG132 (or DMSO) at concentrations ranging from 5 µM to 20 µM 
for 2 and 4 hours. MG132, is a potent drug known to induce to cell death. Therefore, it is 
important to evaluate the concentrations required to inhibit the proteasomal degradation 
pathway without killing the cells. Thereafter, MG132 treatment was optimised and the cell 
pellet collected from 0, 2- and 4-hours post-treatment were analysed by western blotting. 
The optimal concentration of 10 µM MG132 were selected for further analysis. DMSO 
(MG132-reagent diluent) was used as a control treatment (Figure 3.5C). MG132 treatment 
increased DNMT3a protein abundance by 1.2-fold and 1.8-fold at 2 and 4 hours, 
respectively, an effect that was not detected when the proteasomal inhibitor was replaced 
by DMSO (Figure 3.5C). After characterising the effect of acetate on the PTM-modulated 
DNMT3a protein abundance. Acetylation status of Histone 4, a surrogate assessment of 
nutrient treatment efficacy, was investigated. The data obtained showed substantial 
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increase when INS-1 cells were grown in the nutrient regime, i.e. acetate. However, the 
overexpression of IDH2, even under similar treatment conditions, reverted the acetylation 
status of H4 to a similar extension observed in the DNMT3a protein abundance (Figure 
3.5B). 
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Figure 3.5: IDH2 overexpression partly reverts the acetate induced DNMT3a protein 
abundance and histone acetylation in INS-1 cells. Cells were treated with 5mM acetate for 
duration of 48 hours and analysed by RT-qPCR and western blotting. (A) DNMT3a mRNA 
expression showed no significant regulation in the presence of acetate. (B) However, 
acetate increased DNMT3a protein abundance. Cells overexpressing IDH2 were able to 
partially revert the acetate-induced DNMT3a protein abundance. Changes in histone 4 
acetylation were analysed by western blot, where acetate treatment increased the 
acetylation, and IDH2 overexpression significantly reverted the effect. (C) Cells treated with 
MG132 (Proteasomal degradation inhibitor) increased the protein abundance of DNMT3a 
in a time-dependent manner. DMSO, used as a negative control showed no significant 
changes. Values are mean ±SEM (n=3), *P<0.05. (Glu: Glucose 11mM, Ace: Acetate 5mM, 
Glu+Ace+IDH2: Overexpressing IDH2 cells in acetate regime).  
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3.3.5. Effect of Acetate on β-cell mitochondrial function 
Following the determination of acetate's role in regulating DNMT3a, DNA methylation and 
IDH2 expression. The next phase in our research was to investigate the effect of acetate on 
key mitochondrial functions, such as ATP content, -KG levels, mtCOI expression and 
mitDNA copy number. The data obtained showed that acetate led to a decreased ATP 
content in INS-1 cells (Figure 3.6D). Moreover, overexpression of IDH2 partially recovered 
acetate-induced ATP reduction in INS-1 cells (Figure 3.6D). In contrast to the previous data 
of LDHA mRNA expression (section 3.3.1), the lactate levels of acetate treated INS-1 cells 
did not indicate significant changes in the glycolytic activity, i.e. the lactate content of 
acetate treated wild type INS-1 cells and IDH2 overexpressing INS-1 cells displayed no 
significant difference, relative to control (Figure 3.6E). The characterisation of mitDNA 
content and mtCOI expression was assessed under the acetate nutrient regime (Figure 3.6A 
and B). The data showed a significant reduction in mitDNA content, which was correlated 
with a reduced expression of the mtCOI protein in acetate treated INS-1 cells. In addition, 
-KG levels were also decreased in acetate treated INS-1 cells, relative to control (Figure 
3.6C). Overall, -KG, ATP production, mitDNA and mtCOI expression suggested a decrease 
of mitochondrial function, whereas, lactate levels did not indicate a change in the glycolytic 
activity of acetate treated INS-1 cells.  
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Figure 3.6: Acetate alters mitochondrial activity in INS-1 cells. The analysis showed 
acetate-mediated significant decrease in (A) mitDNA copy number, (B) α-KG, (C) mtCOI 
protein expression and (D) ATP content, analysed by qPCR, western blotting, alpha 
ketoglutarate fluorometric assay and ATP luminescence assay, respectively. The 
overexpression of IDH2 in INS-1 cells partially but significantly reverted the acetate-
reduced ATP content. (E) The lactate content of acetate treated wild type INS-1 cells and 
IDH2 overexpressing INS-1 cells displayed no significant difference, relative to control (Glu). 
mitDNA copy number was normalised to nuclear DNA. mtCOII expression was normalised 
to GAPDH. Values are mean ±SEM (n=3), *P<0.05. (Glu: Glucose 11mM, Ace: Acetate 5mM, 
Glu+Ace+IDH2: Overexpressing IDH2 cells in acetate regime) 
 
 
 
 
 
 
 
 
 
 
  
85 
 
3.3.6. Acetate induces insulin gene DNA promoter methylation and downregulates its 
expression 
Acetate treated INS-1 cells exhibited significant downregulation of insulin gene, confirmed 
by RT-qPCR (0.45-fold, Figure 3.7A), and this has a correlative effect on the abundance of 
the insulin, confirmed by ELISA (0.4-fold, Figure 3.7B). To evaluate the contribution of 
epigenetic regulation in the insulin gene, the changes in DNA methylation of the promoter 
region were assessed using previously described methodologies (e.g. SREMA and MeDIP). 
The data showed that acetate led to a significant increase in the 5-mC content of the insulin 
DNA promoter region (Figure 3.7C and D), ranging from 1.5 to 2-fold changes, when 
compared to control media conditions. 
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Figure 3.7: Effect of acetate on insulin mRNA expression, content and DNA promoter 
methylation. (A) Insulin mRNA expression from INS-1 cells treated with acetate was 
assessed by RT-qPCR. Data obtained showed that insulin expression was significantly 
reduced by acetate nutrient regime, normalised to GAPDH. (B) Insulin protein content, 
quantified by ELISA, showed a significant reduction, comparable to that observed in mRNA 
expression, when cells were subjected to acetate nutrient regime. (C and D) Levels of insulin 
promoter methylation in both media conditions (i.e. control and acetate) were assessed 
using MeDIP and SREMA methodologies. Acetate nutrient regime stimulated a significant 
increase in insulin promoter methylation, ranging from 1.5- to 2.2-fold. Quantitative 
analysis of 5mC content showed a negative correlation between insulin mRNA expression 
and DNA methylation status. Values are mean ±SEM (n=3), *P<0.05. (Glu: Glucose 11mM, 
Ace: Acetate 5mM) 
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3.4. Discussion 
 
Diabetes is a metabolic disorder intrinsically linked with lifestyle changes in addition to 
genetic factors. Although population increase and the rising number of ageing population 
may account for some of this increase, but it does not explain the near four-fold rise in 
diabetes prevalence (Zhao et al. 2012; Ang 2018). The nutrient sensing β-cells that secrete 
insulin in response to circulating nutrients (e.g. glucose), play an important role in the 
pathogenesis of T2D (Wollheim, Maechler 2002). These nutrient sensing features suggest 
that the pancreatic β-cell metabolism is more sensitive to nutrients than other cells types. 
Therefore, understanding the effect of acetate nutrient regime on these cells is necessary 
for our quest to understand the pathogenesis of diabetes. Acetate is a potent substrate for 
the intracellular acetyl-CoA level (DeBerardinis, Chandel 2016). The accumulation of acetyl-
CoA is a common metabolic feature in diabetic models (Layden et al. 2012). The main aim 
of this chapter was to characterise the effect of acetate on promoter DNA methylation of 
the selected genes in INS-1 cells, i.e. IDH2 and insulin. To achieve this aim, we analysed the 
role of acetate in the regulation of epigenetics, mitochondrial function and insulin content 
in INS-1 cells. Our data demonstrate the involvement of acetate nutrient in regulating 
metabolism and consequently affecting insulin content by modulating the epigenetic 
profile of INS-1 cells. This data adds to our understanding of the role of DNA methylation 
in regulating key mitochondrial components, such as, mtCOI, mitDNA, ATP content and α-
KG. Additionally, we suggest the role of DNA methylation in the regulation of insulin gene 
expression leading to the reduction in total insulin content of cells, which correlates with 
DNMT3a protein abundance.  
 
3.4.1. Acetate induces IDH2 DNA promoter methylation and downregulates its 
expression 
Mitochondrial dysfunction is shown to largely contribute to the development of T2D (Lu et 
al. 2010). Multiple factors are involved in the regulation of mitochondrial mediated 
pathogenesis of diabetes, including nutrients, epigenetics, SNPs and mutations. These 
factors contribute to the complexity of the underlying mechanisms regulating metabolic 
changes associated with diabetes pathology (Yaribeygi et al. 2018). For example, citrate, a 
key nutrient, known to regulate energy storage and transformation, also serves as a crucial 
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component in cellular metabolism and insulin regulation in pancreatic β-cells (Iacobazzi, 
Infantino 2014). IDH2 is the key player that connects mitochondria and important 
metabolites, such as citrate, acetyl-CoA and -KG, to diabetes. IDH2 catalyses the reaction 
of isocitrate’s conversion into -KG. Previous studies have shown that IDH2 knockdown 
inhibits insulin secretion under high glucose conditions (Macdonald et al. 2013). Therefore, 
understanding the role IDH2 in insulin secreting pancreatic β-cells is crucial to identify the 
underlying mechanisms regulating metabolic changes in diabetes. In our study, INS-1 
pancreatic β-cells treated with 5mM acetate showed downregulation of IDH2 mRNA and 
protein expression. The implications of IDH2 downregulation can include mitochondrial 
redox imbalance, ROS induced damage (YI et al. 2016), fat/cholesterol biosynthesis and 
glutathione metabolism irregularity in the cell (Koh et al. 2004). Pancreatic β-cell are 
exceptionally susceptible to high intracellular ROS content, and its accumulation induces 
apoptotic pathways leading to cell death (Lenzen et al. 1996). IDH2-generated NADPH 
reduces ROS-mediated cell damage by modulating antioxidation (Jo et al. 2001). Therefore, 
the downregulation of IDH2 by acetate can lead to β-cell death. In addition, previous 
studies carried out in IDH2-/- mouse models, showed a significant reduction in 
mitochondrial oxygen consumption and cell viability (White et al. 2018), further elucidating 
the importance of IDH2 in cellular respiration and function. Diabetes progression is a  multi-
step process that involves mitochondrial oxygen consumption downregulation (Mulder, et 
al. 2017). Michael et al. (2013) demonstrated that knockdown of IDH1 and IDH2 leads to 
the inhibition of insulin secretion. In correspondence with these findings, our data showed 
significant decrease in IDH2 expression in acetate treated INS-1 cells, and the supporting 
data from Michael et al. (2013) indicates that this decrease could be substantial to hinder 
the normal physiological function of pancreatic β-cells. Like acetate, oxysterol treatment, 
commonly found in western diet, has also been shown to downregulate IDH2 in human 
aortic endothelial cells (Fu et al. 2014). Overall, our findings and others suggest that IDH2 
can be highly regulated by differential nutrient regimes which is crucial for the normal 
function of pancreatic β-cell. 
Chemical epigenetic modifications, such as acetylation of histones and DNA methylation 
are linked with changes in intracellular metabolic activity. This is particularly evident in the 
epigenetics of cells harbouring mutations in components of the TCA cycle, such as fumarate 
hydratase and succinate dehydrogenase (D’Urso, Brickner 2014). Additionally, it is well 
established that increment in CpG islands methylation leads to transcription repression. 
Thus, we hypothesised that the observed reduction of IDH2 expression could be, to some 
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extent, mediated by CpG island methylation. Based on this, our aim to characterise the 
effect on promoter DNA methylation of IDH2 was executed by three complementary 
methodologies. Because the regions rich in CpG islands has been shown to attract de novo 
methylation, the CpG rich regions of IDH2 promoter were targeted for DNA methylation 
analysis (Edwards et al. 2017). Initially, the promoter methylation changes were detected 
by the combination of a methylation-sensitive restriction enzyme analysis (SREMA) 
followed by qPCR quantification. Our results indicated a significant increase in IDH2 
promoter methylation, supporting the changes observed in IDH2 expression. Furthermore, 
we validated these results by Me-DIP. Once again, the data revealed a significant increment 
in the methylation of the IDH2 promoter region, supporting the findings from SREMA. 
Studies conducted in cancer models has previously revealed that IDH2 can be regulated by 
DNA methylation of the promoter region (Chou et al. 2016). Although our study is carried 
out in rodent β-cells, the functional CpG islands that are regulated by methylation have 
previously been shown to be conserved amongst various species, including human 
(Illingworth et al. 2010). Therefore, these results may be replicated in human primary or 
immortal cell lines. 
The methylation status of IDH2 confirmed using SREMA, MeDIP was also analysed by 
Bisulfite combined sequencing. However, the data obtained from bisulfite combined 
sequencing displayed a lower confidence level in the determination of methylated 
cytosines. Bisulfite treatment converts the unmethylated cytosines to uracils, and the 
methylated cytosines are conserved in the treatment. During PCR amplification step, these 
uracils are converted to thymines by DNA polymerase (Frommer et al. 1992). The limitation 
of bisulfite treated DNA sequencing includes the inability to differentiate between 5-mC 
and 5-hmC (Huang et al. 2010), which can cause variability in the data. However, this 
limitation does not apply to Me-DIP. Moreover, a single cytosine can have different 
methylation profile in different cells of the same treatment which can interfere with the 
confidence level of the methylation determination by sequencing (Song et al. 2005). These 
limitations could explain the low confidence level of the results obtained using Bisulfite 
combined sequencing data.  
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3.4.2. DNMT3a and histone acetylation regulation in INS-1 cells 
CpG islands are generally unmethylated, which allows gene transcription maintenance 
(Jones, Takai 2001). However, the active regulation of DNA methylation in metabolic 
conditions such as T2D is not fully elucidated. DNA methylation is carried out by DNMT1, 
DNMT3a and DNMT3b (Robertson et al. 1999). DNMT1 is involved in the maintenance of 
DNA methylation status in the cell (Du et al. 2010), whereas, DNMT3a participates in the 
de novo promoter methylation of genes (Robertson et al. 1999). In the current study, the 
analysis of DNMT3a mRNA expression under acetate nutrient regime showed no significant 
changes. However, DNMT3a protein abundance was significantly increased in the presence 
of acetate. Similarly, acetylation of histone 4, a surrogate indicator of treatment efficacy, 
was also significantly increased in acetate nutrient regime. It was previously reported that 
histone acetylation correlates with insulin gene expression. In the same study, p300, a 
histone acetyltransferase was found to be modulated by pancreatic and duodenal 
homeobox 1 (Pdx1) that regulate insulin gene transcription (Bernstein et al. 2017). In terms 
of DNA methyltransferase, Park et al. (2008) studied the implications of DNA methylation 
during intrauterine growth in mouse models. Their findings suggested that the 
development of T2D was associated with epigenetic changes, including DNMT3a-initiated 
de novo DNA methylation resulting in the locking of a silenced state of Pdx1 in the 
intrauterine growth, subsequently restricting pancreatic function, ultimately resulting in 
diabetes. Dhawan et al. (2015) also demonstrated the importance of DNA methylation in 
β-cell and insulin secretion. The transition from neonatal to adult β-cell involves a specific 
DNA methylation profile. Neonatal β-cell secretes insulin irrespective of blood glucose 
levels (Blum et al. 2012); however, this mechanism changes during cellular maturity. 
DNMT3a was shown to contribute to neonatal β-cell cellular maturity by initiating glucose-
stimulated insulin secretion, suggesting suitable levels of DNMT3a are required for β-cell 
function. The balance in DNA methylation is an important factor for maintaining the 
identity of pancreatic β-cells. Offsetting the balance of DNMT3a could lead to changes in 
DNA methylation of pancreatic β-cells resulting in loss of identity and functionality. 
Specifically, offsetting the balance of DNMT1 has previously been shown to change the 
identity of β-cells into α-cells after injury induced proliferation (Dhawan et al. 2011). 
According to these findings, we further evaluated DNMT3a and the functionality of acetate 
treated INS-1 cells. 
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Interestingly, in our study, the overexpression of IDH2 in INS-1 cells reverted acetate-
induced DNMT3a abundance and Histone 4 acetylation significantly. The metabolic-
epigenetic connection has been the focus of research over the past few years. The role of 
DNA methylation in mitochondrial proteins and diabetes has been previously described 
(Maghbooli et al. 2015; Reichetzeder et al. 2016; Zhao et al. 2012), however, the 
association of IDH2 with DNA methylation in diabetes is not yet elucidated. Mutations of 
IDH2 in cancers have been associated with increased global DNA methylation, that also 
correlates with the production of 2-hydroxyglutarate (2-HG) (Reitman et al. 2010; Yang et 
al. 2012; Fu et al. 2010). 2-HG is suggested to be an oncometabolite that promotes tumour 
growth by modulating cell epigenetics (Janke et al. 2017). However, in normal cells Malate 
dehydrogenase, 3-phosphoglycerate and LDHA are also shown to promiscuously produce 
2-HG (Ye et al. 2018); likely serving a normal biological function. 2-HG is also the prominent 
hallmark of 2-hydroxyglutaric aciduria, a rare neurometabolic disease where a mutation in 
SLC25A1 (mitochondrial citrate carrier) leads to accumulation of 2-HG (Nota et al. 2013). 
There has been inconsistence observations regarding to the role of 2-HG in cancer (Li et al. 
2018; Fu et al. 2010). Additionally, our data also shows that IDH2 downregulation can likely 
increase DNA methylation, in ways other than producing the oncometabolite, 2-HG.  
IDH2 downregulation can lead to the accumulation of acetyl-CoA. Increase in acetyl-CoA 
levels has been associated with PTMs of intracellular proteins, such as acetylation of lysines 
(Gao et al. 2016). In addition, it was previously found that the catalytic activity of DNMTs 
can be modulated by various PTMs, such as acetylation and phosphorylation (Jeltsch, 
Jurkowska 2016). One study by Cheng et al. (2015) established the role of acetylation in 
mediating DNMT1. Another study by Deplus et al. (2014) demonstrated the role of Casein 
Kinase 2-mediated phosphorylation of DNMT3a in DNA methylation of cells. In addition, 
DNMT3a mediated DNA methylation can also be regulated by ROS (Miozzo et al. 2018) and 
domain rearrangement (Jeltsch, Jurkowska 2016). These findings suggest that acetate 
nutrient regime can induce PTMs and subsequently regulate DNMT3a. In our study, we 
investigated whether the stabilisation or degradation of DNMT3a is regulated by PTMs. 
INS-1 cells were incubated with proteasomal degradation inhibitor MG132. The inhibition 
of proteasomal degradation led to a significant increase in DNMT3a abundance in cells. In 
addition, the mRNA analysis of DNMT3a confirmed the above finding, that there was no 
significant change in DNMT3a transcripts levels after acetate treatment of INS-1 cells, 
despite the significant upregulation observed in protein level. Both combined, the MG123-
mediated significant increase of DNMT3a protein, and acetate-induced DNMT3a 
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abundance while maintaining constant levels of mRNA in acetate, are suggestive of PTMs 
role in regulating DNMT3a protein abundance. Based on these observations, we speculate 
that DNMT3a can be stabilised by acetylation leading to evasion from proteasomal 
degradation pathway. 
In addition to evaluating the role of PTM in DNMT3a regulation, we also evaluated the role 
of acetate in histone acetylation. The data obtained showed that acetate induced 
hyperacetylation of histones in INS-1 cells. Acetylation/deacetylation of histones is carried 
out by HATs and HDACs using acetyl-CoA as a substrate (Pons et al. 2009). Emerging insights 
suggest that the modulation of acetyl-CoA can metabolically regulate the function of other 
epigenetic changes in addition to histone acetylation (Su et al. 2016; Lempradl et al. 2015; 
Tran et al. 2017). Radiolabelled acetate has previously been shown to provide acetyl group 
that binds to histones causing acetylation (Allfrey et al. 1964). Gao et al. (2016) 
correspondingly reported that acetate can induce hyperacetylation of histone 3 in hypoxic 
cells by increasing ACSS1 and ACSS2 expression, leading to the production of acetyl-CoA. 
Moreover, Schug et al. (2015), using 13C2-acetate demonstrated that acetate conversion to 
citrate is mediated by ACSS1 in mitochondria. Both studies combined with our data provide 
evidence that acetate induces hyperacetylation of histones by mediating the expression of 
IDH2, ACSS1 and ACSS2, thereby increasing intracellular acetyl-CoA levels. The 
downregulation of IDH2 mediated by DNA promoter methylation can lead to the 
accumulation of citrate, which can then be transported into cytosol and further increase 
acetyl-CoA concentration. Modifications of histones have been previously shown to play 
an important role in the metabolic memory of diabetic patients (Miao et al. 2014). The 
increase in acetyl-CoA levels has been linked with numerous cellular process 
simultaneously including histone and protein acetylation (Pietrocola et al. 2015). 
Therefore, the increase in histone acetylation in acetate treated INS-1 cells could also 
indicate the increased acetylation of other cellular proteins including DNMT3a, resulting in 
modulated protein abundance. 
The general concept of histone acetylation leading to gene expression came from studies 
conducted in isolated calf thymus nuclei (Allfrey et al. 1964). This was further elucidated by 
cloning HATs and HDACs chromatinised templates that resulted in gene deregulation 
(Brownell et al. 1996; Taunton et al. 1996). Histone acetylation is mainly associated with 
increased gene expression, but our data shows increased histone acetylation can also 
correlate with decreased expression, possibly mediated by DNA methylation. This finding 
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suggests that a relationship between histone acetylation and gene deregulation needs to 
be further elucidated. 
In order to establish a cause-consequence relationship between the observed INS-1 
functional features and the reduced IDH2 content, an ectopic overexpression of IDH2 was 
utilised. INS-1 cells overexpressing IDH2, showed a substantial reversion of DNMT3a 
protein abundance and histone acetylation, suggesting increased IDH2 levels can decrease 
intracellular acetyl-CoA levels resulting in the observed reversion. Supporting evidence 
from Kobayashi et al. (2014) and Pietrocola et al. (2015) demonstrated that IDH2 
overexpression leads to increased TCA cycle and reduces intracellular acetyl-CoA levels. 
 
3.4.3. Acetate decreases mitochondrial activity in INS-1 cells 
The availability and composition of nutrients available to the cell in vivo has been shown to 
dictate the metabolism. Cells can modulate their metabolism according to the predominant 
metabolite from the available nutrients in order to meet the structural and functional need 
(Khurshed et al. 2017). The amounts and availability of metabolites can also be controlled 
by metabolic changes mediated by key metabolic enzymes. For example, the knockdown 
of IDH1 and IDH2 was shown to associate with intracellular decreased α-KG and increased 
citrate levels, indicating a role of deregulating key metabolic genes in controlling the 
composition and availability of metabolites (Macdonald et al. 2013). IDH2 plays a key role 
in TCA cycle by mediating irreversible oxidation and decarboxylation of isocitrate to -KG 
(Zou et al. 2017). Therefore, following acetate-induced IDH2 downregulation, we measured 
the level of α-KG in INS-1 cells. The data obtained showed decreased α-KG levels in acetate 
treated INS-1 cells. α-KG serves as a signal for insulin secretion in β-cells (Iacobazzi, 
Infantino 2014), and the level of α-KG can largely depend on IDHs (Park et al. 2016). IDH2 
overexpression leading to increased α-KG have previously been shown to be associated 
with increased mitochondrial function (Vohwinkel et al. 2011), suggesting that IDH2 can 
regulate α-KG levels and mitochondrial activity, simultaneously. Thereafter, we 
investigated the function of mitochondria by evaluating mtCOI expression, mitDNA 
content, ATP content and α-KG levels in acetate treated INS-1 cells. The results obtained 
indicated a decrease in mitochondrial activity. 
Mitochondria are the central site for energy metabolism and cellular respiration. 
Moreover, mitochondrial dysfunction correlates with insulin secretion and sensitivity (Song 
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et al. 2001). Gong et al. (1998) showed a rapid (<1hr) increase in mitochondrial activity after 
irradiation of cells, which correlated with increased mtCOI expression and ATP production. 
Irradiation of cells displayed the observed changes within a short period, thus suggesting 
that mtCOI expression and ATP production are direct representatives of mitochondrial 
activity rather than an indirect effect from mitochondrial stimulation. In our study, mtCOI 
expression and ATP production were significantly reduced in acetate treated INS-1 cells. 
Complex IV regulates the mitochondrial function and activity. Moreover, impaired complex 
IV gene expression, including mtCOI impairment has been linked with T2D pathology 
(Holvoet et al. 2016). A single missense mutation of mtCOI was associated with a significant 
loss of complex IV activity (Acín-Pérez et al. 2003). Additionally, several cases of diabetes 
were shown to arise from familial mitochondrial related pathologies (Mkaouar-Rebai et al. 
2013). mtCOI is the first gene encoded in mitDNA (Acín-Pérez et al. 2003), and variations in 
mitDNA have been suggested to be a metabolic risk factor for diabetes (Pravenec et al. 
2007). mitDNA and encoded genes are essential components of β-cells function, i.e. insulin 
secretion (Nicholas et al. 2017). Therefore, we assessed the content of mitDNA in acetate 
treated INS-1 cells. The data obtained showed a significant reduction in the mitDNA 
content. Pravence et al. (2007) showed that conplastic strains of rats consisting of the same 
nuclear but different variations of mitDNA, displayed different metabolic risk factors 
towards T2D, suggesting the important role of mitDNA in the pathogenesis of the disease.  
The underlying mechanisms of mitDNA regulation in T2D are yet to elucidate, but insulin-
dependent cellular stress was suggested to damage mitDNA, leading to the loss of mitDNA 
content. The extranuclear location and large copy number (each mitochondrion contains 
several nucleoids consisting of mitDNA) of mitDNA, increases its susceptibility to damage 
(Gilkerson 2016). The acquired decrease in mitDNA copy number of T2D patients was also 
observed in their offspring, indicating the copy number variation of mitDNA can be 
inherited (Song et al. 2001). While a single mutation in nuclear DNA is sufficient for a 
profound effect, a heteroplasmy in mitDNA is required to alter phenotype, due to its large 
copy number in a cell (Mulder 2017). The results from our study also support the previous 
statement that mitDNA is regulated by mechanisms other than mutations in INS-1 cells. 
TCA cycle plays an important role not only in the generation of ATP but also in generating 
metabolic intermediates including α-KG, citrate and etc. Citrate was shown to inhibit the 
TCA cycle, subsequently reducing ATP production (Iacobazzi, Infantino 2014). Acetate 
treated INS-1 cells in our study also demonstrated a reduction in α-KG and ATP content of 
the cells, indicative of a decrease in the TCA cycle activity. The TCA cycle and ATP 
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production was previously shown to play a central role in insulin gene transcription and 
translation (Maechler 2013; Poitout et al. 2006). Additionally, T2D patient-derived islets 
cells showed morphologically altered mitochondria and thereby mitochondrial function 
(Wiederkher, Wollheim 2008), further supporting our findings.  
Barres et al. (2009) indicated that PGC-1 expression correlates with mitDNA copy number 
and mitochondrial content of the cell. This regulation in T2D patients was shown to be 
negatively correlated with DNA methylation status of PGC-1 promoter region. Moreover, 
in the same study, PGC-1 mRNA expression was shown to be regulated by the nutritional 
status of the cells, exhibiting a long-term consequence in T2D patients. (Rodgers et al. 
2005). The rate of lysine acetylation mediated PGC-1 downregulation and consequent 
mitochondrial deregulation is limited by the availability of acetyl-CoA (Fernandez-Marcos, 
Auwerx 2011). Acetylation of PGC-1 can be regulated by GCN5, a protein 
acetyltransferase (Kelly et al. 2009). In addition, ACLY generates intracellular acetyl-CoA, 
that is required for acetylation of proteins and histones. Silencing of GCN5 and ACLY result 
in highly similar cellular changes, suggesting common pathways of action between the two 
(Wellen et al. 2009). Therefore, it is possible that the changes observed in the acetylation 
of histones following the treatment of acetate (in our study) and the reversion of histone 
acetylation by the overexpression of IDH2 can also be observed in PGC-1. 
 
3.4.4. DNA methylation of insulin gene and its correlation with insulin content  
The transcription of Insulin gene was previously shown to be regulated by active DNA 
promoter methylation (Kuroda et al. 2009). Following these findings, we investigated the 
regulation and DNA methylation status of the insulin gene in acetate treated INS-1 cells. 
The data obtained showed increased DNA methylation of insulin DNA promoter region, that 
inversely correlated with insulin mRNA and protein content. Kuroda et al. (2009) 
correspondingly reported that DNA methylation alterations affecting insulin transcription 
is a long-term effect, which can result in the development of diabetes. Moreover, in the 
same study, in vitro methylation of insulin gene resulted in 90% transcription reduction by 
hindering the transcription factor binding to cAMP responsive element (CRE) site of insulin 
promoter region. Insulin secretion is generally higher in female islets in comparison to 
males; however, the DNA sequence of the gene is identical or similar in both. Hall et al. 
(2018) demonstrated that these differences arise from sex-specific DNA methylation 
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associated with a number of genes known to affect insulin transcription. In our study, we 
observed 40% reduction in insulin mRNA and protein levels that inversely correlated with 
increase in DNA methylation. Combination of findings from others and ours, can concluded 
that the acetate-induced reduction in insulin gene can be a result of direct interference 
from increased promoter DNA methylation. Moreover, DNA methylation is heritable; when 
an individual is exposed to nutritional changes, the epigenetic changes can be 
intergenerationally or transgenerationally inherited (Heard, Martienssen 2014).  
Glucotoxicity and lipotoxicity causes a decrease in mitochondrial activity and increased ROS 
production leading to apoptosis in β-cells (Maedler et al. 2003; Fu et al. 2013). Our study 
also demonstrated a reduction of IDH2 and mitochondrial activity, these changes have 
previously been shown to be associated with increased ROS production. Collectively, these 
findings suggest that long term exposure of acetate from the diet can lead to pancreatic β-
cell dysfunction and therefore, diabetes. 
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Figure 3.8: Schematic figure illustrating the conclusion of chapter 3 (for further 
explanation see section 3.5). 
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3.5. Conclusion 
In conclusion, our data shows that in the β-cell model INS-1, increased acetate levels lead 
to a significant decrease in IDH2 and insulin expression by an active epigenetic control. 
These changes were accompanied by reduction in key mitochondrial components including 
mtCOI and mitDNA copy number, α-KG levels and ATP content. Additionally, acetylation of 
histone and stabilisation of DNMT3a was observed, thereby, explaining the increased rate 
of DNA methylation on IDH2 and insulin promoter region. Overexpression of an ectopic 
IDH2 led to functional recovery of the INS-1 cells bioenergetics, with both a decreased 
histone acetylation and DNMT3a protein abundance. Finally, acetate was also found to 
reduce the insulin content of INS-1 cells (Figure 3.8).  Overall, our study provided a rationale 
for the design of therapeutic strategies aiming to modulate the epigenetic mechanism of 
β-cells in metabolic disorders such as T2D. 
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CHAPTER 4: THE EFFECT OF GALACTOSE ON EPIGENETICS AND 
METABOLISM IN THE CANCER MODEL HeLa 
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4.1. Introduction 
 
Otto Warburg and colleagues suggested the concept of ‘The Warburg effect' in 1920s. The 
Warburg effect states that the cancer cells utilise large amounts of glucose in comparison 
to the surrounding tissues and produce an extensive amount of lactate, even in the 
presence of abundant oxygen (Warburg et al. 1927). Herbert Crabtree confirmed the 
findings of Otto Warburg and further elucidated the heterogenicity of aerobic glycolysis in 
tumour cells. Crabtree and colleagues suggested that tumour cells exhibited a substantial 
amount of respiration with a variable degree, therefore, require functional mitochondria 
(Crabtree 1929). However, Warburg and colleagues later suggested in the 1950s that 
dysfunctional mitochondria are the causative for cancer cell's metabolic profiles (Warburg 
1956). Subsequent findings showed that the mitochondria is not defective in tumours, and 
even cancer cells require functional mitochondria to survive (Moreno-Sánchez et al. 2007; 
Weinhouse 1976). These findings suggested the existence of an alternative method of 
mitochondrial and OXPHOS regulation in cancer cells. Cancer was originally thought to be 
regulated only by changes in the genetic sequence of key tumour suppressors and 
proliferation regulators. But, recent findings established the role of epigenetics leading to 
the alterations observed in cancer cells (Berdasco, Esteller 2010). Normal differentiated 
cells primarily rely on OXPHOS for energy expenditure; however, cancer cells instead rely 
on the inefficient method of energy generation called aerobic glycolysis (Figure 4.1). 
Whether the aerobic glycolysis/Warburg effect is a consequence of cancer or inversely a 
pathogenic factor remains to be clarified. Studies also suggest that ‘The Warburg effect' is 
required for tumour growth, and the necessity of aerobic glycolysis in cancer cells extends 
beyond the generation of new cellular components for proliferation (Shim et al. 1998; 
Fantin et al. 2006). 
Cancer cells are observed to proliferate increasingly and have reduced apoptosis. In 
addition to the metabolism, mitochondria also plays a central role in proliferation and 
apoptosis, (Arciuch et al. 2012). Pro-apoptotic proteins such as Bcl-2/adenovirus E1B 19 
kDa-interacting protein 3 Like (NIX) and BCL2 interacting protein 3 (BNIP3), either form an 
integral part of mitochondrial membrane (NIX) or localise to the mitochondrial outer 
membrane (BNIP3), that mediate apoptosis (Chourasia et al. 2015). NIX is a mitochondrial 
protein forming heterodimers with Bcl-XL and Bcl-2 via its transmembrane domain (Abe et 
al. 2005). NIX stimulates mitophagy by the disrupting Beclin-1 and Bcl-2 complex. NIX also 
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stimulates autophagy in malignant cardiomyocytes and glioma cells and trigger apoptosis 
by promoting Bax/Bad-dependent release of pro-apoptotic mediators from the 
mitochondria and by seizing Bcl-2 family proteins (Radogna et al. 2015). Moreover, 
metabolic reprogramming in cancer was shown to be accompanied with downregulation 
of NIX (Drake et al. 2017). 
 
4.1.1. Metabolic changes in cancer 
The role of metabolism in cancer has been the focus of research for decades, however, 
there has always been a discrepancy between studies. It is widely accepted that aerobic 
glycolysis is the main source of energy production, but OXPHOS still contributes to the 
energy production in cancer cells. Tumour cells reprogram nutrient utilisation, and 
therefore the metabolism in order to increase survival and proliferate. Number of therapies 
targeting metabolism are regularly being used in clinical settings, such as asparaginase, 
used for the treatment of acute lymphoblastic leukaemia, by converting the asparagine 
amino acid into ammonia and aspartic acid. Asparagine is usually not synthesised in the 
leukemic cells due to their high protein synthesis and demand, therefore these cancerous 
cells rely solely on the uptake of asparagine from the bloodstream (DeBerardinis et al. 
2007). Similar to glycolysis, the TCA cycle also plays a vital role in providing intermediates 
for macromolecule synthesis in cancer cells; hence the TCA cycle is required even at low 
rate for survival in tumours (Ahn, Metallo 2015). In addition to pyruvate production by 
glycolysis, the TCA cycle can also generate metabolic intermediates and ATP from amino 
acids and fatty acids. The breakdown of fatty acids is known as β-oxidation that generates 
acetyl-CoA, an important intermediate for epigenetic and PTMs. Amino acids including 
valine, leucine and isoleucine are generally elevated in cancer patients, and can also be 
utilised by TCA cycle for acetyl-CoA generation. These factors suggest the adaptability of 
TCA cycle, and therefore an important therapeutic target in cancer research (DeBerardinis, 
Chandel 2016). In order to prohibit the growth of cancerous cells, Israelsen et al. (2013) 
targeted pyruvate kinase to limit glycolysis-mediated ATP production; however, this effort 
failed to prevent tumorigenesis, suggesting an alternative role of glycolysis in cancer. 
Additionally, cancer cells have been shown to reprogram the surrounding tissue and induce 
the Warburg effect (Koit et al. 2017). Whether cancer cells induce the Warburg effect in 
surrounding tissue by secreting metabolic intermediates and consequently causing 
epigenetic modifications, is yet to be fully elucidated.  
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4.1.2. Cancer and epigenetics 
Cancer stem cells (CSC) can arise from normal cells that have undergone epigenetic 
reprogramming to display stem cell-like features. Different CSCs display heterogenic 
features representing different disease entities, and are often resistant to many cancer 
treatments (Poli et al. 2018). Conventionally, genetic factors were thought to be the leading 
cause for cancer plasticity, metastasis, high proliferation rate and apoptotic evasion. 
Genetic mutations rely mainly on the gain or loss of function of the targeted proteins in 
pathogenesis of cancer; however, epigenetic factors dictate the rate of reaction rather the 
complete loss or gain of functionality (Di Cerbo, Schneider 2013). Recently, epigenetics has 
been recognised as a major contributing factor in prompting the distinct features in cancer 
(Sandoval, Esteller 2012). Besides genetic factors, epigenetics play an important role in the 
differences that exist between cancers of the same types and therefore leading to the 
variations in treatment responses. DNA methylation patterns is one of the key players that 
dictate the metabolic differences in different organs (De Sousa E Melo et al. 2013). 
Genome wide hypermethylation of the promoter regions is characterised as a key 
component of many cancers (Miremadi et al. 2007). DNA methylation plays an important 
role in regulating gene expression. Moreover, number of genes involved in cell cycle have 
been shown to be regulated by DNA methylation at the promoter region: including PTEN 
and BRCA1/2 (Minami et al. 2014). In gliomas, MGMT (DNA mismatch repair protein) is 
commonly downregulated but is not mutated; current findings suggest a role of DNA 
methylation in the regulation of this protein in cancer instead of mutations (Jones 2007; 
Baylin, Jones 2011). Furthermore, several genes associated with different cancers have 
been found to be hypermethylated and were suggested as potential biomarkers (Sandoval, 
Esteller 2012). Interestingly, Fernandez et al. (2012) conducted DNA methylation analysis 
on 1628 samples from patients with various cancers, it was found that 1505 CpG sites at 
promoter regions of various genes were hypermethylated during tumorigenesis. In 
addition to DNA methylation, the second main epigenetic modification is histone 
acetylation. The increase in acetylation of histones due to mutations in HDACs was 
associated with higher risk of breast and lung cancer. The acetylation levels also depend on 
HATs and its substrate acetyl-CoA, that can dictate the fate of the cell (Miremadi et al. 
2007). Acetylation of histones should be maintained for gene expression controls and 
genomic stability (Di-Cerbo, Schneider 2013). 
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4.1.3. Nutrients and cancer 
Nutrients play an important role in the prevention of cancer and recovery/treatment of 
patients. The Gerson therapy, a nutrition-based therapy for melanoma, was evaluated in a 
five-year interventional study. This study observed an increased survival rate in comparison 
to other conventional therapies (Hildenbrand et al. 1995; Donaldson 2004). However, the 
cellular mechanisms involved in this nutrition-based diet was not identified, but the 
percentage of patients survived on the Gerson therapy was significantly larger than 
reported by some of the other clinical trials of cancer therapy (Donaldson 2004). Sodeberg 
et al. (1980) and Petrova-benedict et al. (1992) demonstrated that galactose is lethal to 
cells harbouring defective mitochondrial respiratory chain; however, normal cells were 
capable of surviving galactose treatment in cultures. The biological importance of galactose 
extends beyond metabolic intermediate. Galactose is an important constituent of the 
nutrition composition of milk, which forms the disaccharide with glucose to generate 
lactose. Therefore, galactose plays an important role in fetal and neonatal development 
(Coelho et al. 2015). Lactose (glucose and galactose) is known to play an important role in 
health and disease as it is an integral part of almost all species producing milk, however 
marsupials and sea lions do not contain lactose in their milk but instead contain a tri-
saccharide of galactose (Urashima et al. 2014). The cellular mechanism involved in 
galactose utilisation relies on mitochondrial oxidation almost solely for the generation of 
ATP. Galactose in the cells is converted to UDP-glucose mainly by the Leloir pathway 
through subsequent action of multiple enzymes using 2 ATPs as cofactors. Therefore, cells 
relying on glycolysis (generating 2 net ATPs) are forced to utilise OXPHOS to generate 
additional ATP (Coelho et al. 2015). All these findings suggest that galactose may serve as 
an important factor in the treatment of cancers, especially by modulating ‘The Warburg 
effect’. 
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Figure 4.1: Schematic representation of the metabolic changes in cancer cells. Glucose 
metabolism is modified in cancer cells. Instead of OXPHOS, the cells ‘switches’ to a 
phenomena known as aerobic glycolysis (Fu et al. 2017). Initially, glucose is taken up by the 
cells through one of the 13 glucose transporters (GLUTs); i.e. GLUT 1-12 and 
H+/Myoinositol cotransporter. The transported glucose is then phosphorylated to produce 
glucose-6-phosphate by hexokinases (HK). Thereafter, phosphofructokinase-1 (PFK1) can 
catalyse the conversion to fructose-1,6-bisphospate (Hamanaka, Chandel 2012), or 
fructose-2,6-biphosphatase 3 (PFKFB3) can degrade fructose-2,6-biphosphate into 
fructose-6-phosphate by hydrolysis (Shi et al. 2017). Further down the glycolytic pathway, 
pyruvate can enter the mitochondria to be utilised in OXPHOS or get converted to lactate 
by lactate dehydrogenase. In cancer cells, the majority of the glucose transported into the 
cell is metabolised through less efficient (generating 2 ATPs-in comparison to OXPHOS, 
generating 38 net ATPs) aerobic glycolysis pathway. Collectively, these changes in 
metabolism contribute to reduced apoptosis, increased macromolecule biosynthesis and 
balancing of intracellular redox in cancer cells (Fu et al. 2017). 
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4.2. Aims of Chapter 4: Cancer Model/HeLa cells 
• Evaluating the role of galactose in regulating IDH2, NIX and BNIP3 
• Characterising the effect of galactose on promoter DNA methylation of the 
IDH2, NIX and BNIP3 
• Characterising apoptosis and proliferation status of the HeLa cells in galactose 
nutrient regime 
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4.3. Results 
 
The effect of galactose on cancer cell metabolism (in vitro) was studied using HeLa cell line. 
Briefly, cells were grown in 25mM Galactose, and consequently, the effect on 
mitochondrial and apoptotic related genes were investigated. The regulation of IDH2, 
BNIP3 and NIX transcript levels by galactose nutrient regime and subsequent effect on 
protein expression, DNA methylation, DNA hydroxymethylation and functional 
consequence (i.e. cell proliferation and apoptosis) was evaluated.  
 
4.3.1. Galactose upregulates mitochondrial function and reduces lactate in HeLa cells 
Initially, the effect of galactose on lactate production and mitochondrial function was 
investigated. mitDNA is representative of mitochondrial health and function. Therefore, 
qPCR analysis was used to determine the mitDNA content of HeLa cells and normalised to 
the nuclear DNA. The data obtained showed a significant increase in the mitDNA content 
of HeLa cells cultured in galactose nutrient regime for 5 days, exhibiting a 2.7-fold increase 
(Figure 4.2A). Further characterisation of mitochondrial function was carried out by 
investigating mtCOII protein expression under galactose nutrient regime. The data showed 
an upregulation of mtCOII protein, as evaluated by western blotting, demonstrating a 
positive correlation of mtCOII protein expression with mitDNA content of HeLa cells in 
galactose nutrient regime (Figure 4.2B). 
The -KG levels in HeLa cells were quantified using alpha-ketoglutarate assay kit. The data 
obtained showed an increased level of -KG in galactose treated HeLa cells, exhibiting a 
1.75-fold increase (Figure 4.2D). Acquired data from -KG analysis correlated with other 
mitochondrial related analysis, i.e. mitDNA content and mtCOII expression. Additionally, in 
order to assess the effect of galactose on glycolytic activity of HeLa cells, the lactate 
production was analysed using a Lactate Trininty-bitotech assay. HeLa cells were incubated 
in galactose nutrient regime for the duration of 5 days. The supernatant was then collected 
and analysed, demonstrating a significant reduction in lactate production by 52%, relative 
to control (normal DMEM media). The lactate production negatively correlated with 
mitDNA, mtCOII and -KG levels. Collectively, these results indicate a reduction of 
glycolysis and upregulation of mitochondrial function.  
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Figure 4.2: Galactose alters mitochondrial function and lactate production in HeLa cells. 
(A) mitDNA copy number was analysed using qPCR (normalised to nuclear DNA), the data 
obtained showed a significant increase in mitDNA copy number. (B) Lactate production was 
measured in galactose nutrient regime using colorimetric Lactate Trinity-biotech assay. The 
data obtained showed a significant decrease in lactate content in cells. (B) mtCOII protein 
expression was analysed using western blotting (normalised to GAPDH), the data obtained 
showed a significant increase in mtCOII protein expression in galactose nutrient regime of 
HeLa cells. (D) α-KG metabolite levels were measured using fluorometric alpha-
ketoglutarate kit (Abcam), the data obtained showed a significant increase of α-KG levels 
in galactose treated HeLa cells after 5 days, relative to control. Values are mean ±SEM (n=3), 
*P<0.05. (Glu: Glucose 25mM, Gala 2d: Galactose 25mM for 2 days, Gala 5d: Galactose 
25mM for 5 days) 
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4.3.2. Expression analysis in galactose treated HeLa cells 
Following the determination of the role of galactose in regulating mitochondrial function 
and lactate production, we investigated the effect of galactose on key mitochondrial 
related genes. HeLa cells were subjected to galactose nutrient regime for a duration of 5 
days, thereafter DNA, RNA and proteins were extracted. Primer annealing temperatures 
and specificity were optimised by gradient PCR and melt curve analysis. The RNA obtained 
from HeLa cells was subjected to reverse transcriptase reaction using Thermofisher 2 step 
RT kit, followed by mRNA expression analysis by qPCR (AB Biosystem StepOne plus).  
Previous chapter (chapter 3) of this thesis, demonstrated that the downregulation of IDH2 
correlated with a decrease in mitochondrial function. Moreover, in the present chapter, 
mitochondrial function increase was indicated in galactose nutrient regime according to 
the data obtained from lactate, α-KG, mitDNA and mtCOII analysis. Following these 
findings, IDH2 expression was assessed in galactose nutrient regime in HeLa cells, by RT-
qPCR. The data obtained showed a significant increase by 2-fold change in IDH2 expression 
after 5 days of galactose nutrient regime (Figure 4.3A). Following the initial findings of IDH2 
expression, we further investigated mRNA expression of a number of other candidate 
genes related to mitochondrial function (i.e. LDHA and TET2) or forming an integral part of 
mitochondrial structure that can induce apoptosis or reduce proliferation in cancer cells 
(i.e. NIX and BNIP3). 
 
4.3.3. Regulation of key metabolic genes 
In order to determine the regulation of mitochondrial associated genes, HeLa cells were 
incubated in galactose nutrient regime for the duration of 5 days, RT-qPCR based relative 
quantitation approach was then employed. Initially, IDH2, NIX, TET2, BNIP3 and LDHA 
mRNA were analysed after day 5 of galactose treatment. The data obtained showed 
significant changes in IDH2 (2-fold), NIX (1.6-fold) TET2 (1.5-fold) and BNIP3 (0.72-fold), 
whereas, LDHA mRNA expression showed no significant difference (Figure 4.3 A). It was 
interesting to evaluate the time course of expression changes in the highest regulated 
genes by means of RT-qPCR and western blotting. Therefore, we analysed IDH2 and NIX, at 
day 2 of galactose treatment in HeLa cells. The data obtained showed a time dependent 
trend in the upregulation of IDH2: 1.35-fold increase at day 2, and 2-fold increase at day 5. 
NIX also demonstrated a significant increase by 1.5-fold at day 2 and 1.6-fold increase at 
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day 5 of galactose nutrient regime (Figure 4.3B). Subsequent analysis by western blotting 
confirmed previous findings from RT-qPCR analysis, displaying an upregulation of IDH2 and 
NIX expression in galactose treated HeLa cells. IDH2 was found to be upregulated by 1.8-
fold at day 2 and 3.9-fold at day 5. This trend in protein expression change was also evident 
in NIX, displaying a 2-fold increase at day 2 and 5.3-fold at day 5. This response was a time-
dependent increase as previously observed by the mRNA expression analysis. 
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Figure 4.3: Galactose modulates the expression of IDH2, NIX, TET2 and BNIP3. (A) mRNA 
expressions of IDH2, NIX, TET2 were significantly increased, whereas, BNIP3 was 
significantly decreased in galactose treated HeLa cells at 5 days of treatment. LDHA mRNA 
expression analysis showed no significant changes. (B) Highest regulated genes, IDH2 and 
NIX in galactose treated HeLa cells were also analysed at day 2 and 5 of treatment. The RT-
qPCR analysis showed a significant upregulation of IDH2 and NIX mRNA and (C) western 
blotting analysis showed upregulation of IDH2 and NIX in a time-dependent manner, 
confirming previous findings from RT-qPCR analysis. Values are mean ±SEM (n=3), *p<0.05. 
(Glu: Glucose 25mM, Gala 2d: Galactose 25mM for 2 days, Gala 5d: Galactose 25mM for 5 
days) 
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4.3.4. DNA methylation analysis of the IDH2, NIX and BNIP3 promoter region 
4.3.4.1 Galactose decreases methylation and increase hydroxymethylation of DNA 
promoter region of IDH2 and NIX 
In order to examine the relationship between gene expression and promoter DNA 
methylation status of IDH2 and NIX, the target CpG and CCGG islands were identified using 
UCSC Genome browser (GB) (Dec. 2013 assembly genome (NCBI Assembly ID: 5800238) 
(GRCh38.p12)) (IDH2 promoter-Figure 4.4 A). Using GB, the range of potential CpG and 
CCGG islands were mapped on the promoter region within -1200 bp TSS (according to the 
default reference genome build). It was also indicated by GB, that the majority of target 
CpG and CCGG islands were located within -1000 bp from the TSS of IDH2 and within -400 
bp from the TSS of NIX. The identified CpG islands within the high frequency region were 
further subjected to DNA methylation analysis (IDH2-Figure 4.4B, NIX-Figure 4.5). 
Initially, to examine promoter DNA methylation and hydroxymethylation of IDH2 and NIX, 
a methodology combining the action of specific restriction enzyme (i.e. HpaII and MspI) 
and cytosine glycosylation with qPCR, was employed. Briefly, primers designed to target 
the amplification of IDH2 and NIX promoter regions containing a CCGG island were utilised 
in SREMA assay. Specificity of primers used in SREMA were validated by detection of unique 
amplicons in agarose gel electrophoresis and qPCR melting curves. After selecting the 
optimal primers for qPCR, the analysis of IDH2 and NIX was carried out alongside a control 
primer designed to target the genomic region excluding any CpG islands (non-CpG primers). 
The data obtained from SREMA analysis showed that galactose nutrient regime decreased 
DNA methylation and increased hydroxymethylation of both, IDH2 and NIX promoter 
region. This observation was depicted in galactose treated HeLa cells, where significantly 
decreased levels of 5-mC and increased levels of 5-hmC content on IDH2 (Figure 4.4 C and 
D) and NIX (Figure 4.5 A and B) promoter region were detected relative to control cells. 
Also, no change was observed in the region targeted by non-CpG control-primers. The 
overall promoter methylation status of IDH2 using SREMA was significantly decreased by 
0.25-fold and hydroxymethylation status increased by 1.35-fold, and NIX methylation 
decreased by 0.2-fold and hydroxymethylation increased by 1.5-fold in galactose nutrient 
regime of HeLa cells. 
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Figure 4.4: SREMA analysis of the IDH2 DNA promoter methylation and 
hydroxymethylation in galactose treated HeLa cells. (A and B) Distribution of CpG islands 
in the IDH2 promoter region. The gene of interest (i.e. IDH2) and predicted CpG islands are 
represented by green strand and rectangle (outlined in red). Each grey box represents a 
CCGG island within -1000bp upstream of TSS (high frequency CpG region identified using 
GB), and primers spanning these CCGG islands are highlighted above the IDH2 DNA strand 
representation. After galactose treatment, the DNA promoter methylation and 
hydroxymethylation of IDH2 in HeLa cells was significantly decreased and increased, 
respectively. This was confirmed using (C and D) SREMA. Values are mean ±SEM (n=4), 
*p<0.05. (Glu: Glucose 11mM, Gala 5d: Galactose 25mM for 5 days, TSS: Transcription start 
site) 
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Figure 4.5: SREMA analysis of the NIX DNA promoter methylation and 
hydroxymethylation in galactose treated HeLa cells. Cells were subjected to galactose 
nutrient regime for 5 days. (A) DNA promoter methylation status of NIX was analysed using 
SREMA, the results obtained showed a significant decrease in the methylation status of NIX 
promoter region. (B) DNA promoter hydroxymethylation was analysed using SREMA, the 
results obtained showed increase in hydroxymethylation status of NIX promoter region in 
galactose nutrient regime. Values are mean ±SEM (n=3), *p<0.05. (Glu: Glucose 25mM, 
Gala 5d: Galactose 25mM for 5 days) 
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4.3.4.1. Galactose downregulates BNIP3 without significant changes in DNA 
methylation 
In contrast to IDH2 and NIX, BNIP3 mRNA expression was downregulated in galactose 
treated HeLa cells. To further characterise the changes observed in RT-qPCR data, the 
protein expression of BNIP3 was assessed by western blotting. The data obtained showed 
significant downregulation of BNIP3 by 0.7-fold in galactose nutrient regime (Figure 4.6A), 
which is in agreement with mRNA expression analysis. Furthermore, to assess the DNA 
methylation status of BNIP3, the identical SREMA approach as described in chapter 3 
(section 3.3.2.1) was employed. The data obtained showed no significant methylation 
changes at the promoter region (Figure 4.6B).  
 
  
117 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Galactose downregulates BNIP3 expression but displays no significant changes 
in methylation levels at the DNA promoter region. HeLa cells were subjected to galactose 
nutrient regime for a duration of 5 days. (A) The data obtained showed significant 
downregulation of BNIP3 protein expression, analysed by western blotting (normalised to 
GAPDH). (B) DNA promoter methylation status of BNIP3 was analysed using SREMA. The 
data obtained showed no significant changes in the methylation level of the promoter 
region. (Glu: Glucose 25mM, Gala 5d: Galactose 25mM for 5 days) 
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4.3.5. Galactose negatively regulates DNMT3a at the post-transcriptional level 
Previous data from this chapter demonstrated significant changes in DNA methylation 
status of IDH2 and NIX promoter region in galactose treated HeLa cells. In order to extend 
these findings, the modulation of DNMT3a in galactose treated HeLa cells was assessed by 
RT-qPCR and western blotting. The data obtained showed a significant decrease in DNMT3a 
protein abundance in cells treated with 25mM galactose (Figure 4.7A), displaying a 0.6-and 
0.8-fold downregulation after day 2 and day 5, respectively. However, RT-qPCR analysis 
showed no significant changes in DNMT3a mRNA levels in galactose treated HeLa cells at 
day 5 of treatment (Figure 4.7D). The lack of correlation between mRNA and protein 
expression, and previous data (Chapter 3) in rat INS-1 cells suggested that DNMT3a may be 
regulated by other factors, such as PTMs, that may mediate its protein content in HeLa 
cells. To address a possible PTM regulatory mechanism in the modulation of DNMT3a 
abundance, HeLa cells were treated with the proteasomal inhibitor MG132 at 
concentrations of 10 µM. MG132 treatment increased DNMT3a protein abundance by 1.5-
fold and 1.4-fold at 2 and 4 hours, respectively (Figure 4.7B). 
 
4.3.5.1. Galactose decreases histone acetylation in HeLa cells 
After characterising the effect of galactose on the PTM-modulated DNMT3a protein 
abundance, the acetylation status of Histone 3, a surrogate assessment of nutrient 
treatment efficacy, was investigated. The data obtained showed substantial decrease of 
histone 3 acetylation by 0.6-fold and 0.95-fold at day 2 and 5 of galactose treatment, 
respectively in HeLa cells (Figure 4.7C). The acetylation changes observed in histones also 
revealed a time-dependent alteration, similar to DNMT3a. 
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Figure 4.7: Galactose decreases DNMT3a protein abundance and histone 3 acetylation. 
HeLa cells were treated with galactose nutrient regime for 2 and 5 days. (A) DNMT3a 
protein abundance showed significant downregulation in the presence of galactose, in time 
a dependant manner, assessed by western blotting. Changes in histone 3 acetylation were 
analysed by western blotting and demonstrated significant decrease in acetylation of 
galactose treated HeLa cells. (B) Cells treated with MG132 (proteasomal degradation 
inhibitor) increased the protein abundance of DNMT3a in a time dependant manner. (C) 
RT-qPCR analysis of DNMT3a showed no significant changes in galactose treated HeLa cells. 
(Glu: Glucose 25mM, Gala 2d: Galactose 25mM for 2 days, Gala 5d: Galactose 25mM for 5 
days) 
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4.3.6. Galactose reduces proliferation and induces apoptosis  
In order to investigate the functional consequence of galactose on HeLa cells, the rate of 
apoptosis and proliferation were assessed. This was achieved by subjecting HeLa cells to 
25mM galactose for a duration of 5 days. Cisplatin was used as an experimental positive 
control for apoptosis/necrosis assay. The rate of apoptosis and necrosis were then assessed 
using Apoptosis/Necrosis Abcam kit. The data obtained showed a significant increase of 
apoptosis in galactose treated HeLa cells by 92%, relative to control. Whereas, necrosis 
analysis displayed no significant difference between control or galactose nutrient regime. 
In addition to the findings obtained from apoptosis assay, the proliferation in galactose 
treated HeLa cells showed significant decrease in proliferation by 87%, relative to control. 
The data collected from digital microscope also confirms the findings of proliferation assay, 
displaying a substantial decrease in the cells at 5 day of galactose nutrient regime.  
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Figure 4.8: Galactose increases apoptosis and decreases proliferation in HeLa cells. Cells 
were treated with galactose (25mM) for a duration of 5 days. (A) The results obtained 
showed significant increase in cell apoptosis, as analysed by fluorescence based apoxin dye. 
(B) Moreover, no significant changes were observed in necrosis analysis of galactose 
treated HeLa cells. The positive control in apoptosis and necrosis assay was Cisplatin (Cis). 
(C, D) Cell proliferation was significantly decreased as analysed using WST-1 colorimetric 
assay and as demonstrated by digital microscopy. Values are mean ±SEM (n=3), *p<0.05. 
(Glu: Glucose 25mM, Gala 5d: Galactose 25mM for 5 days, Cis: Cisplatin) 
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4.3.7. IDH2 expression can be modulated by inducing hydroxymethylation at the 
promoter region 
To validate the role of epigenetics in the regulation of IDH2 expression, a specific dCAS9-
Tet1CD system was targeted to the DNA promoter region of the IDH2 to induce 
hydroxymethylation. HEK293 cells were transfected with a combination of a specific 
guidance RNA and a construct encoding the fusion of a defective CAS9 and the catalytic 
domain of Tet1 and were used to induce IDH2 promoter hydroxymethylation and protein 
content. Figure 4.9 shows the hydroxymethylcytosine enrichment achieved in the IDH2 
promoter region by the dCAS9-Tet1CD system (over a 9-fold change), when compared to 
control cells. Similarly, the treatment resulted in a significant increase in IDH2 protein 
abundance (Figure 4.9B, over 2.8-fold change increment). 
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Figure 4.9: Changes in IDH2 expression by induction of DNA promoter 
hydroxymethylation. (A) The status of IDH2 promoter DNA hydroxymethylation, induced 
by a specific dCAS9-Tet1CD + IDH2 gRNA system was assessed as described previously 
(section 2.5.3). HEK293 cells transfected with this system (and selected under puromycin 
for 2 days), showed an 9-fold increase in IDH2 promoter hydroxymethylation, when 
compared to mock transfected cells. (B) Representative western blotting analysis from 
these cells showed a 2.8-fold increase in protein abundance, judged by densitometry. 
Values were normalised to internal housekeeping expression. Values are mean ±SEM (n=3), 
*p<0.05. (Ctrl: Untreated/Wild-type HeLa cells, dCAS-TET+gRNA IDH2: HeLa cells targeted 
by dCAS9 methodology) 
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4.4. Discussion 
 
The incompetence of normal proliferating cell to generate sufficient ATP from glucose 
reactivates catabolism and induces cell cycle arrest (Heiden et al. 2009). However, cancer 
cells evade this mechanism and perform aerobic glycolysis in a highly proliferative state; 
this phenomenon is also known as ‘The Warburg effect'. Nevertheless, ‘The Warburg effect' 
in cancer cells remains to be fully understood. An important factor also noted by Warburg 
and colleagues was that depriving the cancer cells of glucose and oxygen did not affect their 
viability. To our understanding of cancer cell's metabolic changes, this chapter confirms 
that galactose is a key regulator of glycolysis and deregulates key mitochondrial-related 
gene expression by inducing epigenetic changes in HeLa cells. Our data demonstrates the 
involvement of galactose nutrient regime in regulating metabolism and epigenetic profile 
of cancer cells. We also found that galactose induces apoptosis and reduces proliferation 
in HeLa cells.  
 
4.4.1. Lactate production and Mitochondrial activity 
Aerobic glycolysis and high levels of lactate production are considered the fundamental 
metabolic changes frequently detected in cancer cells. To assess this metabolic shift, HeLa 
cells were subjected to galactose treatment for a duration of 5 day, followed by subsequent 
metabolic and epigenetic investigations. Cells treated with galactose exhibited a 
substantial reduction in lactate production. Consistently, the generation of lactate has been 
linked with aerobic glycolysis (Fantin et al. 2006), a process often observed in cancer. 
Jimenez et al. ( 2011) correspondingly reported the reduction in lactate production in 
Chinese Hamster Ovaries cells treated with galactose. Lane et al. (2015) also reported 
similar findings in Chromocytes (primary cells). During the presence of glucose, highly 
proliferative cells produce biomass and lactate along with other metabolic components, 
whereas, in the depletion of glucose, cells tend to the consume galactose and lactate 
(Jiménez et al. 2011). These findings suggest that the reduction in lactate observed in our 
study, could be accounted not only by downregulation in lactate production but also by the 
uptake of lactate into the cells.  
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Rogatazki et al. (2015) suggested that lactate production is a result of a near equilibrium 
reaction, this equilibrium invariably favours the production of lactate from pyruvate, and 
support the cytosol-to-mitochondria lactate shuttle, during this process the activity of LDH 
defines the flow of lactate. In order to extend on the findings from lactate assay, LDHA 
mRNA was assessed by RT-qPCR analysis. The LDHA mRNA expression displayed no 
significant regulation in galactose treated HeLa cells. The reduction in lactate production 
and LDHA mRNA expression do not correlate in our study. Similar findings were observed 
in the cerebral cortex of rat, demonstrating the lack of correlation between LDHA activity 
and expression (Nunes et al. 2015). LDHA activity has previously been found to be regulated 
by PTMs, such as acetylation (Zhao et al. 2013), which could suggest the differences 
between mRNA expression and lactate production observed in our study.  
mitDNA copy number and mtCOII are representatives of mitochondrial health and function. 
Defects in mtCOII have been previously linked with reduced Complex IV activity in 
mitochondrial diseases (Clark et al. 1999); complex IV, is a major regulator of OXPHOS 
(Signes, Fernandez-Vizarra 2018). Therefore, studying the regulation of mitDNA copy 
number and mtCOII in galactose treated HeLa cells was an important step in understanding 
the underlying mechanisms involved in galactose-mediated metabolic changes. The data 
obtained from mtCOII expression and mitDNA copy number suggested that galactose 
upregulates mitochondrial activity. mitDNA is a hallmark of mitochondrial health (Rooney 
et al. 2015), proliferation (Baldelli et al. 2014) and is associated with OXPHOS (Deus et al. 
2015). Moreover, mtCOII is a mitDNA-encoded structural subunit that forms the catalytic 
core of Complex IV (Fernández-Vizarra et al. 2009), hence the importance of assessing 
mitDNA and mtCOII together. The upregulation of mtCOII was observed after 2 days of 
galactose nutrient regime, and this change was significantly increased after 5 days. Li et al. 
(2006) reported that complex IV suppression dictates a reduction in total cellular 
respiration. Aguer et al. (2011) correspondingly reported that galactose increased complex 
IV activity in myotubes leading to enhanced aerobic metabolism. Additionally, Deus et al. 
(2015) showed that galactose upregulated mitDNA content in H9c2 cardiomyoblast cells. 
Collectively, these findings and our data suggests that galactose upregulates mitDNA copy 
number and mtCOII protein expression, that may lead to increased OXPHOS. 
Moreover, mitDNA-depleted cells (rho(0)) demonstrated low mitochondrial membrane 
potential loss-mediated apoptosis (Ferraresi et al. 2008), indicating that mitDNA can play 
an important role in cancer's metabolic switch in order to avoid apoptosis. This data in 
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combination with ours suggest that mitDNA downregulation may be an important factor 
for cancer cell's survival, and galactose nutrient regime can revert this effect by restoring 
mitDNA content. Moreover, mitDNA copy number correlates with the expression of 
respiratory genes (van Gisbergen et al. 2015). Seidel-Rogol et al. (2002) showed the effect 
of depleting and repleting the mitDNA content of HeLa cells on mitochondrial transcripts 
and transcription. This ethidium bromide-based regulation demonstrated that the 
mitochondrial proteins are highly coordinated with the mitDNA content. Our data also 
supports these findings, where we found that galactose increases mitDNA copy number 
and mtCOII expression simultaneously.  
In our study, we aimed to assess the role of galactose in regulating key mitochondrial 
proteins including IDH2, and metabolites including α-KG. IDH2 is dysregulated in various 
cancers, and increased IDH2 expression correlates with good patient prognosis (Lv et al. 
2012). In addition, α-KG derived from IDH2/3, is an important intermediate in the TCA cycle 
(Rojanarata et al. 2018). IDH2 and α-KG levels are important aspects of the mitochondrial 
activity and both play a significant role in OXPHOS and tumour suppression (YI et al. 2016; 
Lv et al. 2012). Therefore, we assessed the intracellular levels of α-KG in galactose treated 
HeLa cells. The data obtained showed significant increase in α-KG levels at 5 days of 
galactose nutrient regime. This data also correlates with the regulation of mtCOII and 
mitDNA content of HeLa cells.  
Previously, IDH2 expression abnormalities were reported in multiple cancers: presenting as 
downregulation and upregulation, and in some cancers downregulation at early stages 
followed by upregulation in advanced stages (Lv et al. 2012; Green, Beer 2010; Fu et al. 
2010). These findings require further investigations to elaborate on the role of IDH2 in 
cancer. In our study, IDH2 protein expression analysis by western blotting showed a 
significant upregulation in galactose treated HeLa cells. Increased cellular levels of IDH2 
expression and α-KG content have been previously associated with increased 
mitochondrial function (Vohwinkel et al. 2011), which supports our findings of 
mitochondrial function in galactose treated cells. Moreover, IDH2 mutations in cancer have 
been suggested to incur with simultaneous decrease in the production of α-KG, and gain of 
a new function leading to the production of 2-HG (Reitman et al. 2010; Yang et al. 2012; Fu 
et al. 2010). 2-HG, an oncometabolite known to promote tumour growth by inhibiting TET 
family (Janke et al. 2017). 2-HG mediated TET inhibition hinder 5-mC conversion to 5-hmC, 
resulting in global DNA hypermethylation at promoter regions (Carbonneau et al. 2016). 
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However, in normal cells, Malate dehydrogenase, 3-phosphoglycerate and LDHA have been 
shown to promiscuously produce 2-HG, that likely serves a normal biological function (Ye 
et al. 2018). 2-HG is also a prominent hallmark of 2-hydroxyglutaric aciduria, a rare 
neurometabolic disease caused by mutations in SLC25A1 (mitochondrial citrate carrier) 
leading to the accumulation of 2-HG (Nota et al. 2013). The role of 2-HG in cancer has 
contradictory evidence, where the decreased levels of α-KG have been strongly associated 
with the metabolic shift commonly observed in cancer cells (Li et al. 2018; Fu et al. 2010).  
In our study, we focused on the changes in α-KG levels and the metabolic changes caused 
by galactose, including the reduction in lactate production, increase in mitochondrial 
function and IDH2 expression. Mitochondrial fusion also plays an important role in cellular 
metabolism, however previous studies have found fusion index of cells was not regulated 
by galactose (Aguer et al. 2011), hence it was not explored in our study. 
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Figure 4.10: Schematic diagram depicting the effect of galactose on lactate production 
and mitochondrial function. Galactose nutrient regime was able to reduce the production 
of lactate in HeLa cell. Additionally, upregulation of mitDNA copy number, mtCOII protein 
expression, IDH2 expression and α-KG levels was observed. Collectively, indicating the 
reversion of ‘The Warburg effect’ in cancer cells. 
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4.4.2. Galactose induces epigenetic changes in IDH2 and NIX 
One of the main aims of this chapter was to characterise the effect of galactose on 
promoter DNA methylation of IDH2, NIX and BNIP3. In order to achieve this aim, we 
assessed DNA methylation status of IDH2, NIX and BNIP3 by SREMA combined qPCR 
methodology. The data obtained revealed the dual role of galactose in simultaneously 
regulating DNA methylation and hydroxymethylation of IDH2 and NIX promoter regions. 
Moreover, the data collected demonstrated a positive correlation between gene 
expression and 5hmC levels, and a negative correlation between gene expression and 5mC 
levels of IDH2 and NIX.  
Rheb promotes mitophagy via interactions with NIX and LC3-II. Melser et al. (2013) 
suggested that stimulation of mitochondrial OXPHOS enhances mitophagy by recruiting 
GTPase Rheb to the mitochondrial membrane. Other studies have demonstrated, that NIX 
overexpression can promote mitophagy without substantial loss in mitochondrial content 
and thereby resulting in improved bioenergetics of the cell (Koentjoro et al. 2017; Zhang, 
Ney 2009). IDH2 and NIX form an integral part of mitochondria, either structurally or 
functionally, and the expression of both genes  is substantially reduced in cancer, 
correlating with poor patient prognosis (Zhang, Ney 2009; YI et al. 2016). In our study, RT-
qPCR and western blotting analysis showed a significant upregulation of NIX expression in 
galactose treated HeLa cells. The importance of NIX in cancer was previously explored by 
Du et al. (2017), which revealed that the platinum-based cisplatin drug mechanism of 
action involves NIX pathway mediated by mir-30c leading to apoptosis. Moreover, Wu et 
al. (2016) demonstrated that platinum conjugated to galactose had significantly higher 
toxicity to cancer in comparison to other commonly used drugs, including cisplatin and 
oxaliplatin. This increase in cytotoxicity was hypothesised to be associated with galactose 
motif led advantages associated with ‘The Warburg effect’. Our data in conjunction with 
these studies indicates that both galactose and platinum may include NIX mediated 
apoptosis pathways, therefore the observed effect of increased toxicity of platinum-
conjugated-galactose compared to cisplatin or oxaliplatin could be a result from the 
combined action of galactose and platinum through NIX mediated pathway.  
Other mitochondrial adapter proteins including BNIP3 are also shown to regulate 
mitophagy (Chang et al. 2017). However, in our study we found galactose downregulated 
BNIP3 at mRNA and protein level at 5 days of treatment. NIX and BNIP3 are proteins with 
homology to BCL2 in the BH3 domain, and both proteins induce cytochrome c release 
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leading to apoptosis (Zhang, Ney 2009). Both (NIX and BNIP3) are directly activated by 
hypoxia induced factor (HIF) (Bellot et al. 2009). Despite these similarities, our data 
demonstrated a substantial difference in the expression of NIX and BNIP3 in galactose 
nutrient regime, therefore, suggesting galactose mediated NIX regulation can be 
independent of HIF. NIX, but not BNIP3, has been suggested to be involved in mitophagy 
during development, suggesting a distinct role of the two proteins in certain cellular 
processes (Ney 2015). Furthermore, unlike BNIP3, NIX expression is regulated by p53 
binding to its motif site on NIX, thereby inducing its expression. Moreover, NIX also 
mediates red blood cell differentiation by mitophagy (Fei et al. 2004; Sandoval et al. 2008). 
Collectively, these findings and our data suggests that NIX and BNIP3 can be regulated 
inversely, and this differential regulation correlates with DNA methylation and 
hydroxymethylation status of NIX promoter region. Interestingly, Schweers et al. (2007) 
suggested that cells are unable to carry out selective mitochondrial clearance at the 
autophagosome in the absence of NIX, therefore, suggesting that NIX is essential for 
selective mitochondrial elimination. However, this autophagosome mediated process 
doesn’t require BAK, BAX or BLC-XL. In contrast, BNIP3 mediated proapoptotic activity 
requires BAX or BAK downstream functions (Zhang, Ney 2009; Wei et al. 2001); these 
findings demonstrate the functional differences between NIX and BNIP3, suggesting the 
two proteins may involve distinct upstream and downstream pathways.  
In addition to mitochondrial activity, IDH2 is directly associated with global DNA increase 
of 5hmC levels, and mutations in IDH2 genes leads to impaired 5hmC levels in cancer 
(Rampal et al. 2014). For example IDH2 dysfunction in gastric cancer results in decreased 
5hmC and increased 5mC levels, leading to cancer progression (Chou et al. 2016). Increased 
5hmC levels have previously been shown to be associated with decreased 5mC levels, 
therefore demonstrating an inverse correlation between the two DNA modifications (Vető 
et al. 2018). IDH1, a structurally and functionally similar enzyme to IDH2, has been shown 
to directly influence the 5hmC levels in tumour, which also correlated with α-KG levels (Ge 
et al. 2018; Al-Khallaf 2017). These findings indicate that IDH2 is an important regulator of 
cellular epigenetics in addition to its role in mitochondrial function. Furthermore, α-KG is 
an essential co-factor that facilitates the conversion of 5mC to 5hmC by TET family of 
proteins. The association between the IDH2 expression, α-KG and 5hmC levels have been 
previously described (Mahajan et al. 2017). Interestingly, changes in 5hmC levels in IDH 
mutant cancers, is usually denoted to the modulation of TET proteins (Pelosi et al. 2016). 
However, IDH and TET mutant cancers express significant clinical differences; suggesting 
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distinct differences between the two proteins (Inoue et al. 2016). These findings also 
indicate that the deregulation of IDH2 and α-KG levels can exhibit a global effect on DNA 
methylation status in cancer cell. Collectively, these findings suggest, the observed 5hmC 
increase and 5mC decrease of NIX promoter region can be mediated by IDH2. NIX has 
previously been shown to be downregulated by hypermethylation of DNA promoter region 
in hepatocellular carcinoma (Calvisi et al. 2007), suggesting DNA methylation plays an 
important regulatory role for this protein.  
Additionally, our data showed no significant DNA methylation changes on BNIP3 promoter 
region in galactose treated HeLa cells. BNIP3 has previously been shown to be regulated by 
DNA methylation in other studies (Murai et al. 2005), but our data doesn’t correlate with 
these findings. However, Diest et al. (2010) demonstrated that BNIP3, in invasive breast 
cancer, is not regulated by DNA promoter methylation, suggesting an alternative regulatory 
pathway may mediate BNIP3 expression in galactose treated HeLa cells. Our combined 
findings of NIX and BNIP3 expression and epigenetics contributes to our understanding of 
how multiple pathways may regulate mitochondrial turnover and therefore can be 
explored for cancer treatment. 
The mechanisms involved in DNA methylation alterations in cancer, remain largely not 
understood. In order to advance this understanding, in our study, DNMT3a, a de novo 
methyltransferase, that plays an important role in gene regulation by facilitating active 
promoter methylation (Jia et al. 2016) was examined in galactose treated HeLa cells. 
Notably, western blotting analysis showed downregulation of DNMT3a in a time-
dependant manner. However, RT-qPCR analysis showed no regulation of DNMT3a mRNA 
level. It was previously shown that DNMT3a downregulation correlates with improved 
patient survival and lower recurrence in lung cancer patients, which also correlated with 
reduced global DNA methylation (Liu et al. 2018). In terms of DNMT3a regulation, Gu et al. 
(2017) analysed chorionic villi of early embryos that reached an growth arrest, this study 
found that DNMT3a was significantly downregulated in these villi. However, this 
downregulation was only evident at the protein level, but not at the mRNA level. These 
findings relate to our data in terms of discrepancies observed between DNMT3a mRNA and 
protein levels. 
Furthermore, to demonstrate the reversibility of epigenetic modification in cancer cell by 
genetic interventions, we utilised a targeted dCAS9-Tet1CD system to modulate the IDH2 
promoter hydroxymethylation. The Tet1 enzyme belongs to a family of proteins, catalysing 
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the conversion of 5-mC in 5-hmC, an epigenetic change associated with the induction of 
gene expression (Kroeze et al. 2015). The fused protein between a nuclease defective CAS9 
(dCAS9) and the catalytic domain of Tet1 allowed a targeted action of this enzyme on a 
methylated promoter. HEK293 cells, transfected with a combination of a specific IDH2 
promoter guidance RNA and dCAS9-Tet1CD, showed a significant increase in 
hydroxymethylation of IDH2 promoter region leading to increased protein expression. 
 
4.4.3. Modulation of DNMT3a and Histone acetylation 
DNA methylation is carried out by DNMT1, DNMT3a and DNMT3b (Robertson et al. 1999); 
DNMT1 is widely studied because of its involvement in cell cycle and maintenance of DNA 
methylation during cell division (Du et al. 2010). DNMT3a and its function in somatic cells 
remains vastly unexplained. A number of studies have suggested that DNMT1 is regulated 
by protein acetylation (Cheng et al. 2015; Peng et al. 2011), and depending on the targeted 
Lysine, the PTM can increase or decrease the protein activity. These findings in combination 
with our previous data in this chapter led us to speculate the role of PTM in DNMT3a. 
Therefore, HeLa cells were treated with MG132, a proteasomal degradation inhibitor. The 
data obtained showed that DNMT3a protein abundance increases in a time-dependant 
manner. Therefore, suggesting that DNMT3a degradation can be mediated by ubiquitin 
proteasome pathway and modulated by PTM. Another aspect of the investigation was to 
address the histone acetylation status in galactose treated HeLa cells. The data obtained 
showed a significant and time-dependant decrease in acetylation of histone in galactose 
nutrient regime, demonstrating a similar trend to DNMT3a protein abundance. Histone 
acetylation is associated with transcriptional upregulation leading to cell growth and 
proliferation (Cai et al. 2011). Combined with our findings, these results add to the 
understanding of the epigenetic changes that can be reverted by nutrients in cancer. 
Epigenetic modification also depend on specific metabolites (Tran et al. 2017). For example, 
acetylation of histones is carried out by HATs that require acetyl-CoA to carry out their 
function (Pons et al. 2009). Emerging insights suggests that modulation of these specific 
metabolites can regulate the function of the associated enzymes leading to epigenetic 
modifications (Su et al. 2016; Lempradl et al. 2015; Tran et al. 2017). Collectively, these 
findings suggest that changes in metabolism are reflected in epigenetics of the cell, which 
supports our findings of the changes mediated by galactose in mitochondrial activity and 
IDH2 expression that inversely correlate with DNA methylation and histone acetylation.  
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The impact of metabolic changes on histones is already established, multiple metabolic 
pathways including glycolysis and β-oxidation can lead to changes in acetyl-CoA and 
therefore regulate the acetylation of histones (Etchegaray, Mostoslavsky 2016). In support 
of this, Peleg at al. (2016) also suggested that the level of histone acetylation is susceptible 
to metabolites such as acetyl-CoA. Additionally, Acetyl-CoA has been shown to be tightly 
regulated in yeast and controls growth and survival (Cai et al. 2011; Cai, Tu 2011). In cancer 
cells, the pyruvate derived from glycolysis enters the truncated TCA cycle, and instead of 
being converted into α-KG by IDH2, it gets exported into cytosol as citrate by the 
tricarboxylic transporter, followed by ACLY mediated conversion into acetyl-CoA  
(Hatzivassiliou et al. 2005). These findings combined with our data suggests that galactose 
leading to increased IDH2 expression, mtCOII expression and mitDNA content may 
subsequently result in decreasing the pool of intracellular acetyl-CoA by modulating the 
TCA cycle; this can be further supported by the increase in intracellular α-KG levels. 
Speculatively, the combined data of histone acetylation, DNMT3a protein abundance and 
PTM susceptibility of DNMT3a, suggests that DNMT3a might therefore be regulated by 
acetylation.  
DNA methylation and histone acetylation are conserved between different species and 
serve as major gene regulatory mechanisms. For example, yeast cells have been shown to 
adapt their epigenetic profile and consequently the gene expression according to nutrient 
availability. Histone acetylation and deacetylation is usually associated with increase and 
decrease in transcription, respectively (Etchegaray, Mostoslavsky 2016). However, our data 
shows the complexity of the interplay between histone acetylation and DNA methylation. 
In our study, galactose nutrient regime reduced histone acetylation and DNA methylation, 
and increased hydroxymethylation that correlated with increased mRNA and protein 
expression of IDH2 and NIX. Moreover, DNMT3a was previously shown to bind with the 
histone 3 tails, thereby, increasing the DNA methylation by 8-fold globally. Therefore, the 
IDH2 and NIX upregulation observed in our study could have resulted from the dual action 
of DNMT3a. Firstly, because of decreased protein abundance of DNMT3a, and secondly, 
because of its decreased interactions with histone tails (Ooi et al. 2007; Li et al. 2011). This 
connection between DNMT3a and histone tails was suggested to be a DNA methylation 
checkpoint, suggesting that the deacetylation of histone 3 observed in our study can result 
in lower accessibility of histone tails, leading to reduced DNMT3a mediated DNA 
methylation. 
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4.4.4. Cancer cell proliferation and apoptosis modulation by galactose 
The changes in metabolism, including ‘The Warburg effect' has been extensively studied 
and linked to cancer proliferation and progression. IDH2, an important part of central 
metabolism, generates -KG from the oxidation of isocitrate. Moreover, the 
downregulation of IDH2 has been shown to increase cancer proliferation (Zou et al. 2017; 
Lv et al. 2012). Therefore, we assessed the proliferation of HeLa cells following our findings 
of IDH2 in galactose nutrient regime. The data obtained showed that galactose significantly 
reduced the proliferation of HeLa cells at 5 days of treatment. The connection between 
metabolism and cell proliferation was previously demonstrated and is extensively 
discussed by Colombo et al. (The principal investigator of our group) (2012). 
Understanding the mechanism of galactose is not only important for therapeutics in cancer 
but also for non-cancerous pathologies (e.g. diabetes) and normal cells (e.g. T lymphocytes) 
(Moncada et al. 2012; Swisa et al. 2017). Galactose has been shown to prevent cell death 
by reducing Endoplasmic reticulum (ER) stress. Moreover, radiolabelled tracer studies 
demonstrated that the effect of galactose on cells can last even after the cells have been 
transferred from galactose to glucose (Kase et al. 2013). These findings combined with ours 
suggest that the lasting effect of galactose on cellular metabolism can be due to the 
epigenetic modification (i.e. DNA methylation and histone acetylation) introduced during 
this nutrient regime. Epigenetic modifications are commonly described as epigenetic 
memory. In terms of epigenetics, a stable gene expression profile can be adapted due to 
environmental changes and maintained in the cells for the duration of life cycle (D’Urso, 
Brickner 2014). Cancer cells and fibroblasts cultured in galactose instead of glucose has 
been shown to shift their metabolism towards OXPHOS instead of glycolysis (Marroquin et 
al. 2007; Robinson et al. 1992). The mechanism of this shift can provide essential insights 
into the ‘The Warburg effect’. In our study, we show that the shift in metabolism in 
galactose treated HeLa cells led to changes in DNA methylation, hydroxymethylation, 
histone acetylation and possibly DNMT3a PTM. Moreover, IDH2 and NIX, known to be 
associated with cell proliferation and apoptosis, were upregulated in galactose treated 
HeLa cells. Subsequently, leading to reduced proliferation and increased apoptosis. These 
findings, at least in part suggest mechanisms or purpose for ‘The Warburg effect’.  
Otto Warburg’s observations link the impairment of respiration in cells to mitochondria, 
resulting in a switch to aerobic glycolysis. This modulation of metabolism has been shown 
to assist cell proliferation by facilitating the uptake of nutrients and biosynthesis of amino 
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acids, lipids and nucleotides (Heiden et al. 2009). Sasaoka et al. (2018) correspondingly to 
our data also demonstrated reduced proliferation in galactose treated HEK293 cells. Yi et 
al. (2016) demonstrated that downregulation (RNAi mediated) of IDH2 led to a pro-
proliferative effect in MG-63 and Saos-2 osteosarcoma cells, and it was also noted that 
IDH2 was inversely correlated with cancer metastasis. AML, Glioma, chondrosarcoma and 
cholangiocarcinoma are commonly associated with IDH2 mutations. In these cancers, IDH2 
wild-type activity and -KG production are marginally decreased, corelating with increased 
proliferation (Fujii et al. 2016). Overall, these findings suggest that IDH2 and -KG are 
associated with cellular proliferation. Notably, our data shows galactose increases the 
expression of IDH2 and production of -KG: these two changes are interconnected and 
likely contributed to the observed reduced proliferation in HeLa cells treated with 
galactose. 
As discussed previously in this chapter, NIX, a pro-apoptotic gene, has been shown to be 
frequently downregulated in cancer, and correlating with poor patient prognosis (Zhang, 
Ney 2009; Du et al. 2017). Our findings from galactose treated HeLa cells showed 
upregulation of NIX, therefore we investigated the effect of galactose on apoptosis in HeLa 
cells. The data obtained showed that galactose induced apoptosis in HeLa cells. Although 
necrosis has been considered an unregulated and passive form of cell death, recent findings 
suggest that under extreme conditions the cells induce necrosis in a regulated manner 
(Proskuryakov, Gabai 2010). Peng et al. (2018) demonstrated, in pancreatic acinar cells, 
that galactose reduced the rate of necrosis. Conversely, in our study, we examined the 
effect of galactose on necrosis in HeLa cells. However, we found no significant changes in 
cells treated with galactose.  
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Figure 4.11: Schematic figure illustrating the conclusion of chapter 4 (for further 
explanation see section 4.5).  
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4.5. Conclusion 
In conclusion, our data shows that in the cancer model HeLa, galactose nutrient regime led 
to a significant increase in IDH2 and NIX expression by an active epigenetic modulation of 
the genes (methylation and hydroxymethylation). These changes were accompanied by the 
upregulation of key mitochondrial components, including mtCOII, α-KG levels and mitDNA 
copy number, and reduction of lactate production. Additionally, deacetylation of histone 
and destabilisation of DNMT3a was observed, thereby, explaining the reduced rate of DNA 
methylation observed in IDH2 and NIX promoter region. Finally, cell proliferation and 
apoptosis were found to be reduced and increased, respectively in galactose treated HeLa 
cells. Overall, our study provides a rationale for the design of therapeutic strategies aiming 
to modulate the epigenetic mechanism of a cancer cells in order to reduce cancer 
progression and induce cell death. 
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CHAPTER 5: REGULATION OF CELL CYCLE AND THE ROLE OF ACETATE IN 
RESTRICTION POINT 
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5.1. Introduction 
 
The reproduction and growth of eukaryotes depends on the regulation of cell cycle. The 
multicellular organisms rely on cell cycle for chromosomal replication and subsequent 
distribution of the biological information into the daughter cells (Kheir, Lund 2010). The 
typical cell cycle is divided into four different stages: G1 (Gap 1), S (Synthesis), G2 (Gap 2) 
and M (Mitosis); these are in addition to a quiescent stage called G0 phase (Figure 5.1). Each 
cell cycle stage performs a specific function (Harashima et al. 2013). The current view of 
the cell cycle in eukaryotes is dominated by G1 phase. During the G1 period of the cell cycle, 
differentiated cells carry out their physiological function, and usually do not activate S 
phase from G1 (Cooper 2000). The formation of cyclin D complex with cyclin dependant 
kinase 4/6 (Cdk4/6) is a critical step in G1 phase that performs phosphorylation on 
retinoblastoma (pRB) protein and induces E2f transcription factor, consequently, 
facilitating the expression of various genes required for the cell cycle progression (Farioli-
Vecchioli, Tirone 2015).  In proliferating cells, G1 phase is followed by the S phase, also 
known as the DNA replication phase. In G2 phase cells grow and synthesise proteins for 
mitosis preparation (Cooper 2000). The cell cycle, in particular S phase, was previously 
shown to be shortened in proliferating cells. For example Fariolo-Vecchioli et al. (2015) 
demonstrated that proliferating adult progenitor cells shortened their S phase by 60% in 
comparison to the surrounding tissue. The nutrient sensitive restriction point (R-point) in 
G1 was originally suggested by Arthur Pardee (1974). In nutrient depleted environments, 
cell remain in quiescent state and do not activate the R-point in order to transition into S 
phase. However, cells that pass the R-point will continue to progress in cell cycle and divide 
regardless of nutrient availability after the R-point (before entering quiescent state on the 
next R-point). The role of R-point is to ensure that prerequisites requirement for cellular 
division are fulfilled, therefore, allowing the completion of proliferation once this 
restriction point is passed. R-point is an important factor involved in various biological 
process in several species, including regulation of mitosis, maturation of oocytes, bacterial 
nutrient utilisation and yeast mating response, due to its low maintenance and high 
threshold nature (Yao et al. 2008). 
Cyclins are modulated by the availability of specific nutrients and regulatory metabolic 
enzymes in cell cycle. Cyclins are the regulatory subunits of CDK holoenzyme complexes 
regulating the cell cycle progression through checkpoints by phosphorylating and 
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modulating the function of target substrates (Du et al. 2010). Cyclin-dependant 
degradation plays a key role in the progression of the different cell cycle phases. For 
example, APC/C mediates the progression from mitosis into G1 phase (Pesin, Orr-Weaver 
2008). Moreover, in addition to controlling motifs in the cell cycle, ubiquitin ligase, such as 
anaphase-promoting complex/cyclosome-CDH1 (APC/C-CHD1), also controls glycolysis and 
glutaminolysis by the degrading 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 
isoform 3 (PFKFB3) and Glutaminase 1 (GLS1). During the G1 to S phase transition (through 
the R-point), glycolysis and glutaminolysis are upregulated, that also correlates with a 
decreased APC/C-CDH1 activity. Therefore, suggesting APC/C-CHD1 regulated PFKFB3 and 
GLS1 are crucial factors in the utilisation of nutrients during G1 to S transition (Moncada et 
al. 2012). In correspondence, synchronised HeLa cells deprived of either glucose or 
glutamine were unable to progress from mid-to-late G1 phase indicating the importance of 
the nutrients at this point in the cell cycle (Colombo et al. 2011). Tudzarova et al. (2011) 
correspondingly reported similar findings by silencing the PFKFB3 in HeLa cells exhibiting 
cell cycle arrest in mid G1 phase.  
Under limited nutrient availability during R-point the cells initiate resting state instead of 
progressing into the S phase. The nutrition sensitive checkpoint was first described in 
Saccharomyces cerevisiae as START. After this checkpoint, following successful evaluations 
of the cellular requirements, yeast becomes irreversibly committed to division (Cooper et 
al. 2000). In mammalian cells, epigenetic adjustments have also been observed during the 
transition from G1 to S phase, including chromatin modulation that allows DNA to replicate 
in the process of cell division (Kheir, Lund 2010). The S phase is mainly characterised by the 
DNA and histone replication, in addition to the observed low rate of protein synthesis and 
RNA transcription. The inheritance of DNA methylation is mainly carried out by DNMT1 in 
S phase. During this inheritance, DNMT1 targets the hemimethylated strands and transfers 
the methylation pattern onto the daughter strand. Histone methylation levels have also 
been shown to increase in the late G1 to S phase transition, that correlates with histone 
methyltransferase activity. The role of histone modification in the transition of G1 to S 
phase, is controversial and remains to be elucidated (Kheir, Lund 2010). Moreover, altered 
global histone acetylation and cell cycle deregulation are hallmarks of cancer (Cluntun et 
al. 2015; Farioli-Vecchioli, Tirone 2015). The levels of hyperacetylation of histones were 
shown to correlate with the intracellular acetyl-CoA levels in cancer (Cluntun et al. 2015). 
Interestingly, IDH2, a known regulator of the intracellular acetyl-CoA levels, was also shown 
to be associated in cancer cells (Wise et al. 2011). 
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Cells can be divided into two groups: quiescent or proliferative. A population of 
proliferative cells may harbour subpopulations at different cell cycle phases with different 
proliferative characteristics (Lamerton 1974). Cells at different phases of the cell cycle can 
be identified by their DNA content. For instance, cells in the G1 phase contain diploid 
chromosomal copies. Whereas, in S phase, cell replication increases the number of 
chromosomes by 2-fold, to obtain DNA contents ranging from 2-fold to 4-fold. The DNA 
content then remains at 4-fold for cells in G2 and M phases. These DNA content phase-
specific properties can be utilised to distinguish between cells at different stages of cell 
cycle using combined DNA intercalating dye-flow cytometric analysis (Cooper 2000) (Figure 
5.1). Specific proteins, such as IDH2, shown in our previous data (chapter 3 and 4) to play a 
key role in nutrient mediated epigenetic changes, can be assessed in synchronised cells. 
Moreover, different nutrient regimes combined with synchronised cells can be used to 
identify specific nutrients required for the R-point.  
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Figure 5.1: The nutrient sensitive point in the cell cycle. Cell cycle phases include G1/G0, S, 
G2 and M, and are regulated by binding of cyclin to several cyclin-dependant kinases 
partners, subsequently modulating various checkpoints. These checkpoints play an 
important role in normal and pathological cellular types. Cell cycle-regulated transcription 
can be grouped into three main waves; G1→S, G2→M and M→G1. The nutrition sensitive 
transition of G1→S, is dependent on cellular and environmental availability of the nutrients 
required for DNA synthesis and maintaining genomic structural integrity. Cells deprived of 
nutrients induce cell cycle arrest at G1 phase, thereby, inhibit proliferation. The G1→S 
transition induces transcriptional activation during the late G1 phase, subsequently 
promoting cell’s entry into S phase. Once in S phase, cells turn-off the transcriptional wave 
allowing for DNA replication. Therefore, this point commits the cells to division, and after 
the completion of this restriction point the cells continue to grow irrespective of the 
nutrients available (Bohnsack, Hirschi 2004; Bertoli et al. 2013). 
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5.2. Aims of Chapter 5: Cell cycle model/HeLa cells 
• Evaluating the regulation of IDH2 and histone acetylation 
• Characterising the role of acetate on cell cycle progression through the nutrient 
sensitive restriction point 
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5.3. Results 
Cell cycle deregulation and altered global histone acetylation are hallmarks of cancer 
(Cluntun et al. 2015; Farioli-Vecchioli, Tirone 2015). In this chapter, we initially investigated 
the regulation of histone acetylation and IDH2 expression in synchronised HeLa cells. The 
potential impact of acetate nutrient regime on cell cycle was evaluated using synchronised 
HeLa cells.  
 
5.3.1. The regulation of histone 4 acetylation during cell cycle  
The modulation of histone acetylation in synchronised HeLa cells was assessed by western 
blotting. The data obtained showed a significant increase in histone 4 acetylation status in 
cells synchronised with NCZ (Figure 5.2A), displaying a 1.75-fold increase at 12 hours post 
NCZ release, as assessed by densitometry analysis (Figure 5.2B). The level of histone 
acetylation was normalised to total histone content of the cells. 
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Figure 5.2: The regulation of histone 4 acetylation during cell cycle. (A) Western blotting 
analysis of the NCZ synchronised HeLa cells at 12 hours showed an increase in histone 4 
acetylation relative to total histone 4. (B) Densitometric assessment of the histone 
acetylation analysis by western blotting. (DR; Densitometry ratios, Post NCZ release time 
points are demonstrated as 0, 4, 8 and 12 in the figures, H4; Histone 4). Results are 
representative of n=1. 
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5.3.2. The regulation of IDH2 and Cdh1 during cell cycle  
Following cell synchronisation, the degree of synchronisation was assessed by measuring 
cell cycle progression. Cdh1 was previously shown to regulate G1 to S phase transition (by 
our group’s principal investigator Colombo et al. 2011), hence, it was employed to examine 
the cell cycle progression in our study. Post NCZ release, the protein expression of Cdh1 
was analysed by western blotting of samples collected at different time points; 0, 4, 8 and 
12 hours. The data obtained showed a significant and time-dependant increase of Cdh1 
protein abundance in cells synchronised with NCZ (Figure 5.3A and B). 
Findings from Chapter 3 and 4 suggested that the expression changes in IDH2 can affect 
acetylation of histones. Therefore, to characterise the role of IDH2 in cell cycle, total 
proteins were extracted from synchronised HeLa cells at 0, 4, 8 and 12 hours and analysed 
by western blotting. The data obtained showed no significant difference of IDH2 expression 
at different time-points of NCZ synchronised HeLa cells (Figure 5.3A). In addition, IDH2 was 
also assessed for acetylation status using IDH2 acetylated specific antibody. The data 
obtained showed a significant and time-dependant increase in IDH2 acetylation in cells 
synchronised with NCZ (Figure 5.3A and C). 
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Figure 5.3: Analysis of IDH2 expression and acetylation status during the cell cycle. (A) 
Western blotting analysis of the NCZ synchronised HeLa cells at 0, 4, 8 and 12 hours, 
showed a gradual decrease in Cdh1 expression. Chd1 was used to characterise the G1 to S 
phase transition during cell cycle progression. IDH2 protein abundance analysis showed no 
significant changes between different time-points. Post-NCZ release, the acetylation status 
of IDH2 was increased in a time-dependent manner as observed in western blotting 
analysis of synchronised cells at 4, 8 and 12 hours. (B and C) Cdh1 expression and acetylated 
IDH2 in synchronised HeLa cells are demonstrated in the schematic graph, generated using 
the densitometry ratios. Cdh1 protein expression was normalised to GAPDH, and IDH2 
acetylation levels were normalised to total IDH2 protein content (IDH2 protein content 
normalised to GAPDH). (Post NCZ release time points are demonstrated as 0, 4, 8 and 12 in 
the figures). Results are representative of n=1. 
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5.3.3. The effect of acetate nutrient regime on cell cycle checkpoint in HeLa cells 
In order to characterise the role of acetate in cell cycle, HeLa cells were cultured in low 
glucose levels to deplete the cellular glycogen storage and synchronised using NCZ. 
Following NCZ release, cells were then incubated with acetate or glucose nutrient regimes, 
for 0, 4, 8 and 12 hours. The regulation of cell cycle checkpoint was assessed by cell sorter. 
The data obtained showed that acetate nutrient regime induced cell cycle progression by 
promoting the transition of G1→S phase. Indicating that the substitution of glucose with 
acetate, is sufficient to meet the nutrition demand of R-point and progress through cell 
cycle. 
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Figure 5.4: Cell cycle coordination of HeLa cells in glucose containing media and glucose-
negative acetate containing media. The proportion of cells in different phases is calculated 
based on Propidium Iodide, and therefore DNA content of the cell. Results obtained from 
two-nutrient regimes (glucose and acetate) showed increasing percentage of cells in S and 
G2/M phase.  
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5.4. Discussion 
 
The progression of cells through the division cycle is regulated by checkpoints. It was 
previously proposed that R-point represents the nutrient-sensing point, and the sequential 
transition from the late G1 to S phase is largely regulated by nutritional status of the cell. 
This R-point marks a critical point in cell cycle, after which cells commit to proliferation 
independently of growth factors and extracellular stimuli (Jia et al. 2009). If growth factors 
were deprived prior to R-point, cells exit the cell cycle into a state of quiescence known as 
G0 (Yao et al. 2008). Cancer development and progression are associated with uncontrolled 
cell division caused by a series of changes in the activity of cell cycle regulators. Therefore, 
the characterisation of the mechanisms involved in the regulation of cell cycle, specifically 
the R-point, are important in highlighting important differences between normal cell 
proliferation and cancer initiation (Meeran, Katiyar 2008). 
 
5.4.1. Histone acetylation regulation in cell cycle 
It was previously shown that cancer cells display higher rate of glycolysis and 
hyperacetylation of histones (Cluntun et al. 2015). Approximately 10% of glucose taken up 
by cancer cells is utilised for biosynthesis, and the remaining is mostly converted into 
lactate (Heiden et al. 2009). Lactate levels of synchronised HeLa cells were previously 
demonstrated to increase during the R-point (Colombo et al. 2011). Following these 
findings, we assessed the regulation of histone acetylation in synchronised HeLa cells. The 
data obtained showed a hyperacetylation state of histones following the R-point. These 
findings suggest that various nutrients may be required at the R-point in order to regulate 
the histone acetylation. Liu et al. (2015) demonstrated an increased rate of aerobic 
glycolysis which was associated with open chromatin configuration and histones 
hyperacetylation in cancer cells. In addition, the same group also demonstrated that 
inhibiting glycolysis with pharmacological interventions reverted the open chromatin 
configuration (i.e. open to close) resulting from the deacetylation of histones. Therefore, 
suggesting a close relationship between metabolism and chromatin dynamics.  
 
 
152 
 
5.4.2. IDH2 protein abundance and acetylation in cell cycle 
Moreover, findings from other chapters (Chapter 3 and 4), suggested an inverse 
relationship between the IDH2 expression levels and histone acetylation status. For 
example, low IDH2 expression levels correlated with histone hyperacetylation in INS-1 cells 
(Chapter 3), whereas, high IDH2 expression levels correlated with histone hypoacetylation 
in HeLa cells (Chapter 4). Thus, we investigated the IDH2 expression in synchronised HeLa 
cell. Surprisingly, no changes in the protein expression level of IDH2 were observed. Other 
studies have reported that IDH2 downregulation can accelerate cell cycle progression and 
induce a pro-proliferative state in osteosarcoma cell lines (YI et al. 2016). However, our 
data indicate that IDH2 expression modulation may not an integral part of the cell cycle. 
There is substantial evidence that indicate acetylation of IDH2 can regulate its catalytic 
activity (Yu et al. 2012; Zou et al. 2017; Smolková, Ježek 2012). SIRT3 deacetylase, is located 
in the mitochondria, that modulates protein acetylation thereby regulating the function of 
various mitochondrial protein (Lombard et al. 2007). Moreover, overexpressed SIRT3 has 
also been shown to deregulate cell cycle progression, resulting in G1 cell cycle arrest (Wang 
et al. 2016). Collectively, these findings suggest that protein acetylation may play a key role 
in the modulation of IDH2 catalytic activity in cell cycle.  
Therefore, we carried out IDH2 acetylation analysis at a different time points in HeLa cells 
after NCZ release. The data obtained showed a gradual and significant increase in the 
acetylation status of IDH2 at 4, 8 and 12 hours post NCZ release. This data suggests that the 
IDH2 protein abundance remains constant, whereas, IDH2 acetylation is significantly 
increased during the cell cycle. These findings in combination with previous data from this 
chapter, indicates that IDH2 acetylation and histone acetylation are implicated in the R-
point. The activity of IDH2 can regulate the intracellular acetyl-CoA levels by modulating 
mitochondrial citrate levels (Schug et al. 2015). Supporting evidence from Wellen et al. 
(2009) also showed a direct connection between the histone acetylation and ACLY-
mediated citrate conversion to acetyl-CoA. We also observed from our data, that the 
acetylation of IDH2 occurred before the acetylation of histones in the synchronised HeLa 
cells. Therefore, suggesting the activity (known to be modulated by acetylation) of IDH2 
can possibly modulate histone acetylation as a downstream effect.  
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5.4.3. The regulation of cell cycle by acetate 
Our previous data (from Chapter 3) showed that acetate downregulates IDH2 expression 
and increases histone acetylation. Therefore, according to these findings and to assess our 
second aim, we characterised the impact of acetate nutrient regime on cell cycle. Colombo 
et al. (2011) previsouly demonstrated the impact of specific nutrient regimes, i.e. glucose, 
on distinct stages in the cell cycle. The absence of glucose was shown to inhibit cell cycle 
progression at mid-to-late G1 phase. Based on these findings, the cells in our study were 
deprived of glucose, and synchronised with NCZ, thereafter, released into different nutrient 
regimes, glucose (control) or acetate. The flow cytometric analysis of synchronised HeLa 
cells showed that acetate induced progression from G1 to S phase, independently of 
glucose. In addition, resolving cell cycle distributions at the remaining phases i.e. G1, S and 
G2/M phases, identified similar cell distribution percentages amongst stages in both 
nutrient regimes. Thus, indicating that the substitution of glucose with acetate, is sufficient 
to meet the nutrition demand of R-point and progress through cell cycle. In support of our 
data, Morrish et al. (2010) demonstrated that c-Myc, a cell cycle regulator, induces 
glycolysis and increases mitochondrial synthesis of acetyl-CoA, subsequently upregulating 
histone acetylation. Moreover, 50% of intracellular acetyl-CoA was shown to be generated 
by mitochondria during cell cycle (Morrish et al. 2009). Collectively, these findings and ours 
indicate that acetyl-CoA generation, IDH2 acetylation and histone acetylation are 
intrinsically regulated during the cell cycle. 
 
5.5. Conclusion 
In conclusion, our data showed that IDH2 acetylation and histone acetylation are closely 
regulated during G1, S and G2/M phases. Moreover, IDH2 protein abundance was not found 
to be modulated during cell cycle. Additionally, differential nutrient regimes suggested that 
substitution of glucose with acetate, is sufficient to meet the nutrition demand of R-point 
and progress through cell cycle. 
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CHAPTER 6: GENERAL DISCUSSION, CONCLUSIONS AND FUTURE 
STUDIES 
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6.1 General Discussion 
 
The trans-generational epigenetic inheritance has emerged as a new area of research and 
challenged the central dogma of biology that genetic code is the sole basis for biological 
inheritance. The area of epigenetics has provided new insights into the underlying 
biological mechanisms that can be involved in transmitting traits to subsequent 
generations (Zakhari 2013; Rissman, Adli 2014). DNA methylation and histone acetylation 
are important processes in epigenetic transcriptional regulation. In addition, different 
tissue types display different epigenetic profile in their genomes. Thus, epigenomics 
require the characterisation of variants not only amongst different individuals, but also 
among different tissues, disease types and developmental stages (Reichetzeder et al. 
2016). DNA methylation has long been considered a crucial component in the epigenetic 
network and is the most widely studied mechanism (Zhang 2015). The pathophysiological 
role of DNA methylation is poorly understood. However, several advances have improved 
our understanding of the role of DNA methylation in cancer and diabetes (Etchegaray, 
Mostoslavsky 2016). Therefore, in order to achieve our aim of characterising the epigenetic 
changes and gene regulation by nutrients, we utilised cancer and diabetes cellular models 
to investigate the novel mechanisms that led to functional consequence. Cell proliferation 
and insulin synthesis were assessed in the human derived cancer HeLa cell and rat 
pancreatic β-cell INS-1, respectively. Moreover, certain aspects of DNA methylation are 
well understood, but the cues that designate the de novo methylation of specific CpG 
islands are not well-documented, except for the CpG islands rich regions that has been 
shown to attract de novo methylation (Edwards et al. 2017). Therefore, our study 
characterised a novel mechanism by which nutrient can regulate the methyltransferase-
mediated de novo methylation and elucidates the impact of galactose and acetate nutrient 
regimes on IDH2 deregulation and DNA methylation. Finally, we assessed the significant 
impact of nutrient mediated epigenetic changes and PTMs in cell cycle regulation by 
demonstrating novel pathway of regulating histone acetylation and G1→S phase transition 
by IDH2 acetylation. Moreover, we suggest that acetate without glucose, can meet the 
nutrient requirements of the nutrition sensitive restriction point in cell cycle. 
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6.1.1 Differential nutrient regime deregulates IDH2 expression and its DNA methylation 
profile 
Previously, IDH2 expression abnormalities were reported in multiple cancers: presenting as 
downregulation and upregulation, and in some cancers downregulation at early stages 
followed by upregulation in advanced stages (Lv et al. 2012; Green, Beer 2010; Fu et al. 
2010). These findings require further investigations to elaborate on the role of IDH2 in 
cancer. In diabetes, previous studies have shown that IDH2 knockdown inhibits insulin 
secretion under high glucose conditions (Macdonald et al. 2013). However, the 
mechanisms leading to the regulation of IDH2 in diabetes remains to be elucidated. In our 
study, we used cellular models of cancer (HeLa cells) and diabetes (INS-1 cells) in order to 
investigate the role of nutrients, such as galactose and acetate, in cancer and diabetes, 
respectively. Additionally, we conducted a study on the effect of acetate on cell cycle 
regulation. In the 3rd Chapter of this thesis, we applied well characterised INS-1 pancreatic 
β-cell line in the presence of acetate. The data obtained showed acetate-mediated 
downregulation of IDH2 mRNA and protein expression, that correlated with increased 
promoter DNA methylation and resulted in the reduction of total α-KG levels. IDH2 was 
also assessed in HeLa cancer model in the 4th Chapter. Using a methylation sensitive 
enzyme, we demonstrated that galactose-mediated a reduction in IDH2 DNA methylation 
status, whereas increased the status of hydroxymethylation. These results were associated 
with changes in mRNA and protein expression of IDH2. Collectively, downregulation of 
IDH2 in INS-1 cells was associated with a decrease in insulin content. Moreover, IDH2 
upregulation in HeLa cells was associated with decreased proliferation. Suggesting IDH2 
expression is associated with improved disease outcomes and it can serve as a potential 
therapeutic target in diabetes and cancer. Therefore, to assess whether IDH2 can serve as 
a therapeutic target we overexpressed IDH2 in INS-1 cells, which partially but significantly 
reverted some of the key acetate-induced changes, that has been associated with diabetes. 
DNA hydroxymethylation is a reversible modification, that can be used as a therapeutic to 
upregulate gene expression without inducing changes in the genomic sequence. Therefore, 
dCas9-Tet was used to induce hydroxymethylation and thereby upregulate 
hydroxymethylation-mediated IDH2 expression. The data showed that hydroxymethylation 
was able to upregulate IDH2 significantly. Therefore, suggesting that the ability to drive the 
upregulation of IDH2 using dCas9-TET can serve as a possible future treatment in diabetic 
and cancer patients. Moreover, because of the involvement in the regulation of citrate and 
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-KG, IDH2 is believed to play a crucial regulatory role in DNA methylation and 
histone/protein acetylation. In support of this statement, IDH2 was also concluded in our 
study as a crucial step of epigenetic regulation.  
 
6.1.2 Nutrients regulate histone and IDH2 acetylation 
Another aspect of this thesis was to investigate the changes in histone acetylation. In 
Chapter 4, the data obtained showed that galactose nutrient regime significantly reduced 
histone acetylation in HeLa cells in a time-dependent manner. These findings suggest that 
‘The Warburg effect', usually observed in cancer cells, indeed exceeds the requirement for 
protein and nucleotide synthesis, and includes widely epigenetic modifications. 
Additionally, in Chapter 3 acetate nutrient regime induced significant increase in histone 
acetylation in INS-1 cell. Interestingly, findings from Chapter 3 and Chapter 4, 
demonstrated that histone acetylation inversely correlated with IDH2 expression levels. 
Suggesting that IDH2 may play a key role in the regulation of histone acetylation. Moreover, 
cell cycle regulation also involves the heritable epigenetic changes including histone 
acetylation, and therefore in Chapter 5, we studied the role of IDH2 and histone acetylation 
at different stages of the cell cycle. Histone acetylation was shown to be upregulated during 
the late G1 to S phase transition. Surprisingly, IDH2 protein expression was not regulated in 
the cell cycle. Other than protein expression, protein acetylation is recognised as a major 
regulator of protein function. IDH2 is one of the proteins shown to be downregulated by 
acetylation. Subsequently, we carried out IDH2 acetylation analysis at different time points 
in HeLa cells after NCZ release. The data collected showed a gradual increase in the 
acetylation status of IDH2 during the late G1 and S phase, mimicking the pattern observed 
in histone acetylation. Combined together, the findings from the three chapters (3, 4 and 
5) collectively suggest that the changes in metabolism associates with the changes in 
epigenetics, and therefore supporting our findings of mitochondrial activity and IDH2 
expression inversely correlating with changes in DNA methylation and histone acetylation. 
Multiple metabolic pathways including glycolysis and β-oxidation can lead to changes in 
acetyl-CoA, and therefore regulate the acetylation of histones (Etchegaray, Mostoslavsky 
2016). Peleg at al. (2016) also suggested that the level of histone acetylation is susceptible 
to metabolites such as acetyl-CoA, is highly regulated in yeast and provides evidence that 
acetyl-CoA connects metabolism to growth and survival (Cai et al. 2011). In cancer cells, 
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instead of being converted into -KG by IDH2, the glycolysis-derived pyruvate enters the 
truncated TCA cycle, and is thereafter converted to citrate, subsequently exported into 
cytosol by tricarboxylic transporter. Thereafter, the citrate is converted back to acetyl-CoA 
by ACLY, thereby, regulating histone and protein acetylation (Hatzivassiliou et al. 2005; 
Latham et al. 2012). Likewise, this regulation may explain the observed acetate-induced 
histone acetylation in INS-1 cell by the downregulating of IDH2 and reducing -KG content. 
Furthermore, IDH2 mediated irreversible oxidation and decarboxylation of isocitrate into 
-KG is a crucial step in the TCA cycle determining the level of mitochondrial citrate (Zou 
et al. 2017). These findings combined with ours indicate that galactose may be decreasing 
the pool of acetyl-CoA by regulating IDH2 expression in the HeLa cells and therefore leading 
to deacetylated histones. Conversely, acetate may be increasing the pool of acetyl-CoA 
directly and by regulating IDH2 expression and therefore leading to acetylated histones. 
 
6.1.3 IDH2 expression is not correlated with lactate production in INS-1 cells 
The connection between IDH2 and lactate production has previously been demonstrated 
(Wen et al. 2015). In our study of the diabetic model, lactate levels did not correlate with 
IDH2 expression levels in INS-1 cells. Whereas, lactate production strongly correlated with 
IDH2 expression in HeLa cells. These findings combined suggest that there might not be a 
direct connection between IDH2 and lactate production. However, we did not assess 
protein expression, PTMs or epigenetic regulation of LDHA in both nutrient regimes, 
acetate and galactose. Therefore, to overcome these limitations, further investigation will 
be required. Another outstanding question regarding the association between α-KG levels 
and the 5hmC status in INS-1 cells. However, an increased level of 5mC can presumably 
reduce the level of 5hmC in the cell, further hindering the detection of 5hmC (Ecsedi et al. 
2018). Although, NGS high-throughput sequencing can identify 5hmC levels with increasing 
accuracy and sensitivity (Pang et al. 2016). An investigation focusing on the 5hmC levels in 
β-cells can provide additional insights into gene regulations and subsequently additional 
targets for treatment interventions. Our efforts to relate 5hmC levels on IDH2 promoter 
region and consequently increasing the expression were evident in chapter 4. 
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6.1.4 Regulation of DNMT3a in differential nutrient regimes 
DNMT3a participates in the de novo promoter methylation of genes (Robertson et al. 
1999). DNMT3a regulation was assessed under acetate (Chapter 3) and galactose (Chapter 
4) nutrient regime. In contrast to galactose, acetate induced DNMT3a protein abundance. 
Further investigation, in both chapters using different cell lines, showed that by inhibiting 
proteasomal degradation by MG132, DNMT3a protein abundance was increased in a time-
dependent manner, suggesting DNMT3a can be regulated by PTMs. This mechanism is 
conserved between the two species, as suggested by INS-1 and HeLa cells (rat and human). 
Moreover, DNMT3a was shown to be conversely regulated by IDH2 expression and 
mitochondrial function. Subsequently, leading to increased methylation of DNA promoter 
regions of key metabolic and mitochondrial related genes.  
 
6.1.5 Concluding remarks 
In conclusion, our study considerably enhances the understanding of the role of nutrients 
in DNA methylation and histone acetylation. Furthermore, functional consequence in 
pathological conditions, including diabetes and cancer were elucidated. The role of 
nutrients in the cell cycle was also illustrated in this study: the findings from this study can 
be used to enhance our understanding of the diseases that deregulate cell cycle, in addition 
to our understanding of the normal proliferating cells. IDH2 was shown to participate in the 
development of diabetes-related complication (i.e. downregulation of insulin production), 
regulation of the ‘The Warburg effect' in cancer model and regulation of restriction point 
in the cell cycle. The nutrient-mediated DNMT3a regulation correlated with the observed 
DNA methylation changes in IDH2, insulin and NIX, further explaining the connection 
between nutrients and epigenetics. Molecular interventions including IDH2 overexpression 
was able to revert some of the changes implicated by nutrient regimes, suggesting IDH2 
can serve as a target for future therapeutic interventions. Moreover, dCas9-Tet mediated 
5hmC upregulation in IDH2 promoter region was demonstrated as a potential therapeutic 
tool. The anti-proliferative and apoptotic properties of galactose were demonstrated in 
HeLa cells, that essentially reversed ‘The Warburg effect' commonly observed in many 
cancers. Moreover, acetate demonstrated a negative effect on the INS-1 cells and 
suggested an underline cause of the increasing prevalence of T2D in the population. 
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6.2 Thesis conclusions 
1. In the presence of acetate, IDH2 downregulation inversely correlated with DNA 
promoter methylation. Furthermore, DNMT3a protein abundance was significantly 
increased and mitochondrial activity decreased in acetate nutrient regime. 
  
2. IDH2 overexpression reverted the effect of acetate on DNMT3a protein abundance, 
histone acetylation and cellular ATP levels in INS-1 cells. 
 
 
3. Acetate led to the downregulation of insulin gene expression, correlating with 
increased DNA promoter methylation, ultimately resulting in decreased insulin 
content of INS-1 cells. 
 
4. Galactose mediated upregulation of IDH2 and NIX expression in HeLa cells, 
correlated with DNA hydroxymethylation and inversely correlated with DNA 
methylation. 
 
5. Reduced proliferation and increased apoptosis of HeLa cells correlated with 
upregulation of IDH2, NIX and mitochondrial activity. Furthermore, a significant 
decrease was observed in DNMT3a protein abundance and histone acetylation in 
galactose nutrient regime.  
 
6. dCAS9-Tet mediated increase of IDH2 DNA hydroxymethylation upregulated the 
protein expression. 
 
7. Acetylation of IDH2 and histones was found to be regulated during cell cycle, 
specifically during the nutrition sensitive restriction point.  
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6.3 Future Studies 
The identification of PTM-mediated stabilisation of DNMT3a correlated with changes in 
DNA methylation status of various genes implicated in mitochondrial and cellular activity. 
Following these findings, we speculated the acetylation mediated DNMT3a protein stability 
and the functional consequence can affect global DNA methylation, and therefore can be 
assessed using immunopurification combined mass spectrometry and MethylSeq. 
Furthermore, the role of lysine acetylases and deacetylases in regulating DNMT3a can be 
investigated using proximity ligand assay. In addition to investigating mitochondrial 
regulations in our study, to further characterise mitochondrial role in diabetes and cancer, 
the basal respiration, maximal respiration, proton leak and spare capacity can be assessed 
using the gold standard methodology, seahorse Cell mito stress.  
We successfully upregulated IDH2 using dCAS9-Tet mediated hydroxymethylation. dCAS9 
regulates gene expression without gene editing/direct genetic changes in the genome, 
therefore, serving as an ideal tool for genetic intervention in diabetic and cancer patients. 
Moreover, epigenetic changes can be essentially reversed, suggesting the dCAS9 mediated 
modification can be ‘tuned’ for individuals and serve as a precision medicine tool. We also 
demonstrated overexpression of IDH2 using expression plasmid vector. Gene therapies 
have already been initiated in humans and showed extensive success (George et al. 2017). 
Non-integrating gene therapy is another therapeutical application that can also serve as a 
method to increase the expression of IDH2, using non-integrating vectors with low immune 
response rate. Adenoviral-mediated therapy has previously been shown to be successful in 
diabetic mice, reversing the signs of diabetes (Slosberg et al. 2001). Speculatively, for future 
studies, gene therapy to overexpress IDH2 in pancreatic cells may induce insulin gene 
expression leading to reversion of diabetes via epigenetic modifications. Mitochondrial 
dysfunction has been considered as a major contributor to the development of T2D (Lu et 
al. 2010). Given IDH2 upregulation can be achieved by galactose nutrient regime, it is 
possible that the addition of galactose to pancreatic β-cells can reduce 5mC and increase 
5hmC on IDH2, and subsequently restore the dysfunctional IDH2 protein expression and 
increase mitochondrial activity. Additionally, the insulin gene can be modulated in a similar 
manner to IDH2, and therefore restoring insulin content of the cells. 
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To further characterise cell cycle regulation, synchronised cells in the absence of nutrient 
will need to be utilised as an experimental negative control. Moreover, the production of 
acetyl-CoA from acetate is carried out by ACSS1, 2 and 3 (Lyssiotis, Cantley 2014) and can 
be selectively blocked using pharmacological interventions in the presence of acetate to 
ensure acetate is sufficient for cell cycle progression in the absence of glucose.  
The role of nutrients and metabolic pathways involved in the pathogenesis and treatment 
of diabetes and cancer can be further investigated in a clinical context, using animal models 
to assess the nutrient combined drug therapy or nutrient therapy alone.  
 
  
163 
 
REFERENCES 
 
Abe, T., Toyota, M., Suzuki, H., Murai, M., Akino, K., Ueno, M., Nojima, M., Yawata, A., 
Miyakawa, H., Suga, T., Ito, H., Endo, T., Tokino, T., Hinoda, Y., Imai, K., 2005. 
Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to 
hypoxia-mediated cell death. Journal of Gastroenterology, 40(5), pp.504–510. 
10.1007/s00535-005-1576-1. 
Acín-Pérez, R., Bayona-Bafaluy, M.P., Bueno, M., Machicado, C., Fernández-Silva, P., Pérez-
Martos, A., Montoya, J., López-Pérez, M.J., Sancho, J., Enríquez, J.A., 2003. An 
intragenic suppressor in the cytochrome c oxidase I gene of mouse mitochondrial 
DNA. Human molecular genetics, 12(3), pp.329–39. 10.1093/hmg/ddg021 
Agarwal, S.K., Weinstein, L.S., 2018. Epigenetics. Genetics of Bone Biology and Skeletal 
Disease, pp.25–32. 10.1016/B978-0-12-804182-6.00002-2. 
Aguer, C., Gambarotta, D., Mailloux, R.J., Moffat, C., Dent, R., McPherson, R., Harper, M.-
E., 2011. Galactose Enhances Oxidative Metabolism and Reveals Mitochondrial 
Dysfunction in Human Primary Muscle Cells Luque, R. M., ed. PLoS ONE, 6(12), 
p.e28536. 10.1371/journal.pone.0028536. 
Ahn, C.S., Metallo, C.M., 2015. Mitochondria as biosynthetic factories for cancer 
proliferation. Cancer & metabolism, 3(1), p.1. 10.1186/s40170-015-0128-2. 
Ai, W.-M., Chen, S.-B., Chen, X., Shen, X.-J., Shen, Y.-Y., 2014. Parallel evolution of IDH2 
gene in cetaceans, primates and bats. FEBS Letters, 588(3), pp.450–454. 
10.1016/j.febslet.2013.12.005. 
Akanji, A.O., Humphreys, S., Thursfield, V., Hockaday, T.D.R., 1989. The relationship of 
plasma acetate with glucose and other blood intermediary metabolites in non-diabetic 
and diabetic subjects. Clinica Chimica Acta, 185(1), pp.25–34. 10.1016/0009-
8981(89)90127-7. 
Akram, M., 2014. Citric Acid Cycle and Role of its Intermediates in Metabolism. Cell 
Biochemistry and Biophysics, 68(3), pp.475–478. 10.1007/s12013-013-9750-1. 
Al-Khallaf, H., 2017. Isocitrate dehydrogenases in physiology and cancer: biochemical and 
molecular insight. Cell & Bioscience, 7(1), p.37. 10.1186/s13578-017-0165-3. 
164 
 
Allfrey, V.G., Faulkner, R., Mirskey, A.E., 1964. Acetylation and Methylation of histone and 
their possible role in the regulation of RNA synthesis. Proceedings of the National 
Academy of Sciences of the United States of America, 51(5), pp.786–94. 
10.1073/pnas.51.5.786 
Allis, C.D., Jenuwein, T., 2016. The molecular hallmarks of epigenetic control. Nature 
Reviews Genetics, 17(8), pp.487–500. 10.1038/nrg.2016.59. 
Ang, G.Y., 2018. Reversibility of diabetes mellitus: Narrative review of the evidence. World 
Journal of Diabetes, 9(7), pp.127–131. 10.4239/wjd.v9.i7.127. 
Antico Arciuch, V.G., Elguero, M.E., Poderoso, J.J., Carreras, M.C., 2012. Mitochondrial 
regulation of cell cycle and proliferation. Antioxidants & redox signaling, 16(10), 
pp.1150–80. 10.1089/ars.2011.4085. 
Aquino, E.M., Benton, M.C., Haupt, L.M., Sutherland, H.G., riffiths, L.R.G., Lea, R.A., 2018. 
Current Understanding of DNA Methylation and Age-related Disease. OBM Genetics, 
2(2), pp.1–1. 10.21926/obm.genet.1802016. 
Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P.A., Wollheim, C.B., 1992. Establishment of 
2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. 
Endocrinology, 130(1), pp.167–178. 10.1210/endo.130.1.1370150. 
Atlasi, Y., Stunnenberg, H.G., 2017. The interplay of epigenetic marks during stem cell 
differentiation and development. Nature Reviews Genetics, 18(11), pp.643–658. 
10.1038/nrg.2017.57. 
Bagnati, M., Ogunkolade, B.W., Marshall, C., Tucci, C., Hanna, K., Jones, T.A., Bugliani, M., 
Nedjai, B., Caton, P.W., Kieswich, J., Yaqoob, M.M., Ball, G.R., Marchetti, P., Hitman, 
G.A., Turner, M.D., 2016. Glucolipotoxicity initiates pancreatic β-cell death through 
TNFR5/CD40-mediated STAT1 and NF-κB activation. Cell Death & Disease, 7(8), 
pp.e2329–e2329. 10.1038/cddis.2016.203. 
Baldelli, S., Aquilano, K., Ciriolo, M.R., 2014. PGC-1α buffers ROS-mediated removal of 
mitochondria during myogenesis. Cell Death & Disease, 5(11), pp.e1515–e1515. 
10.1038/cddis.2014.458. 
Barrès, R., Osler, M.E., Yan, J., Rune, A., Fritz, T., Caidahl, K., Krook, A., Zierath, J.R., 2009. 
Non-CpG Methylation of the PGC-1α Promoter through DNMT3B Controls 
Mitochondrial Density. Cell Metabolism, 10(3), pp.189–198. 
165 
 
10.1016/J.CMET.2009.07.011. 
Baylin, S.B., Jones, P.A., 2011. A decade of exploring the cancer epigenome — biological 
and translational implications. Nature Reviews Cancer, 11(10), pp.726–734. 
10.1038/nrc3130. 
Bellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouysségur, J., Mazure, N.M., 
2009. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor 
induction of BNIP3 and BNIP3L via their BH3 domains. Molecular and cellular biology, 
29(10), pp.2570–81. 10.1128/MCB.00166-09. 
Berdasco, M., Esteller, M., 2010. Aberrant Epigenetic Landscape in Cancer: How Cellular 
Identity Goes Awry. Developmental Cell, 19(5), pp.698–711. 
10.1016/J.DEVCEL.2010.10.005. 
Bergman, Y., Cedar, H., 2013. DNA methylation dynamics in health and disease. Nature 
Structural & Molecular Biology, 20(3), pp.274–281. 10.1038/nsmb.2518. 
Bernstein, D., Golson, M.L., Kaestner, K.H., 2017. Epigenetic control of β-cell function and 
failure. Diabetes research and clinical practice, 123, pp.24–36. 
10.1016/j.diabres.2016.11.009. 
Bertoli, C., Skotheim, J.M., De Bruin, R.A.M., 2013. 10.1038/nrm3629. 
Bhagavan, N.V., Ha, C.-E., Bhagavan, N.V., Ha, C.-E., 2015a. Electron Transport Chain, 
Oxidative Phosphorylation, and Other Oxygen-Consuming Systems. Essentials of 
Medical Biochemistry, pp.187–204. 10.1016/B978-0-12-416687-5.00013-0. 
Bhagavan, N.V., Ha, C.-E., Bhagavan, N.V., Ha, C.-E., 2015b. Structure and Properties of 
DNA. Essentials of Medical Biochemistry, pp.381–400. 10.1016/B978-0-12-416687-
5.00021-X. 
Blum, B., Hrvatin, S., Schuetz, C., Bonal, C., Rezania, A., Melton, D.A., 2012. Functional beta-
cell maturation is marked by an increased glucose threshold and by expression of 
urocortin 3. Nature biotechnology, 30(3), pp.261–4. 10.1038/nbt.2141. 
Bohnsack, B.L., Hirschi, K.K., 2004. NUTRIENT REGULATION OF CELL CYCLE PROGRESSION. 
Annual Review of Nutrition, 24(1), pp.433–453. 
10.1146/annurev.nutr.23.011702.073203. 
Brownell, J.E., Zhou, J., Ranalli, T., Kobayashi, R., Edmondson, D.G., Roth, S.Y., Allis, C.D., 
166 
 
1996. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking 
histone acetylation to gene activation. Cell, 84(6), pp.843–51. 
Bubna, A.K., 2015. Vorinostat-An Overview. Indian journal of dermatology, 60(4), p.419. 
10.4103/0019-5154.160511. 
Buse, J.B., Caprio, S., Cefalu, W.T., Ceriello, A., Del Prato, S., Inzucchi, S.E., McLaughlin, S., 
Phillips, G.L., Robertson, R.P., Rubino, F., Kahn, R., Kirkman, M.S., Kirkman, M.S., 2009. 
How do we define cure of diabetes? Diabetes care, 32(11), pp.2133–5. 10.2337/dc09-
9036. 
Cai, L., Sutter, B.M., Li, B., Tu, B.P., 2011. Acetyl-CoA induces cell growth and proliferation 
by promoting the acetylation of histones at growth genes. Molecular cell, 42(4), 
pp.426–37. 10.1016/j.molcel.2011.05.004. 
Cai, L., Tu, B.P., 2011. On acetyl-CoA as a gauge of cellular metabolic state. Cold Spring 
Harbor Symposia on Quantitative Biology. 10.1101/sqb.2011.76.010769. 
Calvisi, D.F., Ladu, S., Gorden, A., Farina, M., Lee, J.-S., Conner, E.A., Schroeder, I., Factor, 
V.M., Thorgeirsson, S.S., 2007. Mechanistic and prognostic significance of aberrant 
methylation in the molecular pathogenesis of human hepatocellular carcinoma. 
Journal of Clinical Investigation, 117(9), pp.2713–2722. 10.1172/JCI31457. 
Capaldi, R.A., 1990. Structure and function of cytochrome c oxidase. Annual review of 
biochemistry, 59(1), pp.569–96. 10.1146/annurev.bi.59.070190.003033. 
Carbonneau, M. et al., 2016. The oncometabolite 2-hydroxyglutarate activates the mTOR 
signalling pathway. Nature Communications, 7(1), p.12700. 10.1038/ncomms12700. 
Cavallucci, V., Fidaleo, M., Pani, G., 2016. Neural Stem Cells and Nutrients: Poised Between 
Quiescence and Exhaustion. Trends in Endocrinology & Metabolism, 27(11), pp.756–
769. 10.1016/J.TEM.2016.06.007. 
Ceccarelli, C., Grodsky, N.B., Ariyaratne, N., Colman, R.F., Bahnson, B.J., 2002. Crystal 
structure of porcine mitochondrial NADP+-dependent isocitrate dehydrogenase 
complexed with Mn2+ and isocitrate. Insights into the enzyme mechanism. The 
Journal of biological chemistry, 277(45), pp.43454–62. 10.1074/jbc.M207306200. 
Center for Disease Control and Prevention, 2018. Health and Economic Costs of Chronic 
Diseases [online]. National Center for Chronic Disease Prevention and Health 
167 
 
Promotion. Available at: https://www.cdc.gov/chronicdisease/about/costs/index.htm 
[Accessed 16 April 2019]. 
Di Cerbo, V., Schneider, R., 2013. Cancers with wrong HATs: the impact of acetylation. 
Briefings in Functional Genomics, 12(3), pp.231–243. 10.1093/bfgp/els065. 
Chang, J.Y., Yi, H.-S., Kim, H.-W., Shong, M., 2017. Dysregulation of mitophagy in 
carcinogenesis and tumor progression. Biochimica et Biophysica Acta (BBA) - 
Bioenergetics, 1858(8), pp.633–640. 10.1016/J.BBABIO.2016.12.008. 
Chatterjee, S., Khunti, K., Davies, M.J., 2017. Type 2 diabetes. The Lancet, 389(10085), 
pp.2239–2251. 10.1016/S0140-6736(17)30058-2. 
Chen, T., Ueda, Y., Dodge, J.E., Wang, Z., Li, E., 2003. Establishment and maintenance of 
genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and 
Dnmt3b. Molecular and cellular biology. 
Chen, T., Ueda, Y., Xie, S., Li, E., 2002. A novel Dnmt3a isoform produced from an alternative 
promoter localizes to euchromatin and its expression correlates with active de novo 
methylation. The Journal of biological chemistry, 277(41), pp.38746–54. 
10.1074/jbc.M205312200. 
Cheng, J., Yang, H., Fang, J., Ma, L., Gong, R., Wang, P., Li, Z., Xu, Y., 2015. Molecular 
mechanism for USP7-mediated DNMT1 stabilization by acetylation. Nature 
Communications, 6(1), p.7023. 10.1038/ncomms8023. 
Chou, N.-H., Tsai, C.-Y., Tu, Y.-T., Wang, K.-C., Kang, C.-H., Chang, P.-M., Li, G.-C., Lam, H.-
C., Liu, S.-I., Tsai, K.-W., 2016. Isocitrate Dehydrogenase 2 Dysfunction Contributes to 
5-hydroxymethylcytosine Depletion in Gastric Cancer Cells. Anticancer research, 36(8), 
pp.3983–90. 
Chourasia, A.H., Boland, M.L., Macleod, K.F., 2015. Mitophagy and cancer. Cancer & 
metabolism, 3, p.4. 10.1186/s40170-015-0130-8. 
Chung, S.A., Nititham, J., Elboudwarej, E., Quach, H.L., Taylor, K.E., Barcellos, L.F., Criswell, 
L.A., 2015. Genome-wide assessment of differential DNA methylation associated with 
autoantibody production in systemic lupus erythematosus. PLoS ONE. 
10.1371/journal.pone.0129813. 
Chung, T.-L., Brena, R.M., Kolle, G., Grimmond, S.M., Berman, B.P., Laird, P.W., Pera, M.F., 
168 
 
Wolvetang, E.J., 2010. Vitamin C Promotes Widespread Yet Specific DNA 
Demethylation of the Epigenome in Human Embryonic Stem Cells. STEM CELLS, 
28(10), pp.1848–1855. 10.1002/stem.493. 
Clark, K.M., Taylor, R.W., Johnson, M.A., Chinnery, P.F., Chrzanowska-Lightowlers, Z.M., 
Andrews, R.M., Nelson, I.P., Wood, N.W., Lamont, P.J., Hanna, M.G., Lightowlers, R.N., 
Turnbull, D.M., 1999. An mtDNA mutation in the initiation codon of the cytochrome C 
oxidase subunit II gene results in lower levels of the protein and a mitochondrial 
encephalomyopathy. American journal of human genetics, 64(5), pp.1330–9. 
10.1086/302361. 
Cluntun, A.A., Huang, H., Dai, L., Liu, X., Zhao, Y., Locasale, J.W., 2015. The rate of 
glycolysis quantitatively mediates specific histone acetylation sites. Cancer & 
Metabolism, 3(1), p.10. 10.1186/s40170-015-0135-3. 
Coelho, A.I., Berry, G.T., Rubio-Gozalbo, M.E., 2015. Galactose metabolism and health. 
Current Opinion in Clinical Nutrition and Metabolic Care, 18(4), pp.422–427. 
10.1097/MCO.0000000000000189. 
Cohen, N.M., Kenigsberg, E., Tanay, A., 2011. Primate CpG islands are maintained by 
heterogeneous evolutionary regimes involving minimal selection. Cell, 145(5), 
pp.773–86. 10.1016/j.cell.2011.04.024. 
Colombo, S.L., Palacios-Callender, M., Frakich, N., Carcamo, S., Kovacs, I., Tudzarova, S., 
Moncada, S., 2011. Molecular basis for the differential use of glucose and glutamine 
in cell proliferation as revealed by synchronized HeLa cells. Proceedings of the National 
Academy of Sciences, 108(52), pp.21069–21074. 10.1073/pnas.1117500108. 
Colombo, S.L., Palacios-Callender, M., Frakich, N., De Leon, J., Schmitt, C. a, Boorn, L., Davis, 
N., Moncada, S., 2010. Anaphase-promoting complex/cyclosome-Cdh1 coordinates 
glycolysis and glutaminolysis with transition to S phase in human T lymphocytes. 
Proceedings of the National Academy of Sciences of the United States of America, 
107(44), pp.18868–18873. 10.1073/pnas.1012362107. 
Cooper, G.M., 2000. The Cell: A Molecular Approach. 2nd edition. 10.1016/B978-0-12-
387738-3.00003-2. 
Cooper, S., 2000. The continuum model and G1-control of the mammalian cell cycle. 
Progress in cell cycle research, 4, pp.27–39. 
169 
 
Crabtree, H.G., 1929. Observations on the carbohydrate metabolism of tumours. The 
Biochemical journal, 23(3), pp.536–45. 
Crick, F.H.C., 1957. Nucleic Acids. Scientific American, 197(3), pp.188–203. 
10.1038/scientificamerican0957-188. 
Cui, H., Onyango, P., Brandenburg, S., Wu, Y., Hsieh, C.-L., Feinberg, A.P., 2002. Loss of 
Imprinting in Colorectal Cancer Linked to Hypomethylation of H19 and IGF2. Cancer 
Res., 61(13), pp.4947–4950. 
Cupp, J.R., McAlister-Henn, L., 1991. NAD(+)-dependent isocitrate dehydrogenase. Cloning, 
nucleotide sequence, and disruption of the IDH2 gene from Saccharomyces cerevisiae. 
The Journal of biological chemistry, 266(33), pp.22199–205. 
D’Urso, A., Brickner, J.H., 2014. Mechanisms of epigenetic memory. Trends in Genetics, 
30(6), pp.230–236. 10.1016/j.tig.2014.04.004. 
Dang, L., Yen, K., Attar, E.C., 2016. IDH mutations in cancer and progress toward 
development of targeted therapeutics. Annals of Oncology, 27(4), pp.599–608. 
10.1093/annonc/mdw013. 
Davegårdh, C., García-Calzón, S., Bacos, K., Ling, C., 2018. DNA methylation in the 
pathogenesis of type 2 diabetes in humans. Molecular metabolism, 14, pp.12–25. 
10.1016/j.molmet.2018.01.022. 
Dawson, M.A., Kouzarides, T., 2012. Cancer Epigenetics: From Mechanism to Therapy. Cell, 
150(1), pp.12–27. 10.1016/J.CELL.2012.06.013. 
Dayeh, T., Volkov, P., Salö, S., Hall, E., Nilsson, E., Olsson, A.H., Kirkpatrick, C.L., Wollheim, 
C.B., Eliasson, L., Rönn, T., Bacos, K., Ling, C., 2014. Genome-Wide DNA Methylation 
Analysis of Human Pancreatic Islets from Type 2 Diabetic and Non-Diabetic Donors 
Identifies Candidate Genes That Influence Insulin Secretion. PLoS Genet., 10(3), 
p.e1004160. 10.1371/journal.pgen.1004160. 
DeBerardinis, R.J., Chandel, N.S., 2016. Fundamentals of cancer metabolism. Science 
advances, 2(5), p.e1600200. 10.1126/sciadv.1600200. 
DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., Thompson, 
C.B., 2007. Beyond aerobic glycolysis: transformed cells can engage in glutamine 
metabolism that exceeds the requirement for protein and nucleotide synthesis. 
170 
 
Proceedings of the National Academy of Sciences of the United States of America, 
104(49), pp.19345–50. 10.1073/pnas.0709747104. 
DeFronzo, R.A., Buse, J.B., Kim, T., Burns, C., Skare, S., Baron, A., Fineman, M., 2016. Once-
daily delayed-release metformin lowers plasma glucose and enhances fasting and 
postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia, 59(8), 
pp.1645–1654. 10.1007/s00125-016-3992-6. 
Deplus, R. et al., 2014. Regulation of DNA Methylation Patterns by CK2-Mediated 
Phosphorylation of Dnmt3a. Cell Reports, 8(3), pp.743–753. 
10.1016/j.celrep.2014.06.048. 
Deus, C.M., Zehowski, C., Nordgren, K., Wallace, K.B., Skildum, A., Oliveira, P.J., 2015. 
Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling 
in H9c2 cardiomyoblasts. Toxicology, 334, pp.1–11. 10.1016/j.tox.2015.05.001. 
Dhawan, S., Georgia, S., Tschen, S.-I., Fan, G., Bhushan, A., 2011. Pancreatic β cell identity 
is maintained by DNA methylation-mediated repression of Arx. Developmental cell, 
20(4), pp.419–29. 10.1016/j.devcel.2011.03.012. 
Dhawan, S., Tschen, S.-I., Zeng, C., Guo, T., Hebrok, M., Matveyenko, A., Bhushan, A., 2015. 
DNA methylation directs functional maturation of pancreatic β cells. Journal of Clinical 
Investigation, 125(7), pp.2851–2860. 10.1172/JCI79956. 
Dick, K.J. et al., 2014. DNA methylation and body-mass index: A genome-wide analysis. The 
Lancet. 10.1016/S0140-6736(13)62674-4. 
van Diest, P.J., Suijkerbuijk, K.P.M., Koop, E.A., de Weger, R.A., van der Wall, E., 2010. Low 
levels of BNIP3 promoter hypermethylation in invasive breast cancer. Analytical 
cellular pathology (Amsterdam), 33(3), pp.175–6. 10.3233/ACP-CLO-2010-0543. 
Ding, B., Ding, Q., Xia, G., Fang, Z., 2009. EGCG inhibits growth and induces apoptosis in 
renal cell carcinoma through TFPI-2 overexpression. Oncology Reports, 21(3), pp.635–
640. 10.3892/or_00000266. 
Ding, J., Li, T., Wang, X., Zhao, E., Choi, J.-H., Yang, L., Zha, Y., Dong, Z., Huang, S., Asara, 
J.M., Cui, H., Ding, H.-F., 2013. The Histone H3 Methyltransferase G9A Epigenetically 
Activates the Serine-Glycine Synthesis Pathway to Sustain Cancer Cell Survival and 
Proliferation. Cell Metabolism, 18(6), pp.896–907. 10.1016/j.cmet.2013.11.004. 
171 
 
Donaldson, M.S., 2004. Nutrition and cancer: a review of the evidence for an anti-cancer 
diet. Nutrition journal, 3, p.19. 10.1186/1475-2891-3-19. 
Dott, W., Mistry, P., Wright, J., Cain, K., Herbert, K.E., 2014. Modulation of mitochondrial 
bioenergetics in a skeletal muscle cell line model of mitochondrial toxicity. Redox 
Biology, 2, pp.224–233. 10.1016/j.redox.2013.12.028. 
Drake, L.E., Springer, M.Z., Poole, L.P., Kim, C.J., Macleod, K.F., 2017. 
10.1016/j.semcancer.2017.04.008. 
Du, B., Dai, X., Li, S., Qi, G., Cao, G., Zhong, Y., Yin, P., Yang, X., 2017. MiR-30c regulates 
cisplatin-induced apoptosis of renal tubular epithelial cells by targeting Bnip3L and 
Hspa5. Cell Death and Disease, 8(8), p.e2987. 10.1038/cddis.2017.377. 
Du, Z., Song, J., Wang, Y., Zhao, Y., Guda, K., Yang, S., Kao, H.-Y., Xu, Y., Willis, J., Markowitz, 
S.D., Sedwick, D., Ewing, R.M., Wang, Z., 2010. DNMT1 Stability Is Regulated by 
Proteins Coordinating Deubiquitination and Acetylation-Driven Ubiquitination. 
Science Signaling, 3(146), pp.ra80-ra80. 10.1126/scisignal.2001462. 
Ecsedi, S., Rodríguez-Aguilera, J., Hernandez-Vargas, H., 2018. 5-Hydroxymethylcytosine 
(5hmC), or How to Identify Your Favorite Cell. Epigenomes. 
10.3390/epigenomes2010003. 
Edwards, J.R., O’Donnell, A.H., Rollins, R.A., Peckham, H.E., Lee, C., Milekic, M.H., Chanrion, 
B., Fu, Y., Su, T., Hibshoosh, H., Gingrich, J.A., Haghighi, F., Nutter, R., Bestor, T.H., 
2010. Chromatin and sequence features that define the fine and gross structure of 
genomic methylation patterns. Genome Research, 20(7), pp.972–980. 
10.1101/gr.101535.109. 
Edwards, J.R., Yarychkivska, O., Boulard, M., Bestor, T.H., 2017. DNA methylation and DNA 
methyltransferases. Epigenetics & Chromatin, 10(1), p.23. 10.1186/s13072-017-0130-
8. 
Estécio, M.R.H., Issa, J.-P.J., 2011. Dissecting DNA hypermethylation in cancer. Febs Letters, 
585(13), p.2078. 10.1016/J.FEBSLET.2010.12.001. 
Etchegaray, J.-P., Mostoslavsky, R., 2016. Interplay between Metabolism and Epigenetics: 
A Nuclear Adaptation to Environmental Changes. 10.1016/j.molcel.2016.05.029. 
Fang, Y., Fullwood, M.J., 2016. Roles, Functions, and Mechanisms of Long Non-coding RNAs 
172 
 
in Cancer. Genomics, Proteomics & Bioinformatics, 14(1), pp.42–54. 
10.1016/J.GPB.2015.09.006. 
Fantin, V.R., St-Pierre, J., Leder, P., 2006. Attenuation of LDH-A expression uncovers a link 
between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 
9(6), pp.425–434. 10.1016/j.ccr.2006.04.023. 
Farioli-Vecchioli, S., Tirone, F., 2015. Control of the Cell Cycle in Adult Neurogenesis and its 
Relation with Physical Exercise. Brain plasticity (Amsterdam, Netherlands), 1(1), 
pp.41–54. 10.3233/BPL-150013. 
Fei, P., Wang, W., Kim, S., Wang, S., Burns, T.F., Sax, J.K., Buzzai, M., Dicker, D.T., McKenna, 
W.G., Bernhard, E.J., El-Deiry, W.S., 2004. Bnip3L is induced by p53 under hypoxia, and 
its knockdown promotes tumor growth. Cancer Cell, 6(6), pp.597–609. 
10.1016/J.CCR.2004.10.012. 
Feng, S., Jacobsen, S.E., Reik, W., 2010. Epigenetic reprogramming in plant and animal 
development. Science (New York, N.Y.), 330(6004), pp.622–7. 
10.1126/science.1190614. 
Fernandez-Marcos, P.J., Auwerx, J., 2011. Regulation of PGC-1α, a nodal regulator of 
mitochondrial biogenesis. The American journal of clinical nutrition, 93(4), p.884S–90. 
10.3945/ajcn.110.001917. 
Fernández-Vizarra, E., Tiranti, V., Zeviani, M., 2009. Assembly of the oxidative 
phosphorylation system in humans: What we have learned by studying its defects. 
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1793(1), pp.200–211. 
10.1016/J.BBAMCR.2008.05.028. 
Fernandez, A.F. et al., 2012. A DNA methylation fingerprint of 1628 human samples. 
Genome research, 22(2), pp.407–19. 10.1101/gr.119867.110. 
Ferraresi, R., Troiano, L., Pinti, M., Roat, E., Lugli, E., Quaglino, D., Taverna, D., Bellizzi, D., 
Passarino, G., Cossarizza, A., 2008. Resistance of mtDNA-depleted cells to apoptosis. 
Cytometry Part A, 73A(6), pp.528–537. 10.1002/cyto.a.20544. 
Flick, F., Lüscher, B., 2012. Regulation of sirtuin function by posttranslational modifications. 
Frontiers in pharmacology, 3, p.29. 10.3389/fphar.2012.00029. 
Friedrich, N., 2012. Metabolomics in diabetes research. The Journal of endocrinology, 
173 
 
215(1), pp.29–42. 10.1530/JOE-12-0120. 
Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., Molloy, P.L., 
Paul, C.L., 1992. A genomic sequencing protocol that yields a positive display of 5-
methylcytosine residues in individual DNA strands. Proceedings of the National 
Academy of Sciences of the United States of America, 89(5), pp.1827–31. 
Fu, X., Huang, X., Li, P., Chen, W., Xia, M., 2014. 7-Ketocholesterol inhibits isocitrate 
dehydrogenase 2 expression and impairs endothelial function via microRNA-144. Free 
Radical Biology and Medicine, 71, pp.1–15. 10.1016/J.FREERADBIOMED.2014.03.010. 
Fu, Y., Huang, R., Du, J., Yang, R., An, N., Liang, A., 2010. Glioma-derived mutations in IDH: 
From mechanism to potential therapy. Biochemical and Biophysical Research 
Communications, 397(2), pp.127–130. 10.1016/J.BBRC.2010.05.115. 
Fu, Y., Liu, S., Yin, S., Niu, W., Xiong, W., Tan, M., Li, G., Zhou, M., 2017. The reverse Warburg 
effect is likely to be an Achilles&#x2019; heel of cancer that can be exploited for cancer 
therapy. Oncotarget. 10.18632/oncotarget.18175. 
Fu, Z., R. Gilbert, E., Liu, D., 2013. Regulation of Insulin Synthesis and Secretion and 
Pancreatic Beta-Cell Dysfunction in Diabetes. Current Diabetes Reviews, 9(1), pp.25–
53. 10.2174/157339913804143225. 
Fujii, T., Khawaja, M.R., DiNardo, C.D., Atkins, J.T., Janku, F., 2016. Targeting isocitrate 
dehydrogenase (IDH) in cancer. Discovery medicine, 21(117), pp.373–80. 
Ganesan, A., 2018. Epigenetics: the first 25 centuries. Philosophical transactions of the 
Royal Society of London. Series B, Biological sciences, 373(1748). 
10.1098/rstb.2017.0067. 
Gao, X. et al., 2016. Acetate functions as an epigenetic metabolite to promote lipid 
synthesis under hypoxia. Nature Communications, 7. 10.1038/ncomms11960. 
Ge, G., Peng, D., Xu, Z., Guan, B., Xin, Z., He, Q., Zhou, Y., Li, X., Zhou, L., Ci, W., 2018. 
Restoration of 5‐hydroxymethylcytosine by ascorbate blocks kidney tumour growth. 
EMBO reports, p.e45401. 10.15252/embr.201745401. 
George, L.A. et al., 2017. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX 
Variant. The New England journal of medicine, 377(23), pp.2215–2227. 
10.1056/NEJMoa1708538. 
174 
 
Gibney, E.R., Nolan, C.M., 2010. Epigenetics and gene expression. Heredity, 105(1), pp.4–
13. 10.1038/hdy.2010.54. 
Gilkerson, R., 2016. Commentary: Mitochondrial DNA damage and loss in diabetes. 
Diabetes/metabolism research and reviews, 32(7), pp.672–674. 10.1002/dmrr.2833. 
van Gisbergen, M.W., Voets, A.M., Starmans, M.H.W., de Coo, I.F.M., Yadak, R., Hoffmann, 
R.F., Boutros, P.C., Smeets, H.J.M., Dubois, L., Lambin, P., 2015. How do changes in the 
mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? 
Challenges, opportunities and models. Mutation Research/Reviews in Mutation 
Research, 764, pp.16–30. 10.1016/J.MRREV.2015.01.001. 
Glossop, J.R., Nixon, N.B., Emes, R.D., Sim, J., Packham, J.C., Mattey, D.L., Farrell, W.E., 
Fryer, A.A., 2017. DNA methylation at diagnosis is associated with response to disease-
modifying drugs in early rheumatoid arthritis. Epigenomics. 10.2217/epi-2016-0042. 
Gnoni, G. V., Priore, P., Geelen, M.J.H., Siculella, L., 2009. The mitochondrial citrate carrier: 
Metabolic role and regulation of its activity and expression. IUBMB Life, 61(10), 
pp.987–994. 10.1002/iub.249. 
Gong, B., Chen, Q., Almasan, A., 1998. Ionizing radiation stimulates mitochondrial gene 
expression and activity. Radiation research, 150(5), pp.505–12. 
Gopalakrishnan, S., Van Emburgh, B.O., Robertson, K.D., 2008. DNA methylation in 
development and human disease. Mutation research, 647(1–2), pp.30–8. 
10.1016/j.mrfmmm.2008.08.006. 
Green, A., Beer, P., 2010. Somatic Mutations of IDH1 and IDH2 in the Leukemic 
Transformation of Myeloproliferative Neoplasms. New England Journal of Medicine, 
362(4), pp.369–370. 10.1056/NEJMc0910063. 
Gu, H., Gao, J., Guo, W., Zhou, Y., Kong, Q., 2017. The expression of DNA 
methyltransferases3A is specifically downregulated in chorionic villi of early embryo 
growth arrest cases. Molecular medicine reports, 16(1), pp.591–596. 
10.3892/mmr.2017.6650. 
Guilloteau, P., Zabielski, R., Hammon, H.M., Metges, C.C., 2009. Adverse effects of 
nutritional programming during prenatal and early postnatal life, some aspects of 
regulation and potential prevention and treatments. Journal of physiology and 
pharmacology : an official journal of the Polish Physiological Society, 60 Suppl 3, 
175 
 
pp.17–35. 
Guo, X., Wang, L., Li, J., Ding, Z., Xiao, J., Yin, X., He, S., Shi, P., Dong, L., Li, G., Tian, C., Wang, 
J., Cong, Y., Xu, Y., 2015. Structural insight into autoinhibition and histone H3-induced 
activation of DNMT3A. Nature, 517(7536), pp.640–644. 10.1038/nature13899. 
Hahn, O., Grönke, S., Stubbs, T.M., Ficz, G., Hendrich, O., Krueger, F., Andrews, S., Zhang, 
Q., Wakelam, M.J., Beyer, A., Reik, W., Partridge, L., 2017. Dietary restriction protects 
from age-associated DNA methylation and induces epigenetic reprogramming of lipid 
metabolism. Genome Biology, 18(1), p.56. 10.1186/s13059-017-1187-1. 
Hall, E., Dekker Nitert, M., Volkov, P., Malmgren, S., Mulder, H., Bacos, K., Ling, C., 2018. 
The effects of high glucose exposure on global gene expression and DNA methylation 
in human pancreatic islets. Molecular and Cellular Endocrinology, 472, pp.57–67. 
10.1016/j.mce.2017.11.019. 
Hamanaka, R.B., Chandel, N.S., 2010. Mitochondrial reactive oxygen species regulate 
cellular signaling and dictate biological outcomes. Trends in Biochemical Sciences, 
35(9), pp.505–513. 10.1016/j.tibs.2010.04.002. 
Hamanaka, R.B., Chandel, N.S., 2012. Targeting glucose metabolism for cancer therapy. The 
Journal of experimental medicine, 209(2), pp.211–5. 10.1084/jem.20120162. 
Hameed, I., Masoodi, S.R., Mir, S.A., Nabi, M., Ghazanfar, K., Ganai, B.A., 2015. Type 2 
diabetes mellitus: From a metabolic disorder to an inflammatory condition. World 
Journal of Diabetes, 6(4), p.598. 10.4239/wjd.v6.i4.598. 
Hanahan, D., Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell, 144(5), 
pp.646–74. 10.1016/j.cell.2011.02.013. 
Harashima, H., Dissmeyer, N., Schnittger, A., 2013. Cell cycle control across the eukaryotic 
kingdom. Trends in Cell Biology, 23(7), pp.345–356. 10.1016/j.tcb.2013.03.002. 
Hatzivassiliou, G., Zhao, F., Bauer, D.E., Andreadis, C., Shaw, A.N., Dhanak, D., Hingorani, 
S.R., Tuveson, D.A., Thompson, C.B., 2005. ATP citrate lyase inhibition can suppress 
tumor cell growth. Cancer cell, 8(4), pp.311–21. 10.1016/j.ccr.2005.09.008. 
Heard, E., Martienssen, R.A., 2014. Transgenerational Epigenetic Inheritance: Myths and 
Mechanisms. Cell, 157(1), pp.95–109. 10.1016/j.cell.2014.02.045. 
Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., 2009. Understanding the Warburg 
176 
 
effect: the metabolic requirements of cell proliferation. Science (New York, N.Y.), 
324(5930), pp.1029–1033. 10.1126/science.1160809. 
Heigwer, F., Kerr, G., Boutros, M., 2014. E-CRISP: fast CRISPR target site identification. 
Nature Methods. 10.1038/nmeth.2812. 
Hildenbrand, G.L., Hildenbrand, L.C., Bradford, K., Cavin, S.W., 1995. Five-year survival rates 
of melanoma patients treated by diet therapy after the manner of Gerson: a 
retrospective review. Alternative therapies in health and medicine, 1(4), pp.29–37. 
Holliday, R., Pugh, J.E., 1975. DNA modification mechanisms and gene activity during 
development. Science (New York, N.Y.), 187(4173), pp.226–32. 
Holt, R.I.G., 2002. Fetal programming of the growth hormone-insulin-like growth factor 
axis. Trends in endocrinology and metabolism: TEM, 13(9), pp.392–7. 
Holvoet, P., Vanhaverbeke, M., Bloch, K., Baatsen, P., Sinnaeve, P., Janssens, S., 2016. Low 
MT-CO1 in Monocytes and Microvesicles Is Associated With Outcome in Patients With 
Coronary Artery Disease. Journal of the American Heart Association, 5(12). 
10.1161/JAHA.116.004207. 
Huang, Y., Pastor, W.A., Shen, Y., Tahiliani, M., Liu, D.R., Rao, A., 2010. The Behaviour of 5-
Hydroxymethylcytosine in Bisulfite Sequencing Liu, J., ed. PLoS ONE, 5(1), p.e8888. 
10.1371/journal.pone.0008888. 
Iacobazzi, V., Infantino, V., 2014. Citrate-new functions for an old metabolite. Biological 
Chemistry, 395(4), pp.387–399. 10.1515/hsz-2013-0271. 
Illingworth, R.S., Gruenewald-Schneider, U., Webb, S., Kerr, A.R.W., James, K.D., Turner, 
D.J., Smith, C., Harrison, D.J., Andrews, R., Bird, A.P., 2010. Orphan CpG Islands Identify 
Numerous Conserved Promoters in the Mammalian Genome Reik, W., ed. PLoS 
Genetics, 6(9), p.e1001134. 10.1371/journal.pgen.1001134. 
Inoue, A., Zhang, Y., 2011. Replication-Dependent Loss of 5-Hydroxymethylcytosine in 
Mouse Preimplantation Embryos. Science, 334(6053), pp.194–194. 
10.1126/science.1212483. 
Inoue, S. et al., 2016. Mutant IDH1 Downregulates ATM and Alters DNA Repair and 
Sensitivity to DNA Damage Independent of TET2. Cancer cell, 30(2), pp.337–348. 
10.1016/j.ccell.2016.05.018. 
177 
 
Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., 
Nakada, K., Honma, Y., Hayashi, J.-I., 2008. ROS-Generating Mitochondrial DNA 
Mutations Can Regulate Tumor Cell Metastasis. Science, 320(5876), pp.661–664. 
10.1126/science.1156906. 
Israelsen, W.J. et al., 2013. PKM2 Isoform-Specific Deletion Reveals a Differential 
Requirement for Pyruvate Kinase in Tumor Cells. Cell, 155(2), pp.397–409. 
10.1016/j.cell.2013.09.025. 
Ito, S., Shen, L., Dai, Q., Wu, S.C., Collins, L.B., Swenberg, J.A., He, C., Zhang, Y., 2011. Tet 
proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. 
Science (New York, N.Y.), 333(6047), pp.1300–3. 10.1126/science.1210597. 
Jacob, A.D., Elkins, N., Reiss, O.K., Chan, L., Shapiro, J.I., 1997. Effects of acetate on energy 
metabolism and function in the isolated perfused rat heart. Kidney international, 
52(3), pp.755–60. 
Jaenisch, R., Bird, A., 2003. Epigenetic regulation of gene expression: how the genome 
integrates intrinsic and environmental signals. Nature Genetics, 33(3s), pp.245–254. 
10.1038/ng1089. 
Janke, R., Iavarone, A.T., Rine, J., 2017. Oncometabolite D-2-Hydroxyglutarate enhances 
gene silencing through inhibition of specific H3K36 histone demethylases. eLife, 6. 
10.7554/eLife.22451. 
Jelinic, P., Shaw, P., 2007. Loss of imprinting and cancer. The Journal of Pathology, 211(3), 
pp.261–268. 10.1002/path.2116. 
Jeltsch, A., Jurkowska, R.Z., 2016. Allosteric control of mammalian DNA methyltransferases 
- a new regulatory paradigm. Nucleic acids research, 44(18), pp.8556–8575. 
10.1093/nar/gkw723. 
Jeong, M. et al., 2014. Large conserved domains of low DNA methylation maintained by 
Dnmt3a. Nature genetics, 46(1), pp.17–23. 10.1038/ng.2836. 
Jia, G., Mitra, A.K., Gangahar, D.M., Agrawal, D.K., 2009. Regulation of cell cycle entry by 
PTEN in smooth muscle cell proliferation of human coronary artery bypass conduits. 
Journal of cellular and molecular medicine, 13(3), pp.547–54. 10.1111/j.1582-
4934.2008.00384.x. 
178 
 
Jia, Y. et al., 2016. Negative regulation of DNMT3A de novo DNA methylation by frequently 
overexpressed UHRF family proteins as a mechanism for widespread DNA 
hypomethylation in cancer. Cell Discovery, 2, p.16007. 10.1038/celldisc.2016.7. 
Jiménez, N.E., Wilkens, C.A., Gerdtzen, Z.P., 2011. Engineering CHO cell metabolism for 
growth in galactose. BMC proceedings, 5 Suppl 8(Suppl 8), p.P119. 10.1186/1753-
6561-5-S8-P119. 
Jin, Z., Liu, Y., 2018. DNA methylation in human diseases. Genes & Diseases, 5(1), pp.1–8. 
10.1016/J.GENDIS.2018.01.002. 
Jo, S.-H., Son, M.-K., Koh, H.-J., Lee, S.-M., Song, I.-H., Kim, Y.-O., Lee, Y.-S., Jeong, K.-S., Kim, 
W.B., Park, J.-W., Song, B.J., Huhe, T.-L., Huhe, T.L., 2001. Control of Mitochondrial 
Redox Balance and Cellular Defense against Oxidative Damage by Mitochondrial NADP 
+ -dependent Isocitrate Dehydrogenase. Journal of Biological Chemistry, 276(19), 
pp.16168–16176. 10.1074/jbc.M010120200. 
Jones, P.A., 2007. ScienceDirect - Cell : The Epigenomics of Cancer. Cell. 
Jones, P.A., Takai, D., 2001. The role of DNA methylation in mammalian epigenetics. Science 
(New York, N.Y.), 293(5532), pp.1068–70. 10.1126/science.1063852. 
Joulie, M., Miotto, B., Defossez, P.-A., 2010. Mammalian methyl-binding proteins: What 
might they do? BioEssays, 32(12), pp.1025–1032. 10.1002/bies.201000057. 
Kaati, G., Bygren, L., Edvinsson, S., 2002. Cardiovascular and diabetes mortality determined 
by nutrition during parents’ and grandparents’ slow growth period. European Journal 
of Human Genetics, 10(11), pp.682–688. 10.1038/sj.ejhg.5200859. 
Kaneda, M., Okano, M., Hata, K., Sado, T., Tsujimoto, N., Li, E., Sasaki, H., 2004. Essential 
role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. 
Nature, 429(6994), pp.900–903. 10.1038/nature02633. 
Kase, E.T., Nikolić, N., Bakke, S.S., Bogen, K.K., Aas, V., Thoresen, G.H., Rustan, A.C., 2013. 
Remodeling of oxidative energy metabolism by galactose improves glucose handling 
and metabolic switching in human skeletal muscle cells. PloS one, 8(4), p.e59972. 
10.1371/journal.pone.0059972. 
Katada, S., Imhof, A., Sassone-Corsi, P., 2012. Connecting Threads: Epigenetics and 
Metabolism. Cell, 148(1–2), pp.24–28. 10.1016/J.CELL.2012.01.001. 
179 
 
Keating, S.T., El-Osta, A., 2015. Epigenetics and Metabolism. Circulation Research, 116(4), 
pp.715–736. 10.1161/CIRCRESAHA.116.303936. 
Kelly, T.J., Lerin, C., Haas, W., Gygi, S.P., Puigserver, P., 2009. GCN5-mediated 
Transcriptional Control of the Metabolic Coactivator PGC-1β through Lysine 
Acetylation. Journal of Biological Chemistry, 284(30), pp.19945–19952. 
10.1074/jbc.M109.015164. 
Kheir, T.B., Lund, A.H., 2010. Epigenetic dynamics across the cell cycle. Essays In 
Biochemistry, 48(1), pp.107–120. 10.1042/bse0480107. 
Khurshed, M., Molenaar, R.J., Lenting, K., Leenders, W.P., van Noorden, C.J.F., 2017. In silico 
gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type 
glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. Oncotarget, 
8(30), pp.49165–49177. 10.18632/oncotarget.17106. 
Kim, C.H., Lee, E.K., Choi, Y.J., An, H.J., Jeong, H.O., Park, D., Kim, B.C., Yu, B.P., Bhak, J., 
Chung, H.Y., 2016. Short-term calorie restriction ameliorates genomewide, age-
related alterations in DNA methylation. Aging Cell, 15(6), pp.1074–1081. 
10.1111/acel.12513. 
Kishikawa, S., Murata, T., Ugai, H., Yamazaki, T., Yokoyama, K.K., 2003. Control elements of 
Dnmt1 gene are regulated in cell-cycle dependent manner. Nucleic acids research. 
Supplement (2001), (3), pp.307–8. 
Kobayashi, H., Sakurai, T., Imai, M., Takahashi, N., Fukuda, A., Yayoi, O., Sato, S., 
Nakabayashi, K., Hata, K., Sotomaru, Y., Suzuki, Y., Kono, T., 2012. Contribution of 
intragenic DNA methylation in mouse gametic DNA methylomes to establish oocyte-
specific heritable marks. PLoS genetics, 8(1), p.e1002440. 
10.1371/journal.pgen.1002440. 
Kobayashi, K., Hattori, T., Hayashi, R., Kirimura, K., 2014. Overexpression of the NADP + -
specific isocitrate dehydrogenase gene ( icdA ) in citric acid-producing Aspergillus niger 
WU-2223L. Bioscience, Biotechnology, and Biochemistry, 78(7), pp.1246–1253. 
10.1080/09168451.2014.918483. 
Koentjoro, B., Park, J.-S., Sue, C.M., 2017. Nix restores mitophagy and mitochondrial 
function to protect against PINK1/Parkin-related Parkinson’s disease. Scientific 
Reports, 7(1), p.44373. 10.1038/srep44373. 
180 
 
Koh, H.-J., Lee, S.-M., Son, B.-G., Lee, S.-H., Ryoo, Z.Y., Chang, K.-T., Park, J.-W., Park, D.-C., 
Song, B.J., Veech, R.L., Song, H., Huh, T.-L., 2004. Cytosolic NADP + -dependent 
Isocitrate Dehydrogenase Plays a Key Role in Lipid Metabolism. Journal of Biological 
Chemistry, 279(38), pp.39968–39974. 10.1074/jbc.M402260200. 
Koit, A., Shevchuk, I., Ounpuu, L., Klepinin, A., Chekulayev, V., Timohhina, N., Tepp, K., 
Puurand, M., Truu, L., Heck, K., Valvere, V., Guzun, R., Kaambre, T., 2017. 
Mitochondrial Respiration in Human Colorectal and Breast Cancer Clinical Material Is 
Regulated Differently. Oxidative Medicine and Cellular Longevity, 2017, pp.1–16. 
10.1155/2017/1372640. 
Kroeze, L.I., van der Reijden, B.A., Jansen, J.H., 2015. 10.1016/j.bbcan.2015.01.001. 
Kuroda, A., Rauch, T.A., Todorov, I., Ku, H.T., Al-Abdullah, I.H., Kandeel, F., Mullen, Y., 
Pfeifer, G.P., Ferreri, K., 2009. Insulin gene expression is regulated by DNA 
methylation. PLoS ONE, 4(9). 10.1371/journal.pone.0006953. 
Lamerton, L.F., 1974. The mitotic cycle and cell population control. Journal of clinical 
pathology. Supplement (Royal College of Pathologists), 7, pp.19–25. 
Lane, R.S., Fu, Y., Matsuzaki, S., Kinter, M., Humphries, K.M., Griffin, T.M., 2015. 
Mitochondrial respiration and redox coupling in articular chondrocytes. Arthritis 
research & therapy, 17, p.54. 10.1186/s13075-015-0566-9. 
Latham, T., Mackay, L., Sproul, D., Karim, M., Culley, J., Harrison, D.J., Hayward, L., 
Langridge-Smith, P., Gilbert, N., Ramsahoye, B.H., 2012. Lactate, a product of glycolytic 
metabolism, inhibits histone deacetylase activity and promotes changes in gene 
expression. Nucleic Acids Res, 40(11), pp.4794–4803. 10.1093/nar/gks066. 
Layden, B.T., Yalamanchi, S.K., Wolever, T.M., Dunaif, A., Lowe Jr., W.L., 2012. Negative 
association of acetate with visceral adipose tissue and insulin levels. Diabetes Metab 
Syndr.Obes., 5, pp.49–55. 10.2147/DMSO.S29244. 
Lempradl, A., Pospisilik, J.A., Penninger, J.M., 2015. Exploring the emerging complexity in 
transcriptional regulation of energy homeostasis. Nature Reviews Genetics, 16(11), 
pp.665–681. 10.1038/nrg3941. 
Lenzen, S., Drinkgern, J., Tiedge, M., 1996. Low antioxidant enzyme gene expression in 
pancreatic islets compared with various other mouse tissues. Free radical biology & 
medicine, 20(3), pp.463–6. 
181 
 
Li, B.-Z., Huang, Z., Cui, Q.-Y., Song, X.-H., Du, L., Jeltsch, A., Chen, P., Li, G., Li, E., Xu, G.-L., 
2011. Histone tails regulate DNA methylation by allosterically activating de novo 
methyltransferase. Cell research, 21(8), pp.1172–81. 10.1038/cr.2011.92. 
Li, H., Hurlburt, A.J., Tennessen, J.M., 2018. A Drosophila model of combined D-2- and L-2-
hydroxyglutaric aciduria reveals a mechanism linking mitochondrial citrate export with 
oncometabolite accumulation. Disease models & mechanisms, 11(9). 
10.1242/dmm.035337. 
Li, Y., Park, J.-S., Deng, J.-H., Bai, Y., 2006. Cytochrome c oxidase subunit IV is essential for 
assembly and respiratory function of the enzyme complex. Journal of bioenergetics 
and biomembranes, 38(5–6), pp.283–91. 10.1007/s10863-006-9052-z. 
Lill, R., Mühlenhoff, U., 2008. Maturation of Iron-Sulfur Proteins in Eukaryotes: 
Mechanisms, Connected Processes, and Diseases. Annual Review of Biochemistry, 
77(1), pp.669–700. 10.1146/annurev.biochem.76.052705.162653. 
Lim, D.H.K., Maher, E.R., 2010. DNA methylation: a form of epigenetic control of gene 
expression. The Obstetrician & Gynaecologist, 12(1), pp.37–42. 
10.1576/toag.12.1.037.27556. 
Lin, R.-K., Wang, Y.-C., 2014. Dysregulated transcriptional and post-translational control of 
DNA methyltransferases in cancer. Cell & bioscience, 4, p.46. 10.1186/2045-3701-4-
46. 
Ling, C., Groop, L., 2009. Epigenetics: a molecular link between environmental factors and 
type 2 diabetes. Diabetes, 58(12), pp.2718–25. 10.2337/db09-1003. 
Liu, T., Wu, X., Chen, T., Luo, Z., Hu, X., 2018. Downregulation of DNMT3A by miR-708-5p 
Inhibits Lung Cancer Stem Cell–like Phenotypes through Repressing Wnt/β-catenin 
Signaling. Clinical Cancer Research, 24(7), pp.1748–1760. 10.1158/1078-0432.CCR-17-
1169. 
Liu, X.-S., LIttle, J.B., Yuan, Z.-M., 2015. Glycolytic metabolism influences global chromatin 
structure. Oncotarget, 6(6), pp.4214–25. 10.18632/oncotarget.2929. 
Liu, X.S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R.A., 
Jaenisch, R., 2016. Editing DNA Methylation in the Mammalian Genome. Cell. 
10.1016/j.cell.2016.08.056. 
182 
 
Liu, Y., Aryee, M.J., Padyukov, L., Fallin, M.D., Hesselberg, E., Runarsson, A., Reinius, L., 
Acevedo, N., Taub, M., Ronninger, M., Shchetynsky, K., Scheynius, A., Kere, J., 
Alfredsson, L., Klareskog, L., Ekström, T.J., Feinberg, A.P., 2013. Epigenome-wide 
association data implicate DNA methylation as an intermediary of genetic risk in 
rheumatoid arthritis. Nature Biotechnology. 10.1038/nbt.2487. 
Liu, Z., Xie, Z., Jones, W., Pavlovicz, R.E., Liu, S., Yu, J., Li, P., Lin, J., Fuchs, J.R., Marcucci, G., 
Li, C., Chan, K.K., 2009. Curcumin is a potent DNA hypomethylation agent. Bioorganic 
& Medicinal Chemistry Letters, 19(3), pp.706–709. 10.1016/J.BMCL.2008.12.041. 
Lombard, D.B. et al., 2007. Mammalian Sir2 Homolog SIRT3 Regulates Global Mitochondrial 
Lysine Acetylation. Molecular and Cellular Biology, 27(24), pp.8807–8814. 
10.1128/MCB.01636-07. 
Lu, H., Koshkin, V., Allister, E.M., Gyulkhandanyan, A. V., Wheeler, M.B., 2010. Molecular 
and Metabolic Evidence for Mitochondrial Defects Associated With  -Cell Dysfunction 
in a Mouse Model of Type 2 Diabetes. Diabetes, 59(2), pp.448–459. 10.2337/db09-
0129. 
Lv, Q., Xing, S., Li, Z., Li, J., Gong, P., Xu, X., Chang, L., Jin, X., Gao, F., Li, W., Zhang, G., Yang, 
J., Zhang, X., 2012. Altered expression levels of IDH2 are involved in the development 
of colon cancer. Experimental and therapeutic medicine, 4(5), pp.801–806. 
10.3892/etm.2012.676. 
Lyssiotis, C.A., Cantley, L.C., 2014. Acetate Fuels the Cancer Engine. Cell, 159(7), pp.1492–
1494. 10.1016/J.CELL.2014.12.009. 
Macdonald, M.J., Brown, L.J., Longacre, M.J., Stoker, S.W., Kendrick, M.A., 2013. 
Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic 
beta cells inhibits insulin secretion. Biochimica et Biophysica Acta - General Subjects, 
1830(11), pp.5104–5111. 10.1016/j.bbagen.2013.07.013. 
Maddocks, O.D.K., Labuschagne, C.F., Adams, P.D., Vousden, K.H., 2016. Serine Metabolism 
Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP 
Synthesis in Cancer Cells. Molecular cell, 61(2), pp.210–21. 
10.1016/j.molcel.2015.12.014. 
Maechler, P., 2013. Mitochondrial function and insulin secretion. Molecular and Cellular 
Endocrinology, 379(1–2), pp.12–18. 10.1016/j.mce.2013.06.019. 
183 
 
Maedler, K., Oberholzer, J., Bucher, P., Spinas, G.A., Donath, M.Y., 2003. Monounsaturated 
fatty acids prevent the deleterious effects of palmitate and high glucose on human 
pancreatic beta-cell turnover and function. Diabetes, 52(3), pp.726–33. 
Maghbooli, Z., Hossein-Nezhad, A., Larijani, B., Pasalar, P., Keshtkar, A.A., 2015. Association 
between alterations in global DNA methylation and predisposing factors in diabetes: 
a high pressure liquid chromatography based study. Minerva medica, 106(4), pp.221–
31. 
Mahajan, N.P., Malla, P., Bhagwat, S., Sharma, V., 2017. WEE1 epigenetically modulates 5-
hmC levels by pY37-H2B dependent regulation of IDH2 gene expression. Oncotarget, 
8(63), pp.106352–106368. 10.18632/oncotarget.22374. 
Marroquin, L.D., Hynes, J., Dykens, J.A., Jamieson, J.D., Will, Y., 2007. Circumventing the 
crabtree effect: Replacing media glucose with galactose increases susceptibility of 
hepG2 cells to mitochondrial toxicants. Toxicological Sciences, 97(2), pp.539–547. 
10.1093/toxsci/kfm052. 
Martín Caballero, I., Hansen, J., Leaford, D., Pollard, S., Hendrich, B.D., 2009. The methyl-
CpG binding proteins Mecp2, Mbd2 and Kaiso are dispensable for mouse 
embryogenesis, but play a redundant function in neural differentiation. Reh, T. A., ed. 
PloS one, 4(1), p.e4315. 10.1371/journal.pone.0004315. 
Mathers, J.C., 2008. Session 2: Personalised nutrition Epigenomics: a basis for 
understanding individual differences? Proceedings of the Nutrition Society, 67(04), 
p.390. 10.1017/S0029665108008744. 
Meeran, S.M., Katiyar, S.K., 2008. Cell cycle control as a basis for cancer chemoprevention 
through dietary agents. Frontiers in bioscience : a journal and virtual library, 13, 
pp.2191–202. 
Melser, S., Chatelain, E.H., Lavie, J., Mahfouf, W., Jose, C., Obre, E., Goorden, S., Priault, M., 
Elgersma, Y., Rezvani, H.R., Rossignol, R., Bénard, G., 2013. Rheb Regulates Mitophagy 
Induced by Mitochondrial Energetic Status. Cell Metabolism, 17(5), pp.719–730. 
10.1016/J.CMET.2013.03.014. 
Mews, P., Donahue, G., Drake, A.M., Luczak, V., Abel, T., Berger, S.L., 2017. Acetyl-CoA 
synthetase regulates histone acetylation and hippocampal memory. Nature., 
546(7658), pp.381–386. 10.1038/nature22405. 
184 
 
De Meyts, P., 2004. Insulin and its receptor: structure, function and evolution. BioEssays, 
26(12), pp.1351–1362. 10.1002/bies.20151. 
Miao, F., Chen, Z., Genuth, S., Paterson, A., Zhang, L., Wu, X., Li, S.M., Cleary, P., Riggs, A., 
Harlan, D.M., Lorenzi, G., Kolterman, O., Sun, W., Lachin, J.M., Natarajan, R., Group,  
the D.R., 2014. Evaluating the Role of Epigenetic Histone Modifications in the 
Metabolic Memory of Type 1 Diabetes. Diabetes, 63(5), pp.1748–1762. 
10.2337/DB13-1251. 
Minami, A., Nakanishi, A., Ogura, Y., Kitagishi, Y., Matsuda, S., 2014. Connection between 
Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair. Frontiers in oncology, 4, 
p.318. 10.3389/fonc.2014.00318. 
Miozzo, F., Arnould, H., de Thonel, A., Schang, A.-L., Sabéran-Djoneidi, D., Baudry, A., 
Schneider, B., Mezger, V., 2018. Alcohol exposure promotes DNA methyltransferase 
DNMT3A upregulation through reactive oxygen species-dependent mechanisms. Cell 
Stress and Chaperones, 23(1), pp.115–126. 10.1007/s12192-017-0829-2. 
Miremadi, A., Oestergaard, M.Z., Pharoah, P.D.P., Caldas, C., 2007. Cancer genetics of 
epigenetic genes. Human Molecular Genetics, 16(R1), pp.R28–R49. 
10.1093/hmg/ddm021. 
Mkaouar-Rebai, E., Chamkha, I., Kammoun, T., Alila-Fersi, O., Aloulou, H., Hachicha, M., 
Fakhfakh, F., 2013. A novel MT-CO1 m.6498C&gt;A variation associated with the 
m.7444G&gt;A mutation in the mitochondrial COI/tRNASer(UCN) genes in a patient 
with hearing impairment, diabetes and congenital visual loss. Biochemical and 
Biophysical Research Communications, 430(2), pp.585–591. 
10.1016/J.BBRC.2012.11.109. 
Moarefi, A.H., Chédin, F., 2011. ICF Syndrome Mutations Cause a Broad Spectrum of 
Biochemical Defects in DNMT3B-Mediated De Novo DNA Methylation. Journal of 
Molecular Biology, 409(5), pp.758–772. 10.1016/j.jmb.2011.04.050. 
Mohammad, H.P., Baylin, S.B., 2010. Linking cell signaling and the epigenetic machinery. 
Nature Biotechnology, 28(10), pp.1033–1038. 10.1038/nbt1010-1033. 
Moncada, S., Higgs, E.A., Colombo, S.L., 2012. Fulfilling the metabolic requirements for cell 
proliferation. Biochemical Journal, 446(1), pp.1–7. 10.1042/BJ20120427. 
Moore, L.D., Le, T., Fan, G., 2013. DNA methylation and its basic function. 
185 
 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology, 38(1), pp.23–38. 10.1038/npp.2012.112. 
Moreno-Sánchez, R., Rodríguez-Enríquez, S., Marín-Hernández, A., Saavedra, E., 2007. 
Energy metabolism in tumor cells. The FEBS journal, 274(6), pp.1393–418. 
10.1111/j.1742-4658.2007.05686.x. 
Morrish, F., Isern, N., Sadilek, M., Jeffrey, M., Hockenbery, D.M., 2009. C-Myc activates 
multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene, 
28(27), pp.2485–2491. 10.1038/onc.2009.112. 
Morrish, F., Noonan, J., Perez-Olsen, C., Gafken, P.R., Fitzgibbon, M., Kelleher, J., VanGilst, 
M., Hockenbery, D., 2010. Myc-dependent mitochondrial generation of acetyl-CoA 
contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. 
The Journal of biological chemistry, 285(47), pp.36267–74. 10.1074/jbc.M110.141606. 
Mulder, H., 2017. Transcribing β-cell mitochondria in health and disease. Molecular 
metabolism, 6(9), pp.1040–1051. 10.1016/j.molmet.2017.05.014. 
Murai, M., Toyota, M., Satoh, A., Suzuki, H., Akino, K., Mita, H., Sasaki, Y., Ishida, T., Shen, 
L., Garcia-Manero, G., Issa, J.-P.J., Hinoda, Y., Tokino, T., Imai, K., 2005. Aberrant DNA 
methylation associated with silencing BNIP3 gene expression in haematopoietic 
tumours. British journal of cancer, 92(6), pp.1165–72. 10.1038/sj.bjc.6602422. 
NCBI, 2019. ClinVar [online]. Available at: https://www.ncbi.nlm.nih.gov/clinvar/? 
[Accessed 27 April 2019]. 
Newell-Price, J., Clark, A.J., King, P., 2000. DNA methylation and silencing of gene 
expression. Trends in endocrinology and metabolism: TEM, 11(4), pp.142–8. 
Ney, P.A., 2015. Mitochondrial autophagy: Origins, significance, and role of BNIP3 and NIX. 
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1853(10), pp.2775–
2783. 10.1016/j.bbamcr.2015.02.022. 
Nicholas, L.M., Valtat, B., Medina, A., Andersson, L., Abels, M., Mollet, I.G., Jain, D., Eliasson, 
L., Wierup, N., Fex, M., Mulder, H., 2017. Mitochondrial transcription factor B2 is 
essential for mitochondrial and cellular function in pancreatic β-cells. Molecular 
metabolism, 6(7), pp.651–663. 10.1016/j.molmet.2017.05.005. 
Nikoloski, G., Van Der Reijden, B.A., Jansen, J.H., 2012. Mutations in epigenetic regulators 
186 
 
in myelodysplastic syndromes. In: International Journal of Hematology. 
10.1007/s12185-011-0996-3. 
Nitert, M.D. et al., 2012. Impact of an Exercise Intervention on DNA Methylation in Skeletal 
Muscle From First-Degree Relatives of Patients With Type 2 Diabetes. Diabetes, 
61(12), p.3322. 10.2337/DB11-1653. 
Nota, B. et al., 2013. Deficiency in SLC25A1, Encoding the Mitochondrial Citrate Carrier, 
Causes Combined D-2- and L-2-Hydroxyglutaric Aciduria. The American Journal of 
Human Genetics, 92(4), pp.627–631. 10.1016/j.ajhg.2013.03.009. 
Nunes, A.R., Alves, M.G., Tomás, G.D., Conde, V.R., Cristóvão, A.C., Moreira, P.I., Oliveira, 
P.F., Silva, B.M., 2015. Daily consumption of white tea (Camellia sinensis (L.)) improves 
the cerebral cortex metabolic and oxidative profile in prediabetic Wistar rats. British 
Journal of Nutrition, 113(05), pp.832–842. 10.1017/S0007114514004395. 
Nunnari, J., Suomalainen, A., 2012. Mitochondria: in sickness and in health. Cell, 148(6), 
pp.1145–59. 10.1016/j.cell.2012.02.035. 
Ohm, J.E., McGarvey, K.M., Yu, X., Cheng, L., Schuebel, K.E., Cope, L., Mohammad, H.P., 
Chen, W., Daniel, V.C., Yu, W., Berman, D.M., Jenuwein, T., Pruitt, K., Sharkis, S.J., 
Watkins, D.N., Herman, J.G., Baylin, S.B., 2007. A stem cell–like chromatin pattern may 
predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. 
Nature Genetics, 39(2), pp.237–242. 10.1038/ng1972. 
Okano, M., Bell, D.W., Haber, D.A., Li, E., 1999. DNA methyltransferases Dnmt3a and 
Dnmt3b are essential for de novo methylation and mammalian development. Cell, 
99(3), pp.247–57. 10.1016/S0092-8674(00)81656-6. 
Okano, M., Bell, D.W., Haber, D.A., Li, E., Li, Y., He, W.., Okumura, K., Li, E., Dongen, J.. van, 
Abreu, R.. De, al.,  et, 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential 
for de novo methylation and mammalian development. Cell, 99(3), pp.247–57. 
10.1016/S0092-8674(00)81656-6. 
Ooi, S.K.T., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., Erdjument-Bromage, H., Tempst, P., 
Lin, S.-P., Allis, C.D., Cheng, X., Bestor, T.H., 2007. DNMT3L connects unmethylated 
lysine 4 of histone H3 to de novo methylation of DNA. Nature, 448(7154), pp.714–717. 
10.1038/nature05987. 
Orgeron, M.L., Stone, K.P., Wanders, D., Cortez, C.C., Van, N.T., Gettys, T.W., 2014. The 
187 
 
impact of dietary methionine restriction on biomarkers of metabolic health. Progress 
in molecular biology and translational science, 121, pp.351–76. 10.1016/B978-0-12-
800101-1.00011-9. 
Painter, R.C., Roseboom, T.J., Bleker, O.P., 2005. Prenatal exposure to the Dutch famine 
and disease in later life: An overview. Reproductive Toxicology, 20(3), pp.345–352. 
10.1016/j.reprotox.2005.04.005. 
De Palma, A., Prezioso, G., Scalera, V., 2005. Kinetic Evidence for the Uniport Mechanism 
Hypothesis in the Mitochondrial Tricarboxylate Transport System. Journal of 
Bioenergetics and Biomembranes, 37(5), pp.279–289. 10.1007/s10863-005-8639-0. 
Palmfeldt, J., Vang, S., Stenbroen, V., Pedersen, C.B., Christensen, J.H., Bross, P., Gregersen, 
N., 2009. Mitochondrial proteomics on human fibroblasts for identification of 
metabolic imbalance and cellular stress. Proteome science, 7, p.20. 10.1186/1477-
5956-7-20. 
Palmieri, F., Pierri, C.L., 2010. Mitochondrial metabolite transport. Essays In Biochemistry, 
47, pp.37–52. 10.1042/bse0470037. 
Pang, A.P.S., Sugai, C., Maunakea, A.K., 2016. High-throughput sequencing offers new 
insights into 5-hydroxymethylcytosine. Biomolecular concepts, 7(3), pp.169–78. 
10.1515/bmc-2016-0011. 
Panning, B., 2008. X-chromosome inactivation: the molecular basis of silencing. Journal of 
biology, 7(8), p.30. 10.1186/jbiol95. 
Pardee,  a B., 1974. A restriction point for control of normal animal cell proliferation. 
Proceedings of the National Academy of Sciences of the United States of America, 
71(4), pp.1286–90. 10.1073/pnas.71.4.1286. 
Park, J.-B., Nagar, H., Choi, S., Jung, S., Kim, H.-W., Kang, S.K., Lee, J.W., Lee, J.H., Park, J.-
W., Irani, K., Jeon, B.H., Song, H.-J., Kim, C.-S., 2016. IDH2 deficiency impairs 
mitochondrial function in endothelial cells and endothelium-dependent vasomotor 
function. Free Radical Biology and Medicine, 94, pp.36–46. 
10.1016/j.freeradbiomed.2016.02.017. 
Park, J.H., Stoffers, D.A., Nicholls, R.D., Simmons, R.A., 2008. Development of type 2 
diabetes following intrauterine growth retardation in rats is associated with 
progressive epigenetic silencing of Pdx1. The Journal of clinical investigation, 118(6), 
188 
 
pp.2316–24. 10.1172/JCI33655. 
Park, S., Sadanala, K.C., Kim, E.-K., 2015. A Metabolomic Approach to Understanding the 
Metabolic Link between Obesity and Diabetes. Molecules and Cells, 38(7), pp.587–
596. 10.14348/molcells.2015.0126. 
Pavlova, N.N., Thompson, C.B., 2016. The Emerging Hallmarks of Cancer Metabolism. Cell 
metabolism, 23(1), pp.27–47. 10.1016/j.cmet.2015.12.006. 
Peleg, S., Feller, C., Ladurner, A.G., Imhof, A., 2016. The Metabolic Impact on Histone 
Acetylation and Transcription in Ageing. Trends in biochemical sciences, 41(8), pp.700–
711. 10.1016/j.tibs.2016.05.008. 
Pelosi, E., Castelli, G., Testa, U., 2016. Isocitrate Dehydrogenase Mutations in Human 
Cancers: Physiopathologic Mechanisms and Therapeutic Targeting. Journal of 
Exploratory Research in Pharmacology, 1, pp.20–34. 10.14218/JERP.2016.00019. 
Peng, D.-F., Kanai, Y., Sawada, M., Ushijima, S., Hiraoka, N., Kitazawa, S., Hirohashi, S., 2006. 
DNA methylation of multiple tumor-related genes in association with overexpression 
of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the 
pancreas. Carcinogenesis, 27(6), pp.1160–1168. 10.1093/carcin/bgi361. 
Peng, L., Yuan, Z., Ling, H., Fukasawa, K., Robertson, K., Olashaw, N., Koomen, J., Chen, J., 
Lane, W.S., Seto, E., 2011. SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) 
protein and alters its activities. Molecular and cellular biology, 31(23), pp.4720–34. 
10.1128/MCB.06147-11. 
Peng, S., Gerasimenko, J. V, Tsugorka, T.M., Gryshchenko, O., Samarasinghe, S., Petersen, 
O.H., Gerasimenko, O. V, 2018. Galactose protects against cell damage in mouse 
models of acute pancreatitis. The Journal of clinical investigation, 128(9), pp.3769–
3778. 10.1172/JCI94714. 
Penn, N.W., Suwalski, R., O’Riley, C., Bojanowski, K., Yura, R., 1972. The presence of 5-
hydroxymethylcytosine in animal deoxyribonucleic acid. The Biochemical journal, 
126(4), pp.781–90. 
Pesin, J.A., Orr-Weaver, T.L., 2008. Regulation of APC/C Activators in Mitosis and Meiosis. 
Annual Review of Cell and Developmental Biology, 24(1), pp.475–499. 
10.1146/annurev.cellbio.041408.115949. 
189 
 
Petrova-Benedict, R., Buncic, J.R., Wallace, D.C., Robinson, B.H., 1992. Selective killing of 
cells with oxidative defects in galactose medium: a screening test for affected patient 
fibroblasts. Journal of inherited metabolic disease, 15(6), pp.943–4. 
Pietrocola, F., Galluzzi, L., Bravo-San Pedro, J.M., Madeo, F., Kroemer, G., 2015. 
10.1016/j.cmet.2015.05.014. 
Poitout, V., Hagman, D., Stein, R., Artner, I., Robertson, R.P., Harmon, J.S., 2006a. 
Regulation of the insulin gene by glucose and fatty acids. The Journal of nutrition, 
136(4), pp.873–6. 136/4/873 [pii]. 
Poitout, V., Hagman, D., Stein, R., Artner, I., Robertson, R.P., Harmon, J.S., 2006b. 
Regulation of the insulin gene by glucose and fatty acids. The Journal of nutrition, 
136(4), pp.873–6. 10.1093/jn/136.4.873. 
Poli, V., Fagnocchi, L., Zippo, A., 2018. Tumorigenic Cell Reprogramming and Cancer 
Plasticity: Interplay between Signaling, Microenvironment, and Epigenetics. Stem cells 
international, 2018, p.4598195. 10.1155/2018/4598195. 
Ponnaluri, V.K.C., Ehrlich, K.C., Zhang, G., Lacey, M., Johnston, D., Pradhan, S., Ehrlich, M., 
2017. Association of 5-hydroxymethylation and 5-methylation of DNA cytosine with 
tissue-specific gene expression. Epigenetics, 12(2), p.123. 
10.1080/15592294.2016.1265713. 
Pons, D., De Vries, F.R., Van Den Elsen, P.J., Heijmans, B.T., Quax, P.H.A., Jukema, J.W., 
2009. 10.1093/eurheartj/ehn603. 
Prasad, R., Groop, L., 2015. Genetics of Type 2 Diabetes—Pitfalls and Possibilities. Genes, 
6(1), pp.87–123. 10.3390/genes6010087. 
Pravenec, M. et al., 2007. Direct linkage of mitochondrial genome variation to risk factors 
for type 2 diabetes in conplastic strains. Genome research, 17(9), pp.1319–26. 
10.1101/gr.6548207. 
Prestridge, D.S., Burks, C., 1993. The density of transcriptional elements in promoter and 
non-promoter sequences. Human molecular genetics, 2(9), pp.1449–53. 
Proskuryakov, S.Y., Gabai, V.L., 2010. Mechanisms of tumor cell necrosis. Current 
pharmaceutical design, 16(1), pp.56–68. 
Purushotham, A., Schug, T.T., Xu, Q., Surapureddi, S., Guo, X., Li, X., 2009. Hepatocyte-
190 
 
specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis 
and inflammation. Cell metabolism, 9(4), pp.327–38. 10.1016/j.cmet.2009.02.006. 
Radogna, F., Dicato, M., Diederich, M., 2015. Cancer-type-specific crosstalk between 
autophagy, necroptosis and apoptosis as a pharmacological target. Biochemical 
pharmacology, 94(1), pp.1–11. 10.1016/j.bcp.2014.12.018. 
Rampal, R. et al., 2014. DNA Hydroxymethylation Profiling Reveals that WT1 Mutations 
Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports. 
10.1016/j.celrep.2014.11.004. 
Reichetzeder, C., Dwi Putra, S.E., Pfab, T., Slowinski, T., Neuber, C., Kleuser, B., Hocher, B., 
2016. Increased global placental DNA methylation levels are associated with 
gestational diabetes. Clinical epigenetics, 8(1), p.82. 10.1186/s13148-016-0247-9. 
Reitman, Z.J., Parsons, D.W., Yan, H., 2010. 10.1016/j.ccr.2010.02.024. 
Rena, G., Hardie, D.G., Pearson, E.R., 2017. The mechanisms of action of metformin. 
Diabetologia, 60(9), pp.1577–1585. 10.1007/s00125-017-4342-z. 
Reznik, E., Miller, M.L., Şenbabaoğlu, Y., Riaz, N., Sarungbam, J., Tickoo, S.K., Al-Ahmadie, 
H.A., Lee, W., Seshan, V.E., Hakimi, A.A., Sander, C., 2016. Mitochondrial DNA copy 
number variation across human cancers. eLife. 10.7554/eLife.10769. 
Rissman, E.F., Adli, M., 2014. Minireview: Transgenerational Epigenetic Inheritance: Focus 
on Endocrine Disrupting Compounds. Endocrinology, 155(8), pp.2770–2780. 
10.1210/en.2014-1123. 
Robert, C. des, Li, N., Caicedo, R., Frost, S., Lane, R., Hauser, N., Neu, J., 2009. Metabolic 
effects of different protein intakes after short term undernutrition in artificially reared 
infant rats. Early Human Development, 85(1), pp.41–49. 
10.1016/J.EARLHUMDEV.2008.06.009. 
Robertson, K.D., Uzvolgyi, E., Liang, G., Talmadge, C., Sumegi, J., Gonzales, F.A., Jones, P.A., 
1999. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA 
expression in normal tissues and overexpression in tumors. Nucleic Acids Research, 
27(11), pp.2291–2298. 10.1093/nar/27.11.2291. 
Robinson, B.H., Petrova-Benedict, R., Buncic, J.R., Wallace, D.C., 1992. Nonviability of cells 
with oxidative defects in galactose medium: a screening test for affected patient 
191 
 
fibroblasts. Biochemical medicine and metabolic biology, 48(2), pp.122–6. 
Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., Puigserver, P., 2005. Nutrient 
control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature, 
434(7029), pp.113–118. 10.1038/nature03354. 
Rogatzki, M.J., Ferguson, B.S., Goodwin, M.L., Gladden, L.B., 2015. Lactate is always the end 
product of glycolysis. Frontiers in Neuroscience, 9, p.22. 10.3389/fnins.2015.00022. 
Rojanarata, T., Laiwattanapaisal, W., Ngawhirunpat, T., Opanasopit, P., Worrawethanakul, 
K., Chantadee, T., Fuangwattana, T., 2018. Fast, affordable and eco-friendly enzyme 
kinetic method for the assay of α-ketoglutaric acid in medical product and sports 
supplements. Enzyme and Microbial Technology, 116, pp.72–76. 
10.1016/J.ENZMICTEC.2018.05.013. 
Rooney, J.P., Ryde, I.T., Sanders, L.H., Howlett, E.H., Colton, M.D., Germ, K.E., Mayer, G.D., 
Greenamyre, J.T., Meyer, J.N., 2015. PCR Based Determination of Mitochondrial DNA 
Copy Number in Multiple Species. In: Methods in molecular biology (Clifton, N.J.). , 
2015, pp. 23–38. 10.1007/978-1-4939-1875-1_3. 
Rosca, M.G., Hoppel, C.L., 2013. Mitochondrial dysfunction in heart failure. Heart Failure 
Reviews, 18(5), pp.607–622. 10.1007/s10741-012-9340-0. 
Sado, T., Okano, M., Li, E., Sasaki, H., 2004. De novo DNA methylation is dispensable for the 
initiation and propagation of X chromosome inactivation. Development, 131(5), 
pp.975–982. 10.1242/dev.00995. 
Sandoval, H., Thiagarajan, P., Dasgupta, S.K., Schumacher, A., Prchal, J.T., Chen, M., Wang, 
J., 2008. Essential role for Nix in autophagic maturation of erythroid cells. Nature, 
454(7201), pp.232–235. 10.1038/nature07006. 
Sandoval, J., Esteller, M., 2012. Cancer epigenomics: beyond genomics. Current Opinion in 
Genetics & Development, 22(1), pp.50–55. 10.1016/j.gde.2012.02.008. 
Sanjana, N.E., Shalem, O., Zhang, F., 2014. Improved vectors and genome-wide libraries for 
CRISPR screening. Nature Methods. 10.1038/nmeth.3047. 
Sasaoka, N., Imamura, H., Kakizuka, A., 2018. A Trace Amount of Galactose, a Major 
Component of Milk Sugar, Allows Maturation of Glycoproteins during Sugar 
Starvation. iScience, 10, pp.211–221. 10.1016/j.isci.2018.11.035. 
192 
 
Schug, Z.T. et al., 2015. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains 
cancer cell growth under metabolic stress. Cancer cell, 27(1), pp.57–71. 
10.1016/j.ccell.2014.12.002. 
Schug, Z.T., Vande Voorde, J., Gottlieb, E., 2016. The metabolic fate of acetate in cancer. 
Nature Reviews Cancer, 16(11), pp.708–717. 10.1038/nrc.2016.87. 
Schweers, R.L., Zhang, J., Randall, M.S., Loyd, M.R., Li, W., Dorsey, F.C., Kundu, M., 
Opferman, J.T., Cleveland, J.L., Miller, J.L., Ney, P.A., 2007. NIX is required for 
programmed mitochondrial clearance during reticulocyte maturation. Proceedings of 
the National Academy of Sciences of the United States of America, 104(49), pp.19500–
5. 10.1073/pnas.0708818104. 
Sebastián, C., Mostoslavsky, R., 2017. The Various Metabolic Sources of Histone 
Acetylation. Trends in Endocrinology & Metabolism, 28(2), pp.85–87. 
10.1016/j.tem.2016.11.001. 
Segal, E., Widom, J., 2009. What controls nucleosome positions? Trends in Genetics, 25(8), 
pp.335–343. 10.1016/j.tig.2009.06.002. 
Seidel-Rogol, B.L., Shadel, G.S., 2002. Modulation of mitochondrial transcription in 
response to mtDNA depletion and repletion in HeLa cells. Nucleic acids research, 30(9), 
pp.1929–34. 
Shen, L., Shao, N., Liu, X., Nestler, E., Sugnet, C., Haussler, D., Kent, W., Razin, A., Cedar, H., 
Bajic, V., Bussemaker, H., 2014. Quick mining and visualization of next-generation 
sequencing data by integrating genomic databases. BMC Genomics, 15(1), p.284. 
10.1186/1471-2164-15-284. 
Shi, L., Pan, H., Liu, Z., Xie, J., Han, W., 2017. Roles of PFKFB3 in cancer. Signal Transduction 
and Targeted Therapy, 2, p.17044. 10.1038/sigtrans.2017.44. 
Shim, H., Chun, Y.S., Lewis, B.C., Dang, C. V, 1998. A unique glucose-dependent apoptotic 
pathway induced by c-Myc. Proceedings of the National Academy of Sciences of the 
United States of America, 95(4), pp.1511–6. 
Signes, A., Fernandez-Vizarra, E., 2018. Assembly of mammalian oxidative phosphorylation 
complexes I-V and supercomplexes. Essays in biochemistry, 62(3), pp.255–270. 
10.1042/EBC20170098. 
193 
 
Slosberg, E.D., Desai, U.J., Fanelli, B., St  Denny, I., Connelly, S., Kaleko, M., Boettcher, B.R., 
Caplan, S.L., 2001. Treatment of type 2 diabetes by adenoviral-mediated 
overexpression of the glucokinase regulatory protein. Diabetes, 50(8), pp.1813–20. 
10.2337/DIABETES.50.8.1813. 
Smolková, K., Ježek, P., 2012. The Role of Mitochondrial NADPH-Dependent Isocitrate 
Dehydrogenase in Cancer Cells. International Journal of Cell Biology, 2012, pp.1–12. 
10.1155/2012/273947. 
Soderberg, K., Nissinen, E., Bakay, B., Scheffler, I.E., 1980. The energy charge in wild-type 
and respiration-deficient chinese hamster cell mutants. Journal of Cellular Physiology, 
103(1), pp.169–172. 10.1002/jcp.1041030121. 
Song, F., Smith, J.F., Kimura, M.T., Morrow, A.D., Matsuyama, T., Nagase, H., Held, W.A., 
2005. Association of tissue-specific differentially methylated regions (TDMs) with 
differential gene expression. Proceedings of the National Academy of Sciences of the 
United States of America, 102(9), pp.3336–41. 10.1073/pnas.0408436102. 
Song, J., Oh, J.Y., Sung, Y.A., Pak, Y.K., Park, K.S., Lee, H.K., 2001. Peripheral blood 
mitochondrial DNA content is related to insulin sensitivity in offspring of type 2 
diabetic patients. Diabetes care, 24(5), pp.865–9. 10.2337/DIACARE.24.5.865. 
De Sousa E Melo, F., Vermeulen, L., Fessler, E., Medema, J.P., 2013. Cancer heterogeneity-
-a multifaceted view. EMBO reports, 14(8), pp.686–95. 10.1038/embor.2013.92. 
Speranzini, V., Pilotto, S., Sixma, T.K., Mattevi, A., 2016. Touch, act and go: landing and 
operating on nucleosomes. The EMBO journal, 35(4), pp.376–88. 
10.15252/embj.201593377. 
Srinivasan, M., Aalinkeel, R., Song, F., Lee, B., Laychock, S.G., Patel, M.S., 2000. Adaptive 
changes in insulin secretion by islets from neonatal rats raised on a high-carbohydrate 
formula. American Journal of Physiology-Endocrinology and Metabolism, 279(6), 
pp.E1347–E1357. 10.1152/ajpendo.2000.279.6.E1347. 
Sterner, D.E., Berger, S.L., 2000. Acetylation of histones and transcription-related factors. 
Microbiology and molecular biology reviews : MMBR, 64(2), pp.435–59. 
van Straten, E.M.E., Bloks, V.W., Huijkman, N.C.A., Baller, J.F.W., Meer, H. van, Lütjohann, 
D., Kuipers, F., Plösch, T., 2010. The liver X-receptor gene promoter is 
hypermethylated in a mouse model of prenatal protein restriction. American Journal 
194 
 
of Physiology-Regulatory, Integrative and Comparative Physiology, 298(2), pp.R275–
R282. 10.1152/ajpregu.00413.2009. 
Stünkel, W., Campbell, R.M., 2011. Sirtuin 1 (SIRT1). Journal of Biomolecular Screening, 
16(10), pp.1153–1169. 10.1177/1087057111422103. 
Su, X., Wellen, K.E., Rabinowitz, J.D., 2016. 10.1016/j.cbpa.2015.10.030. 
Suhre, K., 2014. Metabolic profiling in diabetes. The Journal of endocrinology, 221(3), 
pp.R75-85. 10.1530/JOE-14-0024. 
Swisa, A., Glaser, B., Dor, Y., 2017. 10.3389/fgene.2017.00021. 
Taleat, Z., Mathwig, K., Sudhölter, E.J.R., Rassaei, L., 2015. Detection strategies for 
methylated and hypermethylated DNA. TrAC Trends in Analytical Chemistry, 66, 
pp.80–89. 10.1016/j.trac.2014.11.013. 
Tatton-Brown, K. et al., 2014. Mutations in the DNA methyltransferase gene DNMT3A 
cause an overgrowth syndrome with intellectual disability. Nature genetics, 46(4), 
pp.385–8. 10.1038/ng.2917. 
Taunton, J., Hassig, C.A., Schreiber, S.L., 1996. A mammalian histone deacetylase related to 
the yeast transcriptional regulator Rpd3p. Science (New York, N.Y.), 272(5260), 
pp.408–11. 
Thomas, P., Smart, T.G., 2005. HEK293 cell line: A vehicle for the expression of recombinant 
proteins. Journal of Pharmacological and Toxicological Methods, 51(3), pp.187–200. 
10.1016/j.vascn.2004.08.014. 
Tillmar, L., Carlsson, C., Welsh, N., 2002. Control of Insulin mRNA Stability in Rat Pancreatic 
Islets. Journal of Biological Chemistry, 277(2), pp.1099–1106. 
10.1074/jbc.M108340200. 
de Toro-Martín, J., Guénard, F., Tchernof, A., Deshaies, Y., Pérusse, L., Biron, S., Lescelleur, 
O., Biertho, L., Marceau, S., Vohl, M.-C., 2016. A CpG-SNP Located within the 
&lt;b&gt;&lt;i&gt;ARPC3&lt;/i&gt;&lt;/b&gt; Gene Promoter Is Associated with 
Hypertriglyceridemia in Severely Obese Patients. Annals of Nutrition and Metabolism, 
68(3), pp.203–212. 10.1159/000445358. 
Tran, T.Q., Lowman, X.H., Kong, M., 2017. Molecular Pathways: Metabolic Control of 
Histone Methylation and Gene Expression in Cancer. Clinical cancer research : an 
195 
 
official journal of the American Association for Cancer Research, 23(15), pp.4004–
4009. 10.1158/1078-0432.CCR-16-2506. 
Tudzarova, S., Colombo, S.L., Stoeber, K., Carcamo, S., Williams, G.H., Moncada, S., 2011. 
Two ubiquitin ligases, APC/C-Cdh1 and SKP1-CUL1-F (SCF)-beta-TrCP, sequentially 
regulate glycolysis during the cell cycle. Proceedings of the National Academy of 
Sciences of the United States of America, 108(13), pp.5278–83. 
10.1073/pnas.1102247108. 
Urashima, T., Messer, M., Oftedal, O.T., 2014. Comparative Biochemistry and Evolution of 
Milk Oligosaccharides of Monotremes, Marsupials, and Eutherians. In: Evolutionary 
Biology: Genome Evolution, Speciation, Coevolution and Origin of Life. Cham: Springer 
International Publishing, 2014, pp. 3–33. 10.1007/978-3-319-07623-2_1. 
Verdone, L., Caserta, M., Mauro, E. Di, 2005. Role of histone acetylation in the control of 
gene expression. Biochemistry and Cell Biology, 83(3), pp.344–353. 10.1139/o05-041. 
Vető, B., Szabó, P., Bacquet, C., Apró, A., Hathy, E., Kiss, J., Réthelyi, J.M., Szeri, F., Szüts, D., 
Arányi, T., 2018. Inhibition of DNA methyltransferase leads to increased genomic 5-
hydroxymethylcytosine levels in hematopoietic cells. FEBS Open Bio. 10.1002/2211-
5463.12392. 
Vohwinkel, C.U., Lecuona, E., Sun, H., Sommer, N., Vadász, I., Chandel, N.S., Sznajder, J.I., 
2011. Elevated CO(2) levels cause mitochondrial dysfunction and impair cell 
proliferation. The Journal of biological chemistry, 286(43), pp.37067–76. 
10.1074/jbc.M111.290056. 
Wang, X., Tang, H., Chen, Y., Chi, B., Wang, S., Lv, Y., Wu, D., Ge, R., Deng, H., 2016. 
Overexpression of SIRT3 disrupts mitochondrial proteostasis and cell cycle 
progression. Protein & Cell, 7(4), p.295. 10.1007/S13238-016-0251-Z. 
Warburg, O., 1956. On the origin of cancer cells. Science (New York, N.Y.), 123(3191), 
pp.309–14. 
Warburg, O., Wind, F., Negelein, E., 1927. The Metabolism of Tumors in the Body. The 
Journal of general physiology, 8(6), pp.519–530. 10.1097/00000441-193107000-
00022. 
Wei, M.C., Zong, W.X., Cheng, E.H., Lindsten, T., Panoutsakopoulou, V., Ross, A.J., Roth, 
K.A., MacGregor, G.R., Thompson, C.B., Korsmeyer, S.J., 2001. Proapoptotic BAX and 
196 
 
BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death. Science, 
292(5517), pp.727–730. 10.1126/science.1059108. 
Weinhouse, S., 1976. The Warburg hypothesis fifty years later. Zeitschrift fur 
Krebsforschung und klinische Onkologie. Cancer research and clinical oncology, 87(2), 
pp.115–26. 
Wellen, K.E., Hatzivassiliou, G., Sachdeva, U.M., Bui, T. V., Cross, J.R., Thompson, C.B., 2009. 
ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation. Science, 
324(5930), pp.1076–1080. 10.1126/science.1164097. 
Wellen, K.E., Hatzivassiliou, G., Sachdeva, U.M., Bui, T. V, Cross, J.R., Thompson, C.B., 2009. 
ATP-citrate lyase links cellular metabolism to histone acetylation. Science (New York, 
N.Y.), 324(5930), pp.1076–80. 10.1126/science.1164097. 
Wen, H., Cho, H.R., Yun, T., Kim, H., Park, C.-K., Lee, S.-H., Choi, S.H., Park, S., 2015. 
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 
and 2 mutants and the effects of an inhibitor on the metabolism. Journal of 
Neurochemistry, 132(2), pp.183–193. 10.1111/jnc.12950. 
Wen, L. et al., 2014. Whole-genome analysis of 5-hydroxymethylcytosine and 5-
methylcytosine at base resolution in the human brain. Genome biology, 15(3), p.R49. 
10.1186/gb-2014-15-3-r49. 
White, K., Kim, M.-J., Han, C., Park, H.-J., Ding, D., Boyd, K., Walker, L., Linser, P., Meneses, 
Z., Slade, C., Hirst, J., Santostefano, K., Terada, N., Miyakawa, T., Tanokura, M., Salvi, 
R., Someya, S., 2018. Loss of IDH2 Accelerates Age-related Hearing Loss in Male Mice. 
Scientific reports, 8(1), p.5039. 10.1038/s41598-018-23436-w. 
WHO, 2019. WHO | Economic burden of disease. WHO. 
Wiederkher, A., Wollheim, C., 2008. Impact of mitochondrial calcium on the coupling of 
metabolism to insulin secretion in the pancreatic β-cell. Cell Calcium, 44(1), pp.64–76. 
10.1016/j.ceca.2007.11.004. 
Wise, D.R., Ward, P.S., Shay, J.E.S., Cross, J.R., Gruber, J.J., Sachdeva, U.M., Platt, J.M., 
DeMatteo, R.G., Simon, M.C., Thompson, C.B., 2011. Hypoxia promotes isocitrate 
dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell 
growth and viability. Proceedings of the National Academy of Sciences of the United 
States of America, 108(49), pp.19611–6. 10.1073/pnas.1117773108. 
197 
 
Wollheim, C.B., Maechler, P., 2002. Cell Mitochondria and Insulin Secretion Messenger Role 
of Nucleotides and Metabolites. 
Wu, H., Zhang, Y., 2011. Mechanisms and functions of Tet protein-mediated 5-
methylcytosine oxidation. Genes & Development, 25(23), pp.2436–2452. 
10.1101/gad.179184.111. 
Wu, M., Li, H., Liu, R., Gao, X., Zhang, M., Liu, P., Fu, Z., Yang, J., Zhang-Negrerie, D., Gao, 
Q., 2016. Galactose conjugated platinum(II) complex targeting the Warburg effect for 
treatment of non-small cell lung cancer and colon cancer. European Journal of 
Medicinal Chemistry, 110, pp.32–42. 10.1016/J.EJMECH.2016.01.016. 
Xie, S., Wang, Z., Okano, M., Nogami, M., Li, Y., He, W.W., Okumura, K., Li, E., 1999. Cloning, 
expression and chromosome locations of the human DNMT3 gene family. Gene, 
236(1), pp.87–95. 
Yamada, Y., Jackson-Grusby, L., Linhart, H., Meissner, A., Eden, A., Lin, H., Jaenisch, R., 2005. 
Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. 
Proceedings of the National Academy of Sciences of the United States of America, 
102(38), p.13580. 10.1073/PNAS.0506612102. 
Yan, X.J., Xu, J., Gu, Z.H., Pan, C.M., Lu, G., Shen, Y., Shi, J.Y., Zhu, Y.M., Tang, L., Zhang, X.W., 
Liang, W.X., Mi, J.Q., Song, H.D., Li, K.Q., Chen, Z., Chen, S.J., 2011. Exome sequencing 
identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute 
monocytic leukemia. Nature Genetics. 10.1038/ng.788. 
Yang, H., Ye, D., Guan, K.L., Xiong, Y., 2012. 10.1158/1078-0432.CCR-12-1773. 
Yang, Y., Hu, J.-F., Ulaner, G.A., Li, T., Yao, X., Vu, T.H., Hoffman, A.R., 2003. Epigenetic 
regulation ofIgf2/H19 imprinting at CTCF insulator binding sites. Journal of Cellular 
Biochemistry, 90(5), pp.1038–1055. 10.1002/jcb.10684. 
Yao, G., Lee, T.J., Mori, S., Nevins, J.R., You, L., 2008. A bistable Rb–E2F switch underlies the 
restriction point. Nature Cell Biology, 10(4), pp.476–482. 10.1038/ncb1711. 
Yaribeygi, H., Atkin, S.L., Sahebkar, A., 2018. Mitochondrial dysfunction in diabetes and the 
regulatory roles of antidiabetic agents on the mitochondrial function. Journal of 
Cellular Physiology. 10.1002/jcp.27754. 
Ye, D., Guan, K.-L., Xiong, Y., 2018. Metabolism, Activity, and Targeting of D- and L-2-
198 
 
Hydroxyglutarates. Trends in cancer, 4(2), pp.151–165. 10.1016/j.trecan.2017.12.005. 
YI, W.-R., LI, Z.-H., QI, B.-W., ERNEST, M.E.R., HU, X., YU, A.-X., 2016. Downregulation of 
IDH2 exacerbates the malignant progression of osteosarcoma cells via increased NF-
κB and MMP-9 activation. Oncology Reports, 35(4), pp.2277–2285. 
10.3892/or.2016.4553. 
Yu, W., Dittenhafer-Reed, K.E., Denu, J.M., 2012. SIRT3 protein deacetylates isocitrate 
dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. The Journal of 
biological chemistry, 287(17), pp.14078–86. 10.1074/jbc.M112.355206. 
Yu, Z., Genest, P.-A., ter Riet, B., Sweeney, K., DiPaolo, C., Kieft, R., Christodoulou, E., 
Perrakis, A., Simmons, J.M., Hausinger, R.P., van Luenen, H.G.A.M., Rigden, D.J., 
Sabatini, R., Borst, P., 2007. The protein that binds to DNA base J in trypanosomatids 
has features of a thymidine hydroxylase. Nucleic acids research, 35(7), pp.2107–15. 
10.1093/nar/gkm049. 
Zakhari, S., 2013. Alcohol metabolism and epigenetics changes. Alcohol research : current 
reviews, 35(1), pp.6–16. 
Zhang, J., Ney, P.A., 2009. Role of BNIP3 and NIX in cell death, autophagy and mitophagy. 
Cell Death & Differentiation, 16(7), pp.939–946. 10.1038/cdd.2009.16. 
Zhang, N., 2015. Epigenetic modulation of DNA methylation by nutrition and its 
mechanisms in animals. Animal Nutrition, 1(3), pp.144–151. 
10.1016/J.ANINU.2015.09.002. 
Zhang, Y., Jurkowska, R., Soeroes, S., Rajavelu, A., Dhayalan, A., Bock, I., Rathert, P., Brandt, 
O., Reinhardt, R., Fischle, W., Jeltsch, A., 2010. Chromatin methylation activity of 
Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with the histone 
H3 tail. Nucleic acids research, 38(13), pp.4246–53. 10.1093/nar/gkq147. 
Zhao, D., Xiong, Y., Lei, Q.-Y., Guan, K.-L., 2013. LDH-A acetylation: implication in cancer. 
Oncotarget, 4(6), pp.802–3. 10.18632/oncotarget.1007. 
Zhao, J., Goldberg, J., Bremner, J.D., Vaccarino, V., 2012. Global DNA methylation is 
associated with insulin resistance: a monozygotic twin study. Diabetes, 61(2), pp.542–
6. 10.2337/db11-1048. 
Zou, X., Zhu, Y., Park, S.-H., Liu, G., O’Brien, J., Jiang, H., Gius, D., 2017. SIRT3-Mediated 
199 
 
Dimerization of IDH2 Directs Cancer Cell Metabolism and Tumor Growth. Cancer 
Research, 77(15), pp.3990–3999. 10.1158/0008-5472.CAN-16-2393. 
 
